Monday 10/26 — a.m.: Verizon carries the open into SpaceX tower talks

The frame

Five names before the bell, one that matters. The tape comes in off a second straight down week (S&P 7,623.68, -0.5% Friday), a 5.00% 10-year, and WTI at $103.27, and the reaction function for four sessions has been to sell beats when the slope decelerates or cash burn rises. That sets the bar for Verizon, which reports into a tower-versus-carrier rotation: CCI +11.7% and AMT +7% on SpaceX cell-site talks, while VZ, T and TMUS fell. This is the first carrier print since that move, so the call has to address it.

The rest of the session is a defensive-and-regional mix: Ensign (skilled nursing), Bank of Hawaii (a heavily shorted regional), and Easterly (government-leased office). AstraZeneca is on the Briefing calendar for Monday, but its own Q2 release puts the 9M/Q3 report on Friday 10/30 (see the flagged section). It is a 6-K filer, so Carl's EDGAR 8-K watcher will not catch it either way.

The week behind this session is the heaviest of Q3: GOOGL/MSFT/META-adjacent Wednesday night after the FOMC decision (1:00 PM CT), AMZN/INTC/SNDK Thursday night, XOM/CVX/ABBV Friday, with the first Q3 GDP print midweek. Monday morning is mostly a read on consumer-facing wireless pricing and on how much rate sensitivity the market is carrying into Wednesday.

Tier 1 — before the open

VZ ($44.60) — Raised twice already; the print has to survive the tower trade. Workbook consensus is $1.27 adjusted EPS on $34.85B revenue, 2.1% short, 31.6% implied vol (annualized, not an event move). Last quarter (Q2, 7/24) Verizon posted $1.30 adjusted EPS on $34.3B revenue (-0.7% y/y), 184,000 postpaid phone net adds, and raised FY26 adjusted EPS to $4.99-$5.04 (6-7% growth), with FCF of $21.94-$22.14B, capex of $16.0-$16.5B and buybacks of up to $4.5B for the year (8-K Ex. 99). The Q1 release had already raised EPS and pushed phone net adds guidance to the top half of 750K-1M. FY consensus of $5.02 sits in the upper half of the range, so a third raise is partly in the number.

The stock is 15% above its 52-week low of $38.68 and 14% below the high of $51.68, with a 9.1x forward multiple. The bear case is that Friday's move priced a structural story: if satellite direct-to-cell reduces the coverage moat and tower owners gain leverage, the carriers' wireless service revenue (guided about flat) has no growth to absorb it. The bull case is that the guide is raised, FCF is growing 9-10%, the buyback is $4.5B, and the multiple already reflects a no-growth carrier. The metric that matters is postpaid phone net adds against price-lock churn, then whether the SpaceX question draws anything more than a boilerplate answer on spectrum and tower lease commitments. Release at 7:00 AM ET, webcast 8:30 AM ET (Verizon IR).

ENSG ($175.59) — Raised guidance last time; Texas ramp is the tell. Consensus is $1.97 EPS on $1.51B revenue, up from Q2's $1.92 adjusted EPS on $1.44B (+17.3%). Ensign lifted FY26 adjusted EPS to $7.75-$7.85 from $7.48-$7.62 and revenue to $5.87-$5.92B from $5.81-$5.86B, with same-facility occupancy at 84.1% and 20 new operations added, many in Texas below regional occupancy averages (8-K). Shares are 19% below the $218.00 high, 24% above the low, 3.0% short, 34.2% IV. Watch occupancy and skilled mix on the transitioning cohort, and whether another raise leans on acquisitions.

BOH ($70.60) — 14.4% short for a Hawaii regional. Consensus $1.51 EPS, $202M revenue, FY $5.96. The stock is 18% off its $86.31 high and 13% above the $62.51 low, IV 37.9%. With the 2-year at 4.69% and the 10-year at 5.00%, the questions are net interest margin direction, deposit costs and securities marks. That short interest is the highest in the session and the asymmetry is in how deposit beta reads. No primary-source date was confirmed (workbook only).

DEA ($22.67) — Government-leased office near the lows. Consensus $0.07 EPS on $93M revenue; the 73x forward multiple is a GAAP artifact, not a valuation read. The stock is 13% above its $20.56 low, 6.5% short, IV 27.3%. Lease-renewal and GSA exposure are the items to listen for.

The rest, by cluster

Also placed here from Briefing's Wednesday TBD bucket: LKFN ($58.39) — Lakeland Financial, Q3 consensus $1.09 on $74M; its Q1 and Q2 reports both landed on Monday mornings and aggregators put this one Monday Oct 26 pre-market, but the company has not posted a notice we could find. Indiana commercial bank, 2.2% short, within 10% of its $64.55 high. Everything in the session is covered above. The only cluster is cross-session: the tower and carrier rotation (VZ here; T and TMUS later in the week) is the only theme that spills into later days.

Where the asymmetries sit

VZ implied vol of 31.6% is thin for a stock that just had a sector-wide gap on a structural headline; the print is about the answer on SpaceX, not EPS. BOH at 14.4% short is the crowding in this session, and ENSG at 19% below its high with a recent raise is a setup where a modest beat needs the occupancy line to carry it. AZN has moved to Friday a.m. on this page (company-confirmed Oct 30).

Dominoes

VZ sets the tone for T and TMUS and for CCI and AMT, whatever it says about cell-site leasing or capex; its capex guide ($16.0-$16.5B) also feeds the equipment names later in the week. BOH is the first regional read into the rate week, ahead of FOMC. ENSG reads through to post-acute peers in the healthcare cluster. Threads touched: power/infrastructure financing only indirectly; mostly a rate-sensitivity and consumer-pricing session.

Flagged as unverified

AZN: the Briefing places it Monday a.m., but AstraZeneca's own H1 release lists 9M and Q3 results for 30 October 2026 (Friday); AZN is a foreign private issuer reporting via 6-K, so the EDGAR 8-K watcher will not catch it. Workbook EPS of $1.15 appears to be ADR-basis against a $2.63 ordinary-share core figure. ENSG: Q2 was released 7/27 with the call on 7/29, so the Q3 release may come after the close rather than before the open; timing is unconfirmed. BOH and DEA dates rest on the workbook only. DEA's 73x forward multiple is a GAAP-EPS artifact.

Sources: https://www.verizon.com/about/news/verizon-q3-2026-earnings-report-date · https://www.sec.gov/Archives/edgar/data/0000732712/000073271226000040/a2026q2exhibit99.htm · https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/half-year-financial-report/9687613 · https://www.astrazeneca.com/content/dam/az/PDF/2026/AZN-PreQ3-Aide-memoire-2026.pdf · https://www.sec.gov/Archives/edgar/data/0001125376/000112537626000036/q22026pressrelease.htm

Monday 10/26 — p.m.: Cadence, Nucor, Amkor and the REIT and insurance block

The frame

Twenty-two workbook names after the close, plus two off-workbook: CLS and RMBS also report Monday after the bell (no stats here). RMBS is a direct memory-interface read for the Micron thread (MU ~$880, +3.5% Friday); CLS is the AI-hardware ODM read for the commoditization and SMCI-adjacent thread.

The macro stack is unfriendly to long-duration assets: 10-year at 5.00%, 30-year at 5.33%, WTI $103.27 (+14% MTD), a Fed debate that is hike versus hold (October hike odds about 5%), and FOMC Wednesday at 1:00 PM CT. That puts the REIT and insurance block (WELL, PSA, ARE, SUI, BRX, PECO, HIG, CINF, BRO, PFG) in a rate-sensitivity test, and the industrial prints (NUE, WHR, GBX) in a tariff and input-cost test. The tape has sold beats where the slope decelerates; only commodity-levered beats have been paid (SLB +7% on $103 oil), which is why NE is worth a look.

The two largest single-name reads are CDNS (AI-EDA, and whether agents expand or cannibalize the design-seat model, thread 4) and AMKR (advanced packaging and memory, threads 1 and 5). Both carry implied vol above 50%.

Tier 1 — after the close

CDNS ($316.50) — Guided to the upper half; stock 24% off the high. Consensus $2.05 EPS on $1.62B revenue. Cadence's Q3 outlook was $1.595-$1.625B revenue and $2.01-$2.07 non-GAAP EPS, with FY26 raised to $8.05-$8.15 EPS and $6.26-$6.34B revenue, record backlog $8.1B (Q2 CFO commentary). Consensus sits at the top of both revenue and EPS ranges, so a beat is the base case. The stock is 20% above its $262.75 low but 24% under $416.69, implied vol is 53.6% and 2.1% short. The metric is backlog and the FY raise cadence against an agentic-design narrative: if AI agents compress engineer seats, does EDA consumption (hardware emulation, IP, compute) offset? Watch the Q4 guide, buyback pace (about $200M planned for Q3) and any language on AI-driven design starts. Webcast 2:00 PM PT (Cadence). Note the workbook FY EPS of $4.81 does not match company guidance.

NUE ($258.11) — Consensus is above the company's own guide. Nucor guided Q3 to $5.55-$5.65 per share on September 17 (guidance release); the workbook has $5.83, about 3% above the top end, on $10.79B revenue. Q2 was $5.04 GAAP and $4.84 adjusted, and included $130M of raw-material refunds that do not repeat. Steel mills and steel products were guided up on price and volume, raw materials down, corporate costs up. The stock is 8% under its $280.11 high and 85% of the way up from the $139.21 low, IV 44%. The setup: tariff-protected pricing is already in the stock, so the Q4 commentary on order books, imports and scrap pricing matters more than the beat. Release after the close; call Tuesday 10:00 AM ET.

WELL ($237.32) — Senior-housing compounder, 7% from the high. The workbook's $0.71 EPS and $3.75B revenue are GAAP-style figures; the number the Street trades on is normalized FFO ($1.60 in Q2, +25%). Welltower raised FY26 normalized FFO to $6.36-$6.44 from $6.21-$6.35, same-store NOI growth guided 13.75-16.00% (seniors housing operating +18.5-21.5%), with $15.5B of gross investments closed or under contract YTD (Q2 release). 78% of the way up its 52-week range, 2.8% short, IV 31%. At 68x on the workbook EPS the multiple is a GAAP artifact; the debate is whether occupancy gains keep driving the raise at a 5% 10-year. Release after the close; call Tuesday 9:00 AM ET (Welltower).

PSA ($309.89) — Self-storage near the top of its range. Consensus $2.29 EPS (GAAP-style) on $1.31B revenue; stock 8% under the $335.55 high, 68% up the range, 4.6% short, IV 27.4%. Release after the close, call Tuesday 11:00 AM CT (PSA). Prior guidance was not pulled for this note. Watch same-store revenue, move-in rates and occupancy against a housing market under 5% rates; this is the cleanest read on storage demand ahead of SUI.

HIG ($136.76) — Commercial lines at 9.8x. Consensus $3.17 EPS on $7.41B revenue; 64% up its $120.33-$146.07 range, 1.5% short, IV 24%. Release 4:05 PM ET; webcast Tuesday 9:00 AM ET (Hartford). The numbers to read are the commercial combined ratio, prior-year reserve development and personal lines pricing. Low implied vol means the market expects little surprise; reserve action is where a miss would come from.

AMKR ($39.35) — Down 59% from the high into a guided quarter. Amkor guided Q3 to $1.95-$2.05B revenue, 18.5-19.5% gross margin and $0.72-$0.82 EPS; consensus $0.78 on $2.04B is at the top of revenue and the midpoint of EPS. Q2 delivered $1.90B (+26%), 16.8% gross margin, $0.70, with advanced products 82% of sales and FY capex of $2.5-3.0B against $688M spent in H1 (Q2 8-K). The stock sits at 15% of its $29.50-$96.68 range, 17.3% short, with 82% implied vol, the richest in the session. Bulls point to margin expansion and AI/HPC programs; bears to a capex plan that outruns cash flow and a tape that has sold semis on slope. Read-throughs to RMBS, MU and the packaging cohort. Release after close; call 5:00 PM ET (Amkor).

WHR ($28.30) — At the lows with 30% of the float short. Whirlpool is 3% above its $26.08 low and 70% below the $94.82 high; 29.8% short, IV 76.7%, market cap $1.8B. Q2 (reported late, 8/3) showed ongoing EPS of -$0.21, net sales -6.8% to $3.52B and no common dividend declared; FY26 guidance was cut to ongoing EPS $2.50-$3.00 on higher interest expense, with sales about $15.0B, ~4% EBIT margin and FCF above $300M (Q2 release). Consensus $1.01 on $3.93B implies a sharp sequential step up from Q2. Tariffs, raw materials and fuel were named as the North America margin drag. The question is whether FY guidance holds when Q3 has to deliver the second-half ramp. Release 4:05 PM ET, call Tuesday 8:00 AM ET (Whirlpool).

NE ($47.70) — Offshore driller with a guide cut and $103 oil. Consensus $0.23 EPS on $713M, against Q2 adjusted EPS of $0.01 and adjusted EBITDA of $212M. In July Noble cut FY26 revenue to $2.8-2.9B and EBITDA to $850-925M, citing two suspended Brazil rigs and re-sequenced backlog; utilization 64%, backlog $6.8B, leading-edge drillship rates in the mid-$400Ks (8-K). 73% up the range, 13.1% short, IV 51%. The oil move helps sentiment more than near-term cash flow, since rig contracts reprice slowly. Release time was not stated; call Tuesday 8:00 AM CT (Noble).

ARE ($43.02) — Life-science office, 45% below the high. The workbook EPS of $0.00 and FY $1.46 are GAAP; FFO is the real number. Q2 FFO as adjusted was $1.73; FY26 guidance was narrowed to $6.35-$6.45, with Q4 at the low end of $1.40-$1.50, same-property NOI down 8.5-10.5%, year-end occupancy 86.2-87.8%, and $222.5M of impairments in Q2 (Q2 supplement). The stock is 9% up its $39.41-$78.00 range, 6.4% short, IV 52.6%. Watch dispositions ($2.9B midpoint), the five development projects under review and cash re-leasing spreads (-4.3% in Q2). The report date rests on the Briefing only.

CINF ($176.30), BRO ($72.97), PFG ($108.56) — Insurers and asset managers. CINF: consensus $2.11 on $3.03B, 59% up its range, 3.3% short, IV 29%; the focus is the combined ratio and catastrophe load. BRO: $1.08 on $1.76B, 18% below its $89.05 high, 5.6% short, IV 40%, the most volatile of the group; organic growth and the softening of commercial property pricing are the tells. PFG: $2.42 on $4.26B, 9.1x forward, 70% up its range, IV 27.6%; watch retirement net flows and pension risk transfer. No primary guidance was pulled for these three.

The rest, by cluster

REITs: SUI ($120.24) is 7.8% short with IV 27.6% and sits 37% up its range; manufactured-housing and RV same-store occupancy is the read. BRX ($28.13) is 11.5% short at 26.3% IV; PECO ($38.36) trades at 65.8x GAAP EPS, in the middle of its range. Industrials and autos: SSD ($184.36) 49% up its range with 35.9% IV, a housing-starts proxy; DORM ($125.59) at 51.7% IV and 8.1% short; PSMT ($172.31), 9.7% short, 14% under its $199.84 high; GBX ($38.09) is 12.7% short and sits within 3% of its $37.02 low; CTOS ($9.06) has no workbook IV (shown as "++"). Software and staffing: AGYS ($120.69) carries 70.7% IV and 47.6x forward, 17% under its high; KFRC ($58.50) sits near its $61.68 high (91% of range), 11.1% short, IV 76%.

Where the asymmetries sit

Implied vol is richest where the setup is most fragile: AMKR at 82%, WHR at 77%, KFRC at 76%, AGYS at 71%. Shorts are crowded in WHR (29.8%) and AMKR (17.3%), with NE (13.1%), GBX (12.7%), BRX (11.5%) and KFRC (11.1%) also carrying real float against them. HIG (24%) and PSA (27%) are priced for a quiet print. Names at extremes: WHR and GBX are at their 52-week lows into the print, ARE and AMKR are down 45-59% from highs, and NUE, KFRC and WELL are within 8% of highs where a good number is already priced.

Guidance-reset candidates are WHR (a second-half ramp it has to prove), NE (already cut once in July) and ARE (Q4 guided to the low end). NUE is the only name where consensus sits above the company's own guide.

Dominoes

CDNS and AMKR set tomorrow's tone for semis, packaging and the AI-design-software cohort, and read through to RMBS and CLS the same night. NUE reads to STLD and CMC and to tariff-sensitive industrials later in the week. WELL and PSA lead the REIT block into SUI, BRX and PECO and ahead of FOMC. HIG, CINF and BRO frame the commercial-insurance pricing debate for the rest of the week. WHR reads to home-goods and appliance names and to tariff pass-through; NE reads to the offshore group (VAL, RIG) and to oil-service momentum after SLB.

Flagged as unverified

Dates confirmed from company releases: WELL, PSA, NUE, HIG, WHR, AMKR, CDNS (all Monday after the close; CDNS webcast 2:00 PM PT is the post-close slot). NE: Monday confirmed but release time not stated. ARE, CINF, BRO, PFG, SUI, BRX, SSD, PECO, PSMT, DORM, AGYS, CTOS, GBX, KFRC: the Briefing date only. Workbook oddities: NUE consensus $5.83 sits above the company's $5.55-$5.65 guide; CDNS FY EPS $4.81 conflicts with guidance of $8.05-$8.15; WELL, PSA and ARE EPS and multiples are GAAP, not FFO; CTOS IV shows "++". No foreign private issuers (6-K) in this session; CLS (Canadian) and RMBS are off the workbook.

Sources: https://finviz.com/news/398910/cadence-announces-third-quarter-2026-financial-results-webcast · https://s206.q4cdn.com/597110084/files/doc_financials/2026/q2/Q2-2026-CFO-Commentary-FINAL.pdf · https://s202.q4cdn.com/531038915/files/doc_news/Nucor-Announces-Guidance-for-the-Third-Quarter-of-2026-Earnings-2026.pdf · https://welltower.com/wp-content/uploads/2026/07/2Q26-Earnings-Release-99.1-FINAL.pdf · https://www.sec.gov/Archives/edgar/data/0001047127/000104712726000043/amkr6302026erex-991.htm · https://whirlpool.mediaroom.com/2026-08-03-Whirlpool-Corporation-Announces-Second-Quarter-Results · https://www.sec.gov/Archives/edgar/data/0001895262/000189526226000138/exhibit991-q22026pressrele.htm · https://s2.q4cdn.com/884574073/files/doc_financials/2026/q2/2Q26-EX-99-1-SUPP-Press-Release.pdf · https://s206.q4cdn.com/854710405/files/doc_news/2026/Sep/28/09282026-Q3-Save-the-Date-Final.pdf · https://finviz.com/news/398889/public-storage-to-release-third-quarter-2026-earnings-results-and-host-quarterly-conference-call

Tuesday 10/27 — a.m.: Rate-hike tape meets 48 prints before the open

The frame

Tuesday is the first full-size session of the heaviest week of Q3 season, and it lands in a tape that has punished good numbers for four straight sessions. The S&P closed Friday at 7,623.68, down a second week, with the 10-year at 5.00%, WTI at $103.27 and the debate at the Fed being hike versus hold, not cuts. The reaction function Carl has been watching is specific: beats get sold when the slope decelerates or cash burn rises (BE, FIX, LRCX, WDC, DECK, AXP on a raise with a restructuring charge), and only commodity-levered beats get paid (SLB on $103 oil). Tuesday morning is a test of whether that rule extends to staples, industrials, healthcare services and consumer-credit names, because the 48 reporters are almost entirely "real economy" prints with only one genuine AI-infrastructure name in the top tier (Corning).

The session is front-loaded with read-throughs that matter for the rest of the week. Corning is the optics and fiber leg of the commoditization and "peak capex" threads, reporting a day before the hyperscaler cluster on Wednesday night. American Tower is the first print after Friday's SpaceX-driven rip in towers (CCI +11.7%, AMT +7%), and the first test of whether carrier-churn and DISH cancellations, which were the whole bear case on towers, get reframed by the satellite-to-cell narrative. HCA and Centene together give two angles on the same question, which is who absorbs the loss of exchange coverage. UPS is the Amazon glide-down print, and FCX, JCI, HUBB and the utilities (CNP, CMS) touch the power/grid and copper threads. All of it is read ahead of Wednesday's 1:00 PM CT FOMC decision and the first Q3 GDP print.

Off-workbook, CLS and RMBS reported Monday after the close and are the first optics and memory datapoints Corning will be read against. The session is clean on timing: no Tier 1 name conflicts with Briefing's a.m. placement (see flagged). NVS reports by 6-K, so the 8-K watcher will not see it.

Tier 1 — before the open

KO ($92.84) — a staple at 91% of its 52-week range, priced for a clean beat. The Street has comparable EPS of $0.88 on $12.93B of revenue (workbook), against a Q2 print of $0.97 comparable EPS on $13.4B (seasonally Q3 is lower). On July 28 the company raised its full-year outlook: organic revenue growth of about 5% (from 4% to 5%), comparable EPS growth of 9% to 10% (from 8% to 9%), including about a 3-point currency tailwind, and free cash flow of about $12.4B. For Q3 it flagged about a 3% currency tailwind to comparable EPS and a minimal acquisition/divestiture headwind. Source: the Q2 release on the company IR site. The stock is 3% off its high of $95.37, 38% above the low, with 1.2% short interest and front-month implied vol of 23.3%, the lowest in Tier 1, which says the options market expects a small move on a low-beta name.

The one number that matters is unit-case volume. Q2 volume was +5% with price/mix +2%, concentrate sales running a point behind volume on shipment timing, so there is a timing reversal that could help Q3 concentrate. Zero Sugar +16% and Trademark Coke +5% carry the mix. The bull read is a second consecutive raise with FX doing a third of the EPS growth; the bear read is a 25x forward multiple (workbook) on a company whose guidance raise is a third currency, and where any slip in the volume cadence has nowhere to hide. Watch the guide for any change in the 19.9% tax rate and the FX tailwind, which is the swing item given the dollar.

NVS ($151.12) — Entresto cliff against Kisqali and Pluvicto; a 6-K filer. Consensus is $2.24 EPS on $14.56B (workbook, USD). Q2 net sales were $14.4B, +1% in constant currency (volume added 18 points, generics subtracted 14, pricing subtracted 3), core operating income $5.9B, flat, core margin 41.2%. Kisqali grew 43% cc to $1.70B, Pluvicto 43% to $651M, Cosentyx 10% to $1.82B, and Entresto fell 51% to $1.18B. Full-year guidance as of July: net sales up low single digits cc, core operating income down low single digits cc, with about a 1-point currency tailwind if mid-July rates hold (Novartis 6-K, July 21). The stock sits 11% below its 52-week high with 0.3% short interest and 30% implied vol.

The tension is that volume of +18 points is almost entirely eaten by Entresto generics, so the question is how fast the replacement brands outrun the erosion in Q4 and 2027. Novartis is the only name in the session whose results come through a 6-K, which means Carl's 8-K watcher will not trigger. The Novartis events page gives the date as October 27 in Basel; I could not confirm a release time on it (see flagged).

BA ($188.09) — near the bottom of the range, with free cash flow the only metric. Consensus is a loss of $0.20 on $24.37B (workbook), versus a Q2 core loss of $0.76 on $24.6B and 171 deliveries. Q2 produced $0.6B of free cash flow but first-half FCF is still a $823M outflow, and the company gives no full-year FCF figure in the release. Backlog is a record $715B. The 737 is transitioning to 47 a month, the 737-7 and 737-10 are expected to certify in 2026 with first deliveries in 2027, and 777X first delivery remains 2027. Defense took a $280M VC-25B charge in Q2. Source: Boeing's Q2 release (company mediaroom).

The stock is at 15% of its 52-week range, 26% below the high and 6% above the low, with 1.9% short interest and 39.9% implied vol. The consensus loss narrowing from -$0.76 to -$0.20 means the Street is already modelling a big step-up in Q3 deliveries and the absence of a new charge. The bear case is another program charge (VC-25B has been a repeat offender) or a slower rate ramp; the bull case is that the stock is priced as if the 777X date slips again. Watch 737 monthly rate commentary, FCF in the quarter, and whether management quantifies full-year cash. Release is 10:30 a.m. ET call per Boeing IR.

SPGI ($450.31) — ratings and data into a week where the mortgage-score story is live. Consensus is $4.42 on $3.64B, with full-year EPS of $17.86 (workbook). I did not retrieve the Q2 release or its guidance within the budget, so the prior-guidance anchor is not cited here; check the Q2 release at press.spglobal.com before the call. The stock is 14% below its high, 25% above the low, 2.2% short, 35.6% implied vol. The structural debate is fee-based data and ratings against AI-driven substitution of information workflow (thread 4 in its data/information-services form), plus issuance volumes in a market with a 5% 10-year. The FICO price freeze Friday (FICO -6.6% after hours) is a reminder that pricing power in scored data is being tested by customers. Watch ratings transaction revenue, Market Intelligence growth and the full-year margin guide.

GLW ($123.31) — the optics and AI-commoditization print, 55% off its high. Street is $0.88 on $5.03B, within the company's own Q3 guide of core EPS $0.85 to $0.89 and core sales of $4.9B to $5.0B (the workbook revenue is above the top of the sales guide; other aggregators show about $5.01B). Q2 optical communications sales rose about 32%, and management cites accelerating orders tied to AI, long-term agreements with Amazon, NVIDIA, Meta and Verizon, and plans to expand fiber production by 50% and connectivity capacity tenfold with customer prepayments funding part of it (Hudson Labs preview, summarising the Q2 materials; I did not retrieve the primary release). The stock is the most extreme setup in Tier 1: 24% of its 52-week range, 55% off the $271.78 high, 59% above the $77.39 low, 65.3% implied vol and 2.2% short interest.

For Carl's threads, this is thread 1 and thread 5 in one name. If AI optics and connectivity are standardizing, the tell is price and mix in optical communications, not volume; if the capex cycle is still expanding, it is the prepayments and the capacity plan. A stock that has lost more than half its peak value into a sequentially guided quarter is being asked to deliver more than a guide hit: the market wants the order book and the 2027 capacity story. The risk to the upside is a guide above the street; the risk to the downside is that a beat with decelerating optical growth or a capacity plan that looks more like overbuild gets sold, as the tape has been doing. The date and time (Tuesday 10/27, 7:00 AM ET) rests only on an aggregator; I could not confirm it on Corning's IR page (flagged).

HCA ($469.03) — the guide was already cut; the mix shift is the story. Consensus is $6.63 on $19.32B. On July 14 HCA lowered 2026 guidance: diluted EPS to $28.70 to $30.50 (from $29.10 to $31.50), adjusted EBITDA to $15.40B to $16.10B (from $15.55B to $16.45B), net income to $6.30B to $6.70B, with revenue narrowed to $77.0B to $79.5B. It cited a payer-mix shift from uninsured volume tied to exchange coverage losses, partly offset by Medicaid supplemental payments. Q2 EPS was $7.62 on $20.23B, same-facility admissions +2.5%, adjusted EBITDA margin 19.9% (down from 20.7%), with inpatient surgeries -2.3% and outpatient surgeries -3.4% (HCA 8-K). The workbook full-year consensus of $29.49 sits just below the revised midpoint of $29.60. The stock is 57% of range, 16% off the high, 3.5% short, 40.3% implied.

The metric is the payer mix and surgical volume. Consensus Q3 is $6.63, which is below Q2's $7.62, so the Street already embeds a seasonally weaker quarter. The bull case is a guide-cut washout that reaffirms; the bear case is that surgical volumes are the leading edge of consumer affordability stress. The same-day Centene print tells the other side of the exchange story. Call is 9:00 a.m. CT (10:00 ET) per the HCA release.

FCX ($65.37) — volumes are pre-announced; price, costs and Grasberg are the print. Consensus is $0.83 on $7.40B. The October 2 operational update already set the volume frame: copper sales of about 750M lbs (in line with July), gold sales of about 100 koz (below July, with about 60 koz deferred to Q4 on Indonesian timing), unit net cash costs about 5% above the July estimate of $2.00 a pound on lower by-product credits, and a realized copper price above $6.50 a pound. Grasberg mill throughput averaged about 140,000 tons a day, 67% of pre-September-2025 normal. The 80%-of-capacity target for mid-2027 and near-full by year-end 2027 was reaffirmed, and the Eastern Java smelter restarted in late August (FCX, October 2 update). The stock is 64% of range, 19% off the $80.24 high and 70% above the low, 1.8% short, with 51% implied vol.

So there is little surprise left on volumes; what moves the stock is the 2027 ramp language, capex, and whether management talks about demand or inventory at $6.50 copper in a $103-oil, 5%-yield tape. Copper is the metal underneath thread 6, and this is the cleanest read on it. Release is before the open with a 10:00 a.m. ET call.

AMT ($189.27) — the first print after SpaceX, against a weak organic base. Street is $1.63 EPS on $2.76B (workbook; AFFO per share was $2.71 in Q2, so the Street's AFFO number is the one that matters on the day). Q2 total property revenue was +6.3%, organic tenant billings growth only 1.7% (down from 4.7%), cancellations $92M versus $44M, with the company attributing part of that to one-time DISH churn. It raised 2026 property revenue to $10.70B to $10.85B, adjusted EBITDA to $7.24B to $7.31B, and AFFO per share to $11.00 to $11.17, assuming organic tenant billings growth of about 1% for the year. CoreSite data center revenue was +13.4% to $297M, full-year data centers $1.20B to $1.22B (AMT Q2 release). The stock is 69% of range, 7% below the high, 1.8% short, 35.4% implied vol, after a +7% day Friday on the SpaceX cell-site talks.

The stock is now trading a narrative rather than the billings line: organic growth of 1% is the floor the market is stepping over. The bull read is a guide that reflects any satellite-related leasing optionality and churn peaking; the bear read is that SpaceX is a talk rather than a contract, that the stock moved 7% on headlines, and that the carriers that pay the rent (VZ, T, TMUS) fell on the same news. Watch the churn schedule, the organic growth outlook for 2027, and CoreSite leasing, which touches thread 3 for data-center funding. Release is 7:00 a.m. ET, call 8:30 (AMT release via Business Wire).

JCI ($143.96) — a guide stated, a consensus above it. Consensus is $1.58 on $7.04B for the fiscal fourth quarter, against company guidance given in July of about $1.55 and organic sales growth of 9% to 10%; full-year adjusted EPS was raised to about $5.05 (from about $4.85) and organic growth to about 8% (from about 6%) (these figures come from a Nasdaq/RTTNews summary of the Q3 release; I did not retrieve the JCI primary). The workbook full-year number is $5.07. The stock is 68% of range, 10% below the $160.41 high, 1.9% short, 44.1% implied vol. The metric is orders/backlog in data-center cooling and the margin on it; JCI is the building-systems end of thread 2. The street is asking management to beat its own guide while guiding fiscal 2027, and the 44% implied vol is rich for a name the market regards as steady, which prices a real move on the 2027 framework. Call is 8:30 a.m. ET (JCI release).

UPS ($101.10) — the Amazon glide-down is "complete", and the second-half math is the print. Consensus is $1.62 on $22.28B, below Q2's adjusted $1.76 on $22.8B. The July 28 raise set the 2026 frame: revenue about $91.2B, adjusted operating profit about $8.65B, adjusted EPS about $7.22, capex about $3.0B, with first-half adjusted operating profit of $3.42B implying roughly $5.2B in the second half (that last figure is arithmetic on the release). The CEO said the Amazon glide-down and network reconfiguration were completed as designed, with related initiatives concluding by 2027. The workbook full-year EPS of $7.20 sits at the guide. Stock 38% of range, 17% off the high, 3.8% short, 38.7% implied. The metrics are U.S. domestic margin (8.0% adjusted in Q2) and the peak-season language, in a quarter with $103 oil. The date is confirmed on the UPS IR page; call time not stated there.

SHW ($337.06) — cautious guide, price increase in the pocket. Consensus is $3.69 on $6.78B. Q2 adjusted EPS was $3.70 on $6.79B; the company guided Q3 net sales up mid-to-high single digits and full-year adjusted EPS to $11.80 to $12.20 (workbook consensus $12.09). The CEO said customer sentiment and leading indicators "point to continued demand softness in the second half", and an 8% price increase in Paint Stores took effect September 1. Same-store sales in Paint Stores were +4.2% in Q2 on mid-single-digit price and low-single-digit volume (SHW 8-K). The stock is 54% of range, 11% off the high, 2.8% short, 34.8% implied. Raw-material and energy inflation is the squeeze with oil at $103. Release before the open, call at 10:00 a.m. ET.

RCL ($277.20) — a guide that sits below the Street, 22% off its high. Consensus is $6.38 and $5.61B, which is above the top of RCL's own Q3 adjusted EPS guide of $6.26 to $6.36; the company guided Q3 net yields flat and revenue up 8%, with full-year adjusted EPS of $17.73 to $17.87 (workbook $17.83) (RCL Q2 8-K). Management said it remains "booked at record prices" with a modest near-term hit to some itineraries from prolonged geopolitical activity and 2027 pacing "ahead of historical levels". The stock is 41% of range, 22% off the $356.39 high, with 6.2% short interest and 51.4% implied, the highest of the consumer names. With oil at $103 and Iran headlines, fuel and itinerary risk is the bear side; booked-at-record-price is the bull side. The number is Q4 net yield guidance. Call at 10:00 a.m. ET.

PYPL ($56.87) — stabilization has been a guide, not a growth rate. Consensus is $1.31 on $8.71B. Q2 non-GAAP EPS was $1.38 on $8.7B revenue, transaction margin dollars +1% (excluding interest on customer balances +3%), and the company said branded checkout "has further stabilized" without a growth figure. It raised full-year non-GAAP EPS to about $5.38, and guided Q3 non-GAAP EPS down low single digits year over year; Q2 buybacks were about $1.5B (PayPal Q2 8-K). The workbook full-year consensus is $5.39. The stock is 45% of range, 28% off the high, 3.9% short, 45.6% implied. The metric is branded checkout growth and transaction margin, since buybacks are doing a lot of the per-share work. The date (7:00 a.m. ET) rests on an aggregator only (flagged).

SOFI ($14.58) — at the bottom of its range with 17% of the float short. Consensus is $0.17 on $1.26B. Q2 revenue was $1.21B (+40%), adjusted EBITDA $358M, originations a record $14.8B, members 15.8M (+35%). The company raised full-year adjusted net revenue to $4.75B to $4.85B and left EBITDA (about $1.6B) and EPS (about $0.60) unchanged (SoFi Q2 8-K). The stock is at 4% of its range, 55% below the $32.73 high, 5% above the $13.86 low, 16.9% short, 66% implied vol. A company growing 40% and raising revenue guidance while the stock sits at its low is the cleanest case of the "beats get sold" rule so far in this set; the Street wants EPS to move, and holding EPS guidance flat while lifting revenue is what leaves the print exposed. Watch credit and the loan platform business mix. Release 7:00 a.m. ET, call 8:00.

CNC ($70.17) — the HBR floor, near the 52-week high. Consensus is $0.10 on $46.95B. Q2 adjusted EPS was $2.51, consolidated HBR 89.6%, and the full-year adjusted EPS floor is above $4.80 with HBR of 90.5% to 91.3%, implying a higher second-half HBR; revenue guide $193.5B to $197.5B. Marketplace membership has fallen to about 3.49M from 5.86M, and Medicaid HBR was 93.9% (Centene Q2 8-K). The stock has more than doubled off its low (up 122%), sits at 94% of range, 2.4% short, 52.6% implied. With the stock at the top of its range and a $0.10 quarter, the print is about the second-half HBR path. Release 6:00 a.m. ET, call 8:30.

PCAR ($104.66) — the truck-cycle barometer at the bottom quarter of its range. Consensus is $1.60 on $7.54B, against a Q2 print of $1.43 on $7.55B (aggregator). The stock is 24% of range and 25% off the high, with 2.6% short and 33.5% implied; consensus implies a sizable sequential EPS step-up on flat revenue, a margin-recovery assumption that is the bear target. Order intake and tariff-related cost commentary are the numbers. Date and time rest on an aggregator.

The rest, by cluster

Industrial and building products. ECL ($288.53) is 7% off its high with 2.2% short and an EPS consensus of $2.17. ITW ($275.75, cons $2.97) is 9% off the high at 28% implied, the lowest of the industrials. AIT ($317.00, cons $2.89) is 15% off its high and is the distribution read on MRO demand. XYL ($109.59, cons $1.45) is 29% off its high with 5.8% short. LECO ($255.96, cons $2.81) is 17% off the high. AWI ($168.18, cons $2.39, 4% short) is 18% off the high, and PNR ($55.30, cons $1.07) sits at 7% of its range with a 52-week high of $110.90, half the current price, which looks like either a corporate action or a bad range (flagged). HRI ($128.11, cons $2.92, 12.5% short, 71% implied) is the equipment-rental read and the highest implied vol in this cluster.

Power and utilities. HUBB ($448.10, cons $5.75) is 21% off its high with 5.6% short, the one grid-equipment name here and a thread 6 and 2 read; CNP ($41.07, cons $0.50) has 9.4% short against 20.4% implied, near the bottom of the vol range for the session, and CMS ($69.58, cons $1.35) has 6.2% short and is 13% off its high. ITRI ($88.00, cons $1.56) is the smart-meter name with 19.4% short, 63% implied and 38% below its high.

Travel, leisure and autos. HLT ($349.63, cons $2.36) is at 87% of range, 4% off its high, with 2.9% short, the strongest chart among the travel names. TNL ($64.93, cons $2.06, 14.5% short) and JBLU ($2.62, loss of $0.55 expected, 30.1% short, 167.7% implied vol, 2.40 low) are the stressed end, and JBLU is exposed to $103 oil. PII ($54.82, cons $0.59, 14.1% short, 61% implied) is down 30% from its high. ABG ($172.65, cons $6.42, 12.9% short) is 33% off its high with a 6.4x forward multiple, and the same pattern in auto retail appears in EEFT ($65.59, cons $3.69, 15.6% short, 6x forward multiple).

Healthcare, life science and food. IQV ($279.36, cons $3.28) is at 97% of range, within 1% of its high, with 49% implied; it is the CRO read on pharma R&D spend. RGEN ($176.93, cons $0.46, 13.5% short, 61.9% implied) is at 78% of range. SFD ($18.64, cons $0.26, 11.2% short) is 37% off its high and 3% above its low. SMPL ($10.41, cons $0.40, 14.3% short, 87% implied) is 53% off its high.

Software and tech services. CVLT ($169.37, cons $1.24 on $310M) is at 95% of range after a 136% rise off the low, with 9.8% short and 64% implied, and is a direct thread 4 name: a data-protection/security name that has been bid while seat-based software has not. TRU ($81.48, cons $1.21, 6.2% short, 55% implied) is at 73% of range.

Financials, asset managers and crypto. ARCC ($18.65, cons $0.48) is the BDC read on private credit at 33% of range and 22% implied. WSO ($322.98, cons $4.11, 15.5% short) is 30% off its high; IVZ ($28.06, cons $0.74, 5.3% short) is mid-range; AB ($34.93, cons $0.85) is at 10% of range with 20% implied. CBU ($62.42, cons $1.19) has a broken implied-vol field ("++") in the workbook. GLXY ($14.47, 19.2% short, 110.7% implied) is trading at the bottom of its range, slightly below the stated 52-week low of $14.57, and the BTC tape at about $81K frames it. SXC ($10.01, cons $0.11) is 6% off its high, with 5% short, a coke and steel-input read. MRP ($23.86, cons $0.77) is 28% off its high with 6.3% short.

Where the asymmetries sit

Implied vol looks richest relative to the setup in two places. JCI at 44% for a company that has already guided the quarter to about $1.55 prices in a large reaction to the fiscal 2027 framework, and SHW at 35% is not cheap for a company that pre-warned on second-half demand. Thin vol shows in KO (23%), CNP (20%), AB (20%) and ARCC (22%); for KO that is a stock at 91% of range going into a print where the multiple is the exposure and the options market is pricing a roughly 1.5% one-day standard move.

Crowded shorts into prints are concentrated in the small and mid caps: JBLU (30.1%), GLXY (19.2%), ITRI (19.4%), SOFI (16.9%), EEFT (15.6%), WSO (15.5%), TNL (14.5%), SMPL (14.3%), PII (14.1%), RGEN (13.5%), ABG (12.9%), HRI (12.5%). Of those, SOFI and ITRI are the large-float ones, and SOFI is the one where a guide-neutral beat could squeeze a 5%-above-the-low stock.

Names at 52-week extremes are the cleanest tests of the sell-the-beat rule. At or near the high: IQV (97% of range), CVLT (95%), CNC (94%), KO (91%), HLT (87%), SXC (87%). At or near the low: GLXY (below the low), SOFI (4%), SFD (4%), JBLU (5%), PNR (7%), SMPL (8%), AB (10%). The high-of-range group has the most to lose on a decelerating slope; the low-of-range group is where a stable print can work, as long as guidance does not reset.

Guidance-reset candidates are RCL (consensus is above its own Q3 guide, so a result inside the guide range is a miss against the Street), GLW (consensus revenue above the top of the sales guide), HCA (already reset; the question is whether it needs another), and BA (cash). JCI is the opposite: the consensus is above company guidance for the fourth quarter.

Dominoes

Same day, Corning's optical growth rate and capacity commentary is read directly against Wednesday night's hyperscaler capex numbers and against Thursday's memory and server names (thread 1, 2, 5). A Corning that trims or flattens its capacity plan feeds the "peak capex" argument; one that adds capacity with customer prepayments supports the backlog evidence. HCA and CNC together set the read for the managed-care and hospital names later in the week, with the exchange-coverage-loss theme running through both; Centene's marketplace membership drop (5.86M to 3.49M) is the HCA payer-mix cause in reverse. AMT sets the tower group and the carriers (VZ, T, TMUS) after Friday's SpaceX move; CCI reports later. UPS read-through to FedEx and to Amazon's logistics commentary Thursday night; SHW to the housing and DIY complex; FCX and HUBB to the copper and grid-equipment threads that feed Wednesday's GEV/VRT-adjacent prints; JCI to data-center cooling names. PYPL and SOFI are the consumer-credit read ahead of the card names later in the week, and PYPL's branded checkout line feeds the seat-versus-usage debate only loosely. BA's cash line is the first aerospace datapoint ahead of the rest of the sector.

Flagged as unverified

Dates and times confirmed on company or primary pages: KO (IR: before the open, call 8:30 a.m. ET), BA (IR: call 10:30 a.m. ET), SPGI (IR: release about 7:15 a.m. ET, call 8:30), AMT (Business Wire: 7:00 a.m. ET, call 8:30), HCA (call 9:00 a.m. CT), FCX (company October 2 operational update: before the open, call 10:00 a.m. ET), JCI (company release: call 8:30 a.m. ET), SHW (release before the open, call 10:00 a.m. ET), RCL (call 10:00 a.m. ET), SOFI (about 7:00 a.m. ET, call 8:00), CNC (about 6:00 a.m. ET, call 8:30), UPS (IR headline: October 27; time not stated on the page I could read), NVS (events page: October 27; no time stated). No Tier 1 name differs from the Briefing a.m. session.

Not confirmed from a primary source: GLW (Tuesday 10/27, 7:00 a.m. ET rests on Earnings Whispers; Corning's IR event page did not load a Q3 listing), PYPL (7:00 a.m. ET rests on Earnings Whispers; the IR page showed no listing), PCAR (before the open, call 12:00 p.m. ET from a MarketBeat item only). The JCI fiscal-Q4 and full-year guidance and the PCAR Q2 comparison come from Nasdaq/RTTNews and MarketBeat summaries, not the company releases. GLW's prior-quarter guidance and Q2 detail come from a Hudson Labs preview, not the Corning release. SPGI's prior guidance was not retrieved. The long-tail cluster names use workbook stats only; I did not research dates for them, and the web-search budget ran out before I could.

Workbook oddities: CBU implied vol shows "++"; GLXY last ($14.47) is below its stated 52-week low ($14.57), and its full-year EPS of -$0.76 with a "125x" forward P/E is internally inconsistent; PNR's 52-week high of $110.90 is double the current price, which may be a spin-off or range artifact; GLW's 52-week range ($77.39 to $271.78) is very wide and I did not check for a corporate action; SPGI, HCA and other Q consensus EPS figures are Briefing/Schwab and not reconciled to adjusted definitions (AMT consensus EPS $1.63 is not AFFO per share).

Foreign private issuers reporting via 6-K in this session: NVS only. The 8-K watcher will not catch it.

Sources: https://investors.coca-colacompany.com/news-events/press-releases/detail/1168 · https://investors.coca-colacompany.com/news-events/press-releases/detail/1173/the-coca-cola-company-announces-timing-of-third-quarter-2026-earnings-release · https://investors.boeing.com/investors/news/press-release-details/2026/Boeing-to-Release-Third-Quarter-Results-on-October-27/default.aspx · https://boeing.mediaroom.com/2026-07-28-Boeing-Reports-Second-Quarter-Results · https://press.spglobal.com/2026-09-29-S-P-Global-Schedules-Third-Quarter-2026-Earnings-Announcement-and-Conference-Call-for-Tuesday,-October-27,-2026 · https://www.sec.gov/Archives/edgar/data/0001114448/000111444826000012/nvs-20260630-99_1.htm · https://prod1.novartis.com/events/novartis-financial-results-q3-2026.md · https://www.hudson-labs.com/research/corning-q3-2026-earnings-preview-glw-revenue-and-outlook · https://www.earningswhispers.com/stocks/GLW · https://www.sec.gov/Archives/edgar/data/0000860730/000119312526302539/hca-ex99_1.htm · https://investors.fcx.com/investors/news-releases/news-release-details/2026/Freeport-Provides-Third-Quarter-2026-Operational-Update/default.aspx · https://www.businesswire.com/news/home/20260929819201/en/American-Tower-Plans-Third-Quarter-2026-Earnings-Release-and-Conference-Call · https://www.sec.gov/Archives/edgar/data/0001053507/000105350726000131/pressreleaseq22026.htm · https://www.johnsoncontrols.com/media-center/news/press-releases/2026/10/01/johnson-controls-announces-fourth-quarter-2026-earnings-conference-call-webcast · https://www.nasdaq.com/articles/johnson-controls-boosts-fy26-outlook-stock-4-update · https://www.sec.gov/Archives/edgar/data/0001090727/000162828026049912/exhibit991-earningspressre.htm · https://investors.ups.com/news-events/press-releases · https://finviz.com/news/397611/sherwin-williams-to-announce-third-quarter-2026-financial-results-on-october-27-2026 · https://www.sec.gov/Archives/edgar/data/0000089800/000008980026000046/shwearningsrelease2q2026.htm · https://www.sec.gov/Archives/edgar/data/0000884887/000088488726000036/a2026q2earningsrelease.htm · https://finviz.com/news/400667/royal-caribbean-group-to-hold-conference-call-on-third-quarter-2026-earnings · https://www.sec.gov/Archives/edgar/data/0001633917/000163391726000080/pypl2q-26earningsrelease.htm · https://www.earningswhispers.com/stocks/PYPL · https://s27.q4cdn.com/749715820/files/doc_news/SoFi-Schedules-Conference-Call-to-Discuss-Q3-2026-Results-2026.pdf · https://www.sec.gov/Archives/edgar/data/0001818874/000181887426000050/a2026q2earningsrelease.htm · https://finviz.com/news/404279/centene-corporation-to-host-2026-third-quarter-financial-results-earnings-call · https://www.sec.gov/Archives/edgar/data/0001071739/000107173926000154/a20260728ex991pressrelease.htm · https://www.marketbeat.com/instant-alerts/upcoming-paccar-pcar-set-to-post-earnings-on-tuesday-2026-10-20/

Tuesday 10/27 — p.m.: Memory, payments and gas-to-power into the FOMC

The frame

Tuesday after the close is the setup session for a Wednesday that carries the FOMC decision at 1:00 PM CT and the Alphabet/Microsoft/Meta-adjacent prints that night. Fifty-seven names report, but the weight sits in a handful: Visa ($766B), Seagate ($143B), Waste Management, Robinhood, ONEOK, NXP, Baker Hughes and Teradyne, all north of $48B. The tape comes in with the S&P at 7,623.68 after a second straight weekly decline, the 10-year at 5.00%, WTI at $103.27 and Brent at $116.72 on Iran strike-threat headlines. The reaction function for the last four sessions has been unforgiving: beats were sold when the slope decelerated or cash burn rose (BE -11%, FIX -9%, WDC -3%, DECK -5%, AXP -3.7% on a raise with a restructuring charge), and only commodity-levered beats were paid (SLB +7%).

For Carl's threads, this is a memory-and-test night. Seagate is the cleanest read on whether the AI storage cycle is still being priced as scarcity or has tipped toward supply: the stock is $630 against a 52-week high of $1,145 and has lost roughly a third of its value in a month, with MU (~$880) and SNDK (~$1,231, broke its 200-day) as the barometers. Teradyne and NXP add the test-and-analog legs of the semiconductor read, and UCTT is the small-cap equipment tell. On the power thread, EQT, EXE, RRC (gas-to-power) and ONEOK (gathering and NGLs) all report within hours of each other with Henry Hub-linked commentary and, for the producers, any data-center offtake language. FE is the lone regulated utility.

On agents versus seats, Manhattan Associates (supply-chain software, at its 52-week high) and CoStar, plus F5 on the infrastructure-software side, are the live tests. Most of Tier 1 calls land Wednesday morning, ahead of the Fed, so the first trades on the print will be after-hours Tuesday and then re-priced against a 1:00 PM CT policy decision where the debate is hike versus hold. HOOD's $2.2B 0%-coupon financing and OKE's $5B debt-paydown plan touch the funding-strain thread at one remove.

Implied vols tell you what the market thinks of the setup: STX 75%, ENPH 82%, TER 79%, HOOD 75%, UCTT 104%, CSGP 71%, against 25.5% for Visa and 27% for WM. Those are workbook implied vols, not event-only moves.

Tier 1 — after the close

V ($408.12) — Payments toll road at the high into a rates shock. Visa reports fiscal Q4 and full-year FY26 after the close, with the webcast at 2:00 PM PT / 5:00 PM ET (Visa IR: investor.visa.com). The Street has $3.44 EPS on $12.09B revenue. The last print, fiscal Q3, was net revenue of $11.6B (+14%, +13% constant dollar), non-GAAP EPS $3.32 (+11%), payments volume +10% constant dollar and cross-border +13% (+12% ex intra-Europe), per the 8-K. The same 8-K showed GAAP opex up 19% and non-GAAP opex up 17%, faster than the 11% non-GAAP EPS growth, which is the line to watch for margin pressure. Consensus Q4 revenue of $12.09B is about 4% above Q3's level sequentially, so the bar is a continuation of low-teens growth, not an acceleration.

The stock sits at $408.12, 1.6% under its 52-week high of $414.60 and 39% above the low, with 1.2% short interest and a 25.5% implied vol: the market is pricing a quiet print. The one metric that matters is cross-border volume growth, the highest-yield piece of the franchise, with US payments volume read as the consumer-health check given UMich sentiment at 48.0 and 1-year inflation expectations at 4.7%. Both sides are straightforward. The bull read is a company at its high with double-digit revenue growth and a nominal-spend tailwind from inflation. The bear read is that the group has not been rewarded for in-line beats lately, a 27x forward multiple leaves little room for FY27 opex guidance that runs ahead of revenue, and any regulatory headline on interchange or the card-competition proposals is a gap risk the vol does not price. Watch FY27 net revenue growth guidance and the opex growth range.

STX ($630.00) — The memory-cycle barometer, 45% off the high. Seagate reports fiscal Q1 FY27 after the close; call 2:00 PM PT / 5:00 PM ET (Seagate IR: investors.seagate.com). The Street is at $7.40 EPS and $4.14B revenue. Company guidance from the prior quarter was revenue of $4.10B (plus or minus $100M) and non-GAAP EPS of $7.30 (plus or minus $0.20), per the 24/7 Wall St preview summarizing the guide (second-tier; the 8-K is the primary), so consensus sits just above the midpoint on both lines. The last print was $5.71 EPS on $3.629B revenue (+48.5%), a fifth straight beat according to the same source.

The price action is the story. STX has fallen from about $923 on Sept. 23 to $630, roughly 32% in a month, after printing a 52-week high of $1,145. Short interest is only 3.1% and implied vol 74.9%, so the market is pricing a large move without a crowded short to squeeze. The bear catalyst in the tape is the reported Toshiba plan to double AI hard-disk output, which feeds the commoditization thread: if a second supplier adds nearline capacity, the pricing-per-exabyte argument weakens. The bull counter is management's claim that the vast majority of nearline exabytes are allocated into calendar 2028 and the 44TB Mozaic 4 HAMR ramp with the two largest cloud providers, with a target of 50% of HAMR exabytes on Mozaic 4 by the end of calendar 2026. Product transitions carry yield risk. The one number is gross margin against the December-quarter guide, and the phrasing of long-term agreements: how many of the allocated exabytes carry price. Read-through goes to WDC, SNDK and MU.

HOOD ($94.90) — Record quarter comps, prediction-markets and funding in the questions. Robinhood reports Q3 after the close; call 2:00 PM PT / 5:00 PM ET (Robinhood IR press release, Oct. 1). The Street is at $0.55 EPS on $1.43B revenue. Q2 was a record $1.31B in revenue (+32%), EPS of $0.62, adjusted EBITDA of $741M (57% margin), net deposits of $22B and nearly 1 million funded customers added, with the company lowering and tightening 2026 adjusted opex plus stock-based comp to $2.675-$2.775B (MarketBeat call summary; second-tier, check the 8-K). Consensus EPS of $0.55 is below the Q2 actual of $0.62 while revenue is higher, which implies the Street is modeling the expense step-up or lower other income; that gap is the first thing to check.

The stock is at $94.90, 37% under the 52-week high of $150.47, with 5.1% short interest and implied vol of 74.8%. The company said July net deposits were tracking toward about $4B, and that trading volumes in equities, options and event contracts were near Q2 levels, so the Q3 quarter is the test of whether volumes held. Watch prediction-market revenue (about 2 million customers have used the product), crypto transaction revenue given BTC near $81K, net interest income as the Fed stays on hold-or-hike, Gold subscriber count (4.8 million at Q2) and the buyback pace ($664M year to date at Q2). The funding angle: $2.2B of 0%-coupon financing in June adds a dilution overhang that the market has to weigh against the repurchases.

NXPI ($236.40) — Auto and industrial recovery, consensus on the midpoint. NXP reports Q3 after the close with a 4:30 PM ET call (NXP conference-call announcement). The Street has $4.12 EPS on $3.76B. Guidance given with Q2 was revenue of $3.65-$3.85B (midpoint $3.75B), non-GAAP operating margin of 36.0-37.6% and non-GAAP EPS of $3.89-$4.32 (midpoint $4.11), per the Q2 8-K, so consensus sits at the midpoint on revenue and a hair above on EPS. Q2 was $3.50B (+19% year over year, +10% sequentially) with 58.0% non-GAAP gross margin and $3.61 EPS; Industrial & IoT was the fastest grower at $755M (+38%), and Automotive was $1.94B (+12%).

The stock is $236.40, 30% below its $339.95 high, with 3.0% short interest and 58% implied vol. After a Q2 beat the shares fell, so the print has a history of selling good numbers. The metric is the Q4 guide against a consensus that has to be rising sequentially; a flat-to-down Q4 in autos would revive the late-cycle read, while another double-digit industrial/IoT quarter would support the broad analog recovery. Read-through goes to STM, MPWR and the memory/industrial thread.

TER ($307.20) — AI test demand, a record quarter and a 37% drawdown. Teradyne reports Q3 after 4:30 PM ET Tuesday with the call Wednesday at 8:30 AM ET (Teradyne IR, Oct. 15 announcement). Consensus is $2.05 EPS on $1.27B. Q3 guidance was revenue of $1.20-$1.30B and non-GAAP EPS of $1.85-$2.15, so the Street is a touch above the midpoint on both ($1.25B and $2.00). Q2 revenue was $1.329B (+104% year over year) and non-GAAP EPS $2.47, the second consecutive record, with Semiconductor Test at $1.122B and record memory revenue driven by DRAM and a resurgence in NAND final test.

The stock trades at $307.20 against a high of $487.91 (-37%), with 6.4% short interest and 79% implied vol. Notice that the Q3 revenue guide ($1.20-$1.30B) was below the Q2 actual of $1.329B, so sequential decline is already in consensus; the question is the Q4 shape and whether AI compute test demand keeps up while memory test cools or stays elevated. TER is the direct memory-barometer tie-in to Seagate and MU: the Q2 release called out record DRAM test. The call is Wednesday morning, so the first read is the after-hours move and the Q4 guide.

WM ($237.20) — Defensive compounder 4% under its high. Waste Management releases after the close with its call Wednesday at 10 AM ET (WM press release, Sept. 24). Consensus is $2.18 EPS on $6.81B. The stock is $237.20 against a $248.13 high with 1.9% short interest and 27% implied vol. I did not pull the prior-quarter guidance from the 8-K in this pass; the workbook FY EPS of $8.14 gives a forward multiple of 23.1x. The metrics that matter are collection and disposal core price, volume, and the recycling commodity price, plus renewable-gas and service-line margins. On a tape that is selling anything with decelerating slope, a defensive at 23x with 1.9% short has little cushion if collection-and-disposal yield slows. Fuel is a cost headwind with WTI at $103.

OKE ($95.83) — NGL volumes and a leverage story near the high. ONEOK reports after the close; the call is Wednesday at 11 AM ET / 10 AM CT (ONEOK IR). Consensus is $1.50 EPS on $10.39B. The stock is $95.83, 4% under its $99.85 high, with 4.4% short interest and 33% implied vol. The financing item is the $2B tender offer announced Aug. 31 as part of a $5B debt-repayment plan (StreetInsider headline; check the filing). Gas-to-power thread: watch Permian and Rocky Mountain volumes, the pace of Gulf Coast NGL export pull, and capex commentary against a deleveraging story. Oil at $103 helps the commodity-linked parts of the fee-and-spread mix more than the contractual fees.

BKR ($55.61) — Oilfield services plus gas-power turbines, with oil at six-month highs. Baker Hughes releases Tuesday at 5 PM ET / 4 PM CT with the webcast Wednesday at 9:30 AM ET (Baker Hughes IR, Sept. 28 announcement). Consensus is $0.61 EPS on $7.75B. The stock is $55.61 against a range of $44.26-$70.41 (21% under the high), short interest 2.8%, implied vol 43%. SLB's +7% on $103 oil is the setup: Baker's gas-technology and LNG equipment orders feed the power-bottleneck thread. Watch equipment orders and backlog, any data-center-related gas-turbine orders, and the oilfield services margin.

EQT ($55.63) — Gas-to-power producer, seasonally low quarter. EQT reports after the close with the call Wednesday at 10 AM ET (EQT IR announcement). Consensus is $0.36 EPS on $1.79B against full-year EPS of $3.88, so the Street sees a seasonally soft third quarter and a strong fourth; the quarter's realized price and curtailment decisions matter more than the EPS print. The stock is $55.63, 18% under the $68.24 high, with 4.1% short interest and 37% implied vol. The thread read: any new long-term gas supply agreement for power generation or data centers, the Mountain Valley expansion timeline, and the 2027 capex and volume framing. RRC (14.8% short) and EXE report the same night, so the group will trade as a block.

FFIV ($455.42) — Fiscal Q4 and the FY27 guide, at the high. F5 reports fiscal Q4 FY26 after the close, with the webcast at 4:30 PM ET (F5 IR, Oct. 8 announcement). Consensus is $4.26 EPS on $885M; FY27 EPS in the workbook is not shown (the $17.33 figure is the current-year estimate). The stock is $455.42, 6% below its $483.30 high and roughly double the $223.76 low, with 2.9% short interest and a 56.6% implied vol, so the market is expecting a large move for a name that has rallied hard. F5 is a test of the AI-infrastructure-demand narrative applied to networking and security: application delivery and multi-cloud security, plus the systems refresh cycle. The metric is the FY27 revenue and EPS guide against a stock that has already priced a lot of it.

LPLA ($315.61) — Wealth platform 21% under the high. LPL reports after the close with the call at 5:00 PM ET (LPL IR). Consensus is $5.69 EPS on $5.35B. The stock is $315.61 versus a $400.16 high, with 2.5% short and 50% implied vol, a big number for a broker-dealer. The levers are advisory assets and net new assets, the sensitivity to cash sweep rates as the Fed sits at hold-or-hike, and the integration and recruiting pipeline. Equity levels (S&P down two weeks running) feed straight into advisory fees with a one-quarter lag.

ENPH ($31.60) — Solar at the lows, safe-harbor shipments propping the guide. Enphase hosts its call Tuesday at 4:30 PM ET (Enphase IR, Oct. 6 announcement). Consensus is $0.50 EPS on $305M. Q3 guidance was $290-$320M of revenue (midpoint $305M, so consensus is exactly at the midpoint) with non-GAAP gross margin of 44-47% including roughly 2 points of tariff impact and non-GAAP opex of $76-$80M; the guide included about $75M of safe-harbor shipments and 130-150 MWh of IQ Batteries (Q2 8-K). Q2 revenue was $291.9M, down from $363.2M a year ago, with non-GAAP EPS of $0.46 and $84.3M of safe-harbor revenue.

The shares are $31.60, 57% under the $73.74 high and 23% above the $25.78 low, with 25.6% short interest and 82% implied vol, the highest short-and-vol combination on the page. The underlying run-rate revenue ex-safe-harbor is roughly $215-$230M, so the real question is what Q4 looks like once the safe-harbor pull-forward fades. Watch battery attach, the sale price of advanced manufacturing tax credits (93% of face in Q1), European demand and the residential-credit sunset commentary. A crowded short with a heavy implied vol makes this a two-way gap.

CSGP ($33.88) — 57% off the high, the investment-spend debate. CoStar reports after the close; call at 5:00 PM ET (CoStar IR). Consensus is $0.34 EPS on $959M. The stock is $33.88 against a $79.08 high, 3.3% short and 71% implied vol, which is the signature of a name where the market is arguing about the earnings power rather than the quarter. I did not verify the cause of the drawdown in this pass. The questions that usually decide the reaction are Homes.com spend and traffic against the profit path, Apartments.com growth and margin, and the guidance for full-year EBITDA. Forward P/E of 18x on 2026 EPS of $1.36 is where the stock sits relative to its own history.

MANH ($238.19) — Agents versus seats, at the high. Manhattan Associates reports after the close with the call at 4:30 PM ET (MANH IR). Consensus is $1.46 EPS on $297M. The stock is $238.19, 2% under the $242.63 high, 7.1% short interest and 61% implied vol; at 40x forward earnings it is the most expensive of the software names on the card. The agents-versus-seats read is specific: MANH sells supply-chain execution to retailers and logistics, and the cloud transition drives the revenue mix. Watch cloud revenue growth, RPO, full-year guide, and any language on agentic features priced by usage rather than per seat. With 7% short and a stock at the high on a tape that has been selling decelerating beats, the asymmetry runs against a clean in-line print.

LOGI ($109.66) — Supplier incident and tariff refunds in the numbers. Logitech reports fiscal Q2 FY27 at 1:00 PM PT (4:00 PM ET) with the call at 1:30 PM PT (Logitech IR). Consensus is $1.33 EPS on $1.21B. The Q2 outlook given in June was sales of $1,185-$1,220M and non-GAAP operating income of $185-$210M, which included roughly a $20M headwind from a late-June semiconductor-supplier closure; the Q1 release flagged up to $200M of lost sales in the December quarter from the same incident and expected it largely resolved by Q4. Q1 sales were $1.23B (+7%) and non-GAAP operating income $290M, including $61M of tariff refunds. Consensus revenue of $1.21B sits above the guide midpoint ($1.2025B).

The stock is $109.66 vs a $129.66 high, with 8.1% short and 48% implied vol. The metric is the Q3 guide: the supplier outage caps what Q3 can be, so the call is about how much is deferred versus lost. The tariff-refund line is one-time and the release lists the refund treatment as a risk. No memory-cost language appeared in the Q1 release, which matters for a company whose peripherals sit downstream of the DRAM price spike.

ICLR ($185.27) — CRO at a 52-week high, 60% implied. ICON releases after the close with the call Wednesday at 8:00 AM ET (ICON IR). Consensus is $2.63 EPS on $2.01B. The stock is $185.27, 9% under the $203.91 high and nearly triple the $66.57 low; implied vol is 61% and short interest 4.1%. A near-tripling means the print is not about whether the quarter is fine but whether book-to-bill and cancellations are improving, plus the biotech funding backdrop. I did not pull the prior guidance in this pass. ICON is Irish-domiciled; see the 6-K note below.

UHS ($186.89) — Date moved; behavioral-health and acute margins. Universal Health Services moved its release to Tuesday after the close with a call Wednesday at 8:00 AM ET, to avoid conflicts with other healthcare calls (UHS announcement of date and time change; the original date was not stated in what I read). Consensus is $5.15 EPS on $4.71B. The stock is $186.89, 24% under the $246.33 high, with 6.2% short and 40.6% implied vol. At 7.3x forward earnings it is among the cheapest names on the card, which is the market pricing either an earnings reset or a policy risk on Medicaid supplemental payments and behavioral-health reimbursement. Watch admissions and same-facility revenue growth, labor and the guidance range.

PPG ($110.61) — Coatings with a low-growth guide. PPG releases after the close, with the teleconference Wednesday at 8:00 AM ET (PPG IR, Sept. 28). Consensus is $2.12 EPS on $4.28B. Q2 adjusted EPS was $2.23 (flat) on $4,495M of sales (+7%, organic +4%, volume +2%, price +2%). Guidance for Q3 was low-to-mid single-digit organic growth with adjusted EBITDA margin flat to down 100bp, and full-year adjusted EPS of $7.70-$8.10 was reaffirmed (Q2 8-K). Consensus Q3 EPS of $2.12 is under the Q2 figure; the workbook FY EPS of $7.88 is inside the guide, just below the $7.90 midpoint. The stock is $110.61 against a $93.39-$133.43 range, with 3.4% short and 34.7% implied vol. With oil at $103, raw-material and energy cost pass-through is the margin question; a narrowed guide toward the low end would match what the tape has been punishing.

The rest, by cluster

Banks and regionals. UMBF ($135.51) has a $13.27 FY EPS and a 9.6x multiple, 6.1% short. RNST ($41.57) trades 7% under its $44.54 high, FFBC ($32.64) 10% under its $36.25 high, TRMK ($46.31) 5% under, NTB ($59.91) 7% under its $64.17 high at 8.1x, and NBHC ($38.88) has a 56% implied vol, the widest in the group, with a $35.06-$47.28 range. BANC ($17.92) sits 18% under its high. The common questions are net interest margin and deposit costs with the 2-year at 4.69% and the 10-year at 5.00%, and credit-reserve builds on commercial real estate. APAM ($33.57, asset manager) is down 28% from its $46.53 high and carries a 50% implied vol, a read on equity-market-linked fees.

Insurance and reinsurance. ACGL ($101.69) is 5% under its $107.09 high at 9.8x forward earnings; RNR ($352.60) is 3% under its $363.84 high at 8.1x with a Street $10.41 EPS. Both are pricing-cycle and catastrophe-loss reads; I did not pull their prior-quarter commentary.

REITs. VTR ($86.80, 3.7% short) and EXR ($143.41) are the larger ones; ESS ($278.35, 6.3% short) trades 8% under its high, WPC ($63.90) is only 3% above its $62.24 low, STAG ($36.43) is 4% above its $35.14 low, and BXP ($62.10) carries the highest short interest at 10.4%, with HIW ($30.51) at 16.6% short. The office pair (BXP, HIW) is the occupancy and leasing-spread test at a 5.00% 10-year; the workbook EPS figures for REITs are not FFO, which is why forward P/Es in the table look distorted.

Utilities. FE ($46.15), the session's only regulated utility, has 7.3% short interest and a 19% implied vol, the lowest on the card. Rate-base growth, data-center load queue and Pennsylvania transmission capex are the power-bottleneck markers.

Gas, midstream and oilfield. EXE ($93.17) and RRC ($45.52, 14.8% short, 2% under its $48.31 high) join EQT in the gas-to-power group; NOV ($19.76, 13.8% short, 54% implied vol, within 10% of its $21.93 high) and NBR ($81.03, a loss-making driller at -$0.90 EPS, 64% implied vol) read through Baker Hughes on the oil-price move. With WTI at $103, rig-count and day-rate commentary is the swing factor.

Industrials, transport and materials. CR ($182.89) at 25x forward earnings is 20% under its $230.50 high; ZWS ($48.55) is 12% under its $55.00 high; CHE ($512.98, healthcare services) is 8% under its high; LSTR ($165.79) is 27% under its $228.46 high with 6.2% short and a freight-cycle read; WERN ($28.80) is 39% under its $47.49 high with 11% short and a loss-adjacent $0.16 EPS; OI ($6.47) is 62% off its $16.91 high with 14.3% short and 79% implied vol, the glass-container distress read; ST ($40.38) is 25% under its high at 8.8x.

Semicap and technology hardware. UCTT ($44.85) has the widest implied vol on the page at 103.8%, 11% short, and a workbook 52-week range of $21.49-$144.22 that looks implausible for a $2.1B company and is flagged below. Its quarterly guide is the semicap read-through to Teradyne and the memory-capex thread. RBBN ($1.40, 89% implied vol) is a telecom-software micro-cap near its $1.28 low. BBAI ($2.14, 29.5% short, 97% implied vol) is a loss-making AI small-cap at its 52-week low of $2.07.

Business services and software. EXLS ($42.26) is only 4% under its $43.88 high with 8.1% short and 52.6% implied vol; as a business-process and analytics services firm it is the agents-versus-seats-adjacent name of the cluster, though I did not verify its exposure. INTA ($47.99, 62.5% implied vol) sits at its $48.19 high, which has more than doubled from the $19.01 low.

Consumer, restaurants and gaming. CAKE ($107.00) carries the highest short interest on the whole card at 39.3% and sits 10% under its $118.63 high at 22x forward earnings; a restaurant at a high with that short is the squeeze/fade candidate of the session. RUSHA ($44.95, truck dealer) is 19% under its $55.74 high with 11.3% short. CZR ($28.70, 11.8% short) is a negative FY EPS name ($-0.72), within 7% of its $30.88 high; the workbook implied vol shows a "++" placeholder. MIR ($14.81, 22.8% short) is 51% under its $30.28 high with a 65.6% implied vol and sits 5% above its $14.04 low.

Where the asymmetries sit

Seagate is the high-stakes print: a 75% implied vol on a stock that is down roughly 32% in a month with only 3.1% short interest. There is no squeeze fuel, so the move is driven by the guide and the pricing language. Consensus ($7.40) sits above the guided midpoint ($7.30) by 1.4%, and the stock has already de-rated; the asymmetry is that a clean beat with the December guide above consensus can reverse part of the drawdown, while any hint that pricing per exabyte is flattening confirms the Toshiba concern.

Enphase has the most crowded setup: 25.6% short interest, 82% implied vol, and a Q3 guide that leaned on roughly $75M of safe-harbor shipments. Consensus is dead on the guide midpoint, so the stock reacts to Q4. Teradyne and NXP both come in with consensus at or just above the guide midpoint, 79% and 58% implied vol respectively, and with prior-quarter reactions that punished good numbers (NXP fell after its Q2 beat).

Names at 52-week extremes: V (1.6% under the high), MANH (2% under the high), OKE (4% under), WM (4% under), FFIV (6% under), INTA (at the high), EXLS (4% under), STX and CSGP (45% and 57% under). For the at-the-high group, the tape's four-session pattern is to sell beats when the slope decelerates, so FFIV (56.6% implied vol) and MANH (61%) price a larger move than Visa (25.5%) or WM (27%).

Short crowding beyond ENPH: CAKE at 39.3% is the outlier, then BBAI at 29.5%, MIR at 22.8%, HIW at 16.6%, RRC at 14.8%, OI at 14.3% and NOV at 13.8%. Reset candidates are the names with guides that shrink sequentially (LOGI with the supplier incident, ENPH with the safe-harbor fade, PPG with flat-to-down EBITDA margin) and UHS at 7.3x forward earnings.

Dominoes

Same night: STX read-throughs to WDC, SNDK and MU into Wednesday and Thursday's SNDK print; TER and NXPI both feed the memory and analog legs of the thread and then STM and MPWR later in the week; UCTT is the equipment tell. EQT, EXE, RRC and OKE trade together, with Baker Hughes and NOV on the oil side; their commentary on data-center gas demand feeds the power thread and the Thursday and Friday XOM/CVX read. V's payment volumes and HOOD's volume trends are the consumer and retail-participation read going into Wednesday's GDP print.

Wednesday: the FOMC decision at 1:00 PM CT sets the tone for everything that reports Tuesday night; a hike-versus-hold surprise matters most for the rate-sensitive group (LPLA, HOOD, regional banks, REITs). The Wednesday-night names (the Alphabet/Microsoft/Meta-adjacent prints) set the AI-capex-versus-backlog read that STX, TER and FFIV have already tried to price. MANH and CSGP feed the agents-versus-seats thread alongside NOW and PEGA later in the week. LOGI feeds the memory-cost question for consumer hardware, and its Q3 supplier-incident commentary reads through to other fabless names with common suppliers.

Flagged as unverified

All dates and times below were confirmed on company IR pages or the company's own press-release text for the Tier 1 names, and none conflicts with the Briefing session (Tuesday p.m.). Where a call falls on Wednesday morning, the release itself is Tuesday after the close: TER, WM, OKE, BKR, EQT, UHS, ICLR and PPG. No Tier 1 date rests only on an aggregator. UHS changed its schedule (date and time change release) to Tuesday after the close with an 8:00 AM ET Wednesday call; the Briefing session is consistent with that.

Prior-quarter guidance was verified from filings or company releases for NXPI, TER, ENPH, LOGI, PPG and V's last-quarter results. STX guidance comes from a 24/7 Wall St preview, a second-tier source, and should be checked against the fiscal Q4 8-K. Robinhood's Q2 summary comes from a MarketBeat call recap. WM, OKE, BKR, EQT, FFIV, LPLA, CSGP, MANH, ICLR and UHS prior guidance was not pulled in this pass, and the long tail is workbook-only.

Workbook oddities: UCTT's 52-week range of $21.49-$144.22 against a $44.85 price and $2.1B cap looks off. CZR implied vol shows "++". STAG and BBAI forward P/E show 0.0 (not meaningful). REIT forward P/Es (VTR 128x, ESS 44x, HIW 66x, BXP 39x) use GAAP EPS, not FFO. HOOD's consensus EPS ($0.55) is below its Q2 actual ($0.62) on higher revenue. FFIV's FY EPS cell is the current-year estimate, not the FY27 guide.

Foreign private issuers: ICLR (Irish; ICON has historically filed on Form 20-F/6-K, status not verified in this pass, so treat Carl's 8-K watcher as possibly blind to it). LOGI (Swiss), NXPI (Dutch), STX (Irish), ACGL, RNR and NBR (Bermuda) are non-US domiciled; I believe all file 10-K/8-K as domestic filers, but did not check each in this pass.

Sources: https://investor.visa.com/news/news-details/2026/Visa-to-Announce-Fiscal-Fourth-Quarter-and-Full-Year-2026-Financial-Results-on-October-27-2026/default.aspx · https://www.sec.gov/Archives/edgar/data/0001403161/000140316126000103/q32026earningsrelease.htm · https://investors.seagate.com/news/news-details/2026/Seagate-Technology-to-Report-Fiscal-First-Quarter-2027-Financial-Results-on-October-27-2026/default.aspx · https://247wallst.com/investing/2026/10/24/seagates-q1-earnings-dilemma-on-oct-27-blockbuster-ai-data-demand-confronts-rising-oversupply-fears/ · https://www.globenewswire.com/news-release/2026/10/01/3373375/0/en/index.html · https://www.marketbeat.com/instant-alerts/robinhood-markets-q2-earnings-call-highlights-2026-07-29/ · https://finviz.com/news/399191/nxp-semiconductors-announces-conference-call-to-review-third-quarter-2026-financial-results · https://www.sec.gov/Archives/edgar/data/0001413447/000141344726000044/nxp2q26exhibit991.htm · https://investingnews.com/teradyne-to-announce-third-quarter-2026-results/ · https://www.sec.gov/Archives/edgar/data/0000097210/000119312526321933/ter-ex99_1.htm · https://www.businesswire.com/news/home/20260924859097/en/WM-Sets-Date-for-Third-Quarter-2026-Earnings-Conference-Call · https://finviz.com/news/398900/oneok-schedules-third-quarter-2026-conference-call-and-webcast · https://finviz.com/news/395814/baker-hughes-announces-dates-for-third-quarter-earnings-release-and-webcast · https://finviz.com/news/400046/eqt-corporation-schedules-third-quarter-2026-earnings-release-and-conference-call · https://finviz.com/news/400628/f5-to-report-fourth-quarter-and-fiscal-year-2026-financial-results · https://finviz.com/news/399511/lpl-financial-announces-third-quarter-2026-earnings-release-date-and-conference-call · https://finviz.com/news/399170/enphase-energy-announces-conference-call-to-review-third-quarter-2026-financial-results · https://investor.enphase.com/news-releases/news-release-details/enphase-energy-reports-financial-results-second-quarter-2026 · https://finviz.com/news/397994/costar-group-to-report-financial-results-for-third-quarter-on-october-27-2026 · https://finviz.com/news/399827/manhattan-associates-announces-date-for-reporting-third-quarter-2026-financial-results · https://finviz.com/news/399532/logitech-announces-date-for-release-of-second-quarter-financial-results-for-fiscal-year-2027 · https://ir.logitech.com/news/news-details/2026/Logitech-Announces-Q1-Fiscal-Year-2027-Results/default.aspx · https://finviz.com/news/400324/icon-schedules-third-quarter-2026-earnings-conference-call · https://finviz.com/news/400964/universal-health-services-inc-announces-date-and-time-change-for-third-quarter-2026-earnings-release-and-conference-call · https://investingnews.com/ppg-to-announce-third-quarter-2026-results-oct-27/ · https://www.sec.gov/Archives/edgar/data/0000079879/000007987926000246/exhibit99-2q2026earningsre.htm

Wednesday 10/28 — a.m.: FOMC day opens with grid, interconnect and refiners

The frame

Wednesday is the pivot of the heaviest week of Q3 season. The FOMC decision lands at 1:00 PM CT, with the October hike at roughly 5% odds, so the debate is hike versus hold, not cuts. The 10-year is 5.00%, the 2-year 4.69% and the 30-year 5.33%. S&P 500 closed Friday at 7,623.68, down a second straight week, with the 7,600 put wall just below and the 7,650 wall just above. The morning session is 65 names, but the weight sits in a few clusters: power and electrification (GEV, VRT, APH, TEL, FLEX, AEP, NI, OGE), refiners and tankers into $103 WTI and $117 Brent (PSX, DINO, STNG), and a handful of large foreign and financial names (UBS, GSK, AON, ADP). The tape's rule for four sessions has been that beats get sold when the slope decelerates or cash burn rises, and only commodity-levered beats got paid (SLB +7%). Wednesday morning tests both halves of that rule at once: GEV, VRT and APH are the backlog-and-slope names, PSX and DINO are the commodity-levered ones.

The AI-capex threads converge here before the hyperscaler prints after the close (GOOGL, MSFT and META-adjacent names report Wednesday night, AMZN, INTC and SNDK Thursday). GEV, VRT, APH, TEL and FLEX are the supply-side evidence on "peak AI capex" versus backlog: GEV's backlog was $176B at the last print, APH's IT datacom was 43% of sales, and VRT's guide implied 34 to 36% organic growth for the quarter. All three are well below or near the middle of their 52-week ranges (GEV 32% under its high, VRT 49% under, FLEX 54% under). The market is pricing something between a slope problem and a funding problem, not a demand problem. Implied vols reflect it: VRT 69%, GEV 57%, APH 53%, FLEX 92%.

On the macro side, the first Q3 GDP print arrives midweek and the flash PMIs (composite 57.6, manufacturing 56.0) argue against a growth scare, while UMich 1-year inflation expectations of 4.7% and oil at six-month highs argue against a dovish surprise. Today's names that feel that directly are the refiners (crack spreads), ODFL and CHRW (freight, with diesel up), the building-products group (MAS, LII, FELE) and the utilities, which trade as bond proxies against a 5.00% 10-year while also being the grid bottleneck thread.

Search coverage note: Tier 1 company-guidance figures below come from the companies' own releases where cited. The budget for web research ran out before the last six Tier 1 names (AON, GRMN, ODFL, GEHC, OTIS, DINO), so those carry workbook numbers only.

Tier 1 — before the open

GEV ($813.00) — the backlog is the bull case; the question is whether the stock needed more than a raise. The Street has EPS $4.01 on $12.00B revenue, $217B market cap. At the Q2 print (July 22), GE Vernova reported orders of $24.2B, up 88% organically, with backlog at $176B, up $13.0B sequentially. Revenue was $11.1B (12% organic) and diluted EPS $2.47. The full-year guide was raised: revenue $45.5B to $46.5B (from $44.5B to $45.5B), free cash flow $11.5B to $12.5B (from $6.5B to $7.5B), Power organic growth 18 to 20% (from 16 to 18%), Electrification $14.5B to $15.0B including about $3.1B from Prolec GE. Wind is the drag: organic revenue down low double digits and roughly $400M of segment EBITDA losses. The company said it remains on track for 20 GW annualized gas turbine output in Q3 and at least 125 GW of gas equipment under contract by year-end (GEV Q2 8-K).

The stock sits at $813 against a 52-week range of $530 to $1,196, so it is 32% off the high after a guide that nearly doubled the free-cash-flow range. Short interest is only 2.8%, implied vol 57%. The one metric is gas turbine slot reservation and pricing: backlog growth of $13B a quarter is the "peak capex" rebuttal, and the question this quarter is whether the sequential add decelerates from the last two prints. Second is the free-cash-flow raise, which was mostly customer deposits and timing; a deposit-driven number is exactly what a tape that sells cash-burn and slope questions will interrogate. Wind losses and Prolec integration are the bear column. Watch the call for turbine price per kW, slot availability into 2029 and 2030, and any change to the 125 GW year-end contracted target. Read-through: AEP, NI and OGE this morning on the demand side, VRT and ETN-type electrification names on the equipment side.

APH ($73.87) — datacom is nearly half the company and the CommScope bridge is being tested. Consensus is EPS $0.73 on $9.49B revenue, $183B cap. Amphenol's own Q3 guide was sales of $9.3B to $9.4B and adjusted EPS of $1.40 to $1.42; the workbook's $0.73 EPS against a $141 average Q2 buyback price and today's $73.87 share price implies a 2-for-1 split has occurred, so $0.73 is post-split (about $1.46 pre-split, a nickel above the top of guidance). I could not confirm the split from the company in the time available, so treat that as inferred. At the Q2 print (July 29) sales were $8.8B, up 55% reported and 30% organic, adjusted EPS $1.35, orders a record $10.7B for a 1.23 book-to-bill. IT datacom was 43% of sales, up 63% organically, and management guided it up mid-teens sequentially in Q3. CommScope contributed more than $1.2B in Q2 sales, and the 2026 CommScope sales contribution was raised to $4.6B from $4.1B (APH Q2 call summary, second-tier).

The stock is 18% under its $89.93 high with 1.4% short interest and 53% implied vol. The metric that matters is book-to-bill: above 1.2 with record orders is the backlog evidence, and a drop toward 1.0 would read as the slope turning. The bear side is concentration (datacom is the swing factor in a business that was diversified three years ago) and the commoditization thread: copper interconnect and cables are the "standard infrastructure" layer if hyperscalers dual-source aggressively. Watch the mid-teens datacom sequential claim and the Q4 guide against the $9.49B revenue consensus that already sits above the high end of Q3 guidance.

VRT ($194.47) — the cleanest "peak capex" barometer in the morning session. Street EPS $1.82 on $3.76B revenue, $75B cap. Vertiv guided Q3 net sales to $3.65B to $3.85B (34 to 36% organic) and adjusted EPS to $1.77 to $1.83, and full-year to $13.8B to $14.2B in sales (30 to 32% organic), EPS $6.65 to $6.75 and adjusted free cash flow $2.4B to $2.6B (VRT Q2 release). The release did not report orders or backlog, so the backlog and book-to-bill data points will come from the call; the headline numbers are Q2 sales of $3.27B (up 24%, 18% organic) and adjusted EPS $1.52 (up 60%). Consensus sits at the midpoint of the revenue guide and at the top of the EPS range.

The stock is the problem. At $194.47 it is 49% below its $379.94 high with 3.7% short interest and the highest implied vol of the big names at 69%. That is a fundamentals-up, multiple-down setup (forward P/E 33.8), not an estimates-down one, which is what makes it the barometer for the whole thread: either the market is discounting that backlog converts to lower-margin, more commoditized liquid cooling as competition (and hyperscaler in-house designs) arrives, or it is discounting the funding side of the data-center build. The questions for the call are backlog and book-to-bill, gross margin under tariff and mix pressure, and whether the 34 to 36% organic Q3 is the peak growth rate or a plateau. A beat-and-raise that still sells would be the strongest signal of the week that the market is pricing slope, not level.

UBS ($46.37) — capital rules, not the quarter, are the stock. Workbook shows EPS $0.96 (ADR basis) on $10.86B revenue, $142B cap, and 6-K filer, so Carl's EDGAR 8-K watcher will not catch it. UBS reports Q3 on October 28 per German-language press reports of its financial calendar (aggregator-tier; the company calendar at ubs.com/calendar should be checked). At Q2 UBS reported net profit of $2.8B (EPS CHF 0.87), underlying pre-tax profit up 45% to CHF 3.9B, CET1 of 14.4%, a cost/income ratio of 70% and a new CHF 3B buyback through Q2 2027, with at least CHF 1B planned over the following three months, explicitly conditional on keeping CET1 near 14% and on the Swiss parliament's deliberations on foreign-subsidiary capitalization. It raised 2026 wealth-management NII growth to about 10% and flagged about CHF 750M more integration expense in H2 (Q2 call summary, second-tier; UBS Q2 release). The stock is mid-range ($36.30 to $55.98), 0.2% short, 39% implied vol. Watch the buyback pace against the capital-rule timeline and the integration run-rate.

ADP ($304.16) — the labor-market and float-income read, a day before it matters to the Fed. Street EPS $2.77 on $5.47B, $120B cap, fiscal Q1. The company confirmed October 28 for the release (ADP IR). The FY27 outlook issued July 29: revenue up 5% to 6%, adjusted EBIT margin up 70 to 90 bp, adjusted EPS up 9% to 11%, US Employer Services pays per control up only 0% to 1%, client-funds interest of $1.54B to $1.56B on a yield rising to about 3.7% (ADP FQ4 8-K). Fiscal Q4 pays per control was +1% and adjusted EPS $2.64 (+17%). The stock is $304 against a $309.40 high, 2.8% short, 35% implied vol, so the print is priced to confirm. The single metric is pays per control: 0 to 1% growth is the thinnest employment-growth guide in the group and, with a 5.00% 10-year lifting the float yield, the quality of beat will be about float income versus underlying employment. Also a seat-based software angle: ADP is a seat-and-employee-count business, and the agents-versus-seats thread would show up in the pricing and attach commentary.

PSX ($283.18) — the refiner that sets the sector's tone at $103 WTI. Street EPS $11.79 on $43.23B, $113.5B cap, 12.9x forward. Q2 adjusted EPS was $9.41, against $0.49 in Q1 and $2.38 a year ago, on refining pre-tax of $3.09B, a realized margin of $24.08/bbl (from $10.11) and 96% crude utilization. Debt fell $6.6B to $20.6B; Q2 buybacks were $379M. The release has no Q3 guidance (PSX Q2 8-K). The stock is $283, near the $299 high; 1.6% short, 48% implied vol. The tension is that WTI is up 14% month to date, which lifts crude cost, so the question is whether product cracks followed crude or lagged it. A Street number of $11.79 is a further 25% step up from Q2, so the bar is high. Watch the realized margin capture, renewable fuels credit pricing (Renewable Fuels went from a $41M loss to a $544M profit in Q2) and the midstream growth projects. Read-through: DINO this morning, VLO and MPC in coming sessions.

GSK ($50.75) — a 6-K print with an R&D reset behind it. Workbook has EPS $1.33 (per ADS in dollars) on $8.83B revenue (which appears to be sterling, comparable to £8.4B in Q2), 9.8x forward, $102B cap. I could not confirm the Q3 date from GSK's own calendar; the workbook's Wednesday morning placement rests on Briefing.com, and the third-party preview pages do not state a date. At Q2 (July 28), turnover was £8.4B (+5% CER), Specialty Medicines +14%, Vaccines +8%, General Medicines -9%, core EPS 50.5p (+9%). Guidance was reaffirmed with sales and core operating profit growth in the upper half of their ranges and core EPS growth in the lower half, which reflects the Nuvalent acquisition's financing cost. Total EPS fell 69% on a £1.3B camlipixant impairment, and GSK launched an "Accelerate Growth" program for £1.9B of annual savings by 2029 (GSK Q2 6-K). Stock is $50.75 versus $42.89 to $61.70, 0.7% short, 32% implied vol. Watch Exdensur, Blenrep and the Nuvalent-asset launch uptake, Trelegy pricing under the IRA, and whether the guidance bias holds.

AEP ($129.50) — 69 GW of contracted load and a financing bill to match. Street EPS $2.04 on $6.60B, $70.6B cap, 17.7x. Q2 operating EPS was $1.36 (down from $1.43), but 2026 operating EPS guidance was raised to $6.25 to $6.55 from $6.15 to $6.45. AEP added 6 GW of signed load in Q2, mostly in Texas, bringing contracted load through 2030 to 69 GW, against a $78B 2026-2030 capital plan; it completed a $3B marketed equity offering, targets FFO-to-debt of 14 to 15%, and is evaluating a GenCo structure to serve large customers (AEP Q2 8-K; call summary, second-tier). The stock is $129.50 against a high of $140.58, with 5.4% short interest (high for a regulated utility) and 26% implied vol. This is the funding-strain thread applied to the grid: the load is real, but the equity needed to build for it dilutes per-share growth. Watch the contracted-load conversion, any change in the capital plan, and the equity issuance cadence. Read-through to NI and OGE.

BSX ($45.79) — what happened: a franchise slowdown, not a miss. The stock is down 57% from $105.65, at $45.79 with a market cap of $66B, 28.5x forward and 52% implied vol. The sequence: in late May the CEO told a Bernstein conference that Watchman sales were flattening, shares fell roughly 15% in a week, and Wells Fargo downgraded and cut its target (Motley Fool, second-tier). Then at Q2 (adjusted EPS $0.86, organic sales +7%, revenue $5.44B) the full-year organic guide was cut to 5% to 6% (it had been 6.5% to 8% in May) and EPS guided to $3.28 to $3.32. Watchman grew only 4% as new stroke-risk clinical evidence reduced referrals for "soft indications"; full-year Watchman is now flat to low single digits with a mid-to-high single-digit decline in the second half. Electrophysiology grew 9% (US only 3%) as pulsed-field ablation reached 80 to 85% of the US AF market and competitors took share, with global EP guided flat in H2. Management said 2027 EPS growth will be limited and announced a restructuring targeting $500M of run-rate savings by 2029; the Penumbra acquisition is expected to close in H2 (Q2 call summary, second-tier; I did not pull the 8-K).

Workbook oddity: consensus EPS of $0.72 sits below Boston Scientific's own Q3 guide of $0.80 to $0.82, and revenue consensus of $5.05B looks low against a Q3 organic guide of 3% to 5%. Either the Street is sandbagging or the workbook is stale; I have flagged it. With the setup this washed out, the print is about the second-half Watchman decline (does it stay mid-to-high single digits), whether US EP stabilizes, and the cost program. Short interest is 2.9%, so there is no squeeze fuel.

AON ($303.52) — insurance brokerage at the low end of its range. Street EPS $3.30 on $4.08B, $64B cap, 13.8x forward; stock is 21% below its $382 high, 2.0% short, 36% implied vol. Workbook numbers only; I did not pull Aon's Q2 release. The stock-specific question is organic revenue growth in a softening property-casualty pricing cycle against a flat-to-lower rate environment for reinsurance, plus margin delivery from its cost program.

TEL ($208.05) — the memory-adjacent connector name with a clean guide to beat. Street EPS $3.07 on $5.28B, $60B cap. TE guided fiscal Q4 sales to about $5.25B (+11%) and adjusted EPS to about $3.05 (+18%), after a Q3 of $5.16B and $2.94, with record orders of $5.7B (+27%) and digital data networks sales +34%. It agreed to buy Astrodyne TDI for about $1.4B to add power content (TE Q3 release). The stock is $208 versus a $252.56 high, 2.9% short, 44% implied vol. TE has beaten its own guide repeatedly, so the metric is orders and the fiscal 2027 outlook: whether it can hold double-digit growth into next year. First read on FY27.

GRMN ($293.74) — near the high with a 47% implied move. Street EPS $2.38 on $1.98B, $56.6B cap, 24.8x, range $186.67 to $314.28, 2.0% short. Workbook only. The question is whether fitness and auto OEM strength continue and whether tariff costs bite gross margin; at a 7% premium to the range midpoint, guidance is the swing factor.

ODFL ($182.88) — freight in a $103 oil world. Street EPS $1.61 on $1.57B, $38B cap, 27.6x forward, 5.3% short, 42% implied vol, range $126 to $252. Workbook only. The monthly operating statistics are the key input (tons per day, revenue per hundredweight); diesel surcharge helps revenue per hundredweight at the cost of fuel timing, and the stock at 27.6x forward is priced for a freight recovery.

BIIB ($246.01) — guidance is a mess of charges. Street EPS $1.97 on $2.63B, $37B cap, at the top of a $138 to $254 range, 4.5% short, 49% implied vol. Q2 non-GAAP EPS was $3.60 against $5.47 a year earlier and total revenue $2.74B (+3%). Reported FY non-GAAP guidance fell to $12.00 to $13.00, the third change this year (from $15.25 to $16.25 in February), as roughly $3.00 of acquired IPR&D and about $0.85 of Apellis dilution came in, while underlying guidance rose $0.60 to $15.85 to $16.85. The Growth Portfolio of $1.06B exceeded legacy MS ($767M). Products: Skyclarys $168M (+29%), Leqembi $184M in-market (+15%), Spinraza $402M (+2%), Syfovre $162M, Empaveli $46M (Biogen Q2 8-K). Workbook oddity: the consensus $1.97 for the quarter is far below Q2's $3.60, which presumably reflects IPR&D charges in the number; compare on the company's definition.

GEHC ($71.45) — imaging demand and tariff math. Street EPS $1.20 on $5.35B, $32B cap, 16.7x forward, 4.7% short, 42% implied vol, range $58.75 to $89.77. Workbook only. The price is 20% under the high; I did not pull the Q2 guide, so the call to listen for is the full-year EPS range versus consensus $4.92 and any tariff change.

FLEX ($76.30) — highest implied vol in the group, and the SMCI-thread ODM. Street EPS $1.06 on $8.18B (fiscal Q2 FY27), $28B cap, 24.6x forward, 2.4% short, 91.5% implied vol, range $53.07 to $166.86. Flex guided fiscal Q2 revenue to $7.95B to $8.25B (consensus is in the upper half) and adjusted operating income to $535M to $565M, with Cloud and Power Infrastructure growth of 45 to 55%. The FY27 guide: revenue $33.7B to $35.2B, adjusted EPS $4.42 to $4.74, free cash flow conversion cut to about 40% from 60%, partly spin-off costs. The CPI segment (Q1 revenue $2.2B, +35%) is to be spun off in the first calendar quarter of 2027 (call summary, second-tier; I did not locate the 8-K). The setup is that the AI power/cooling segment is the growth story and the other two segments are ordinary EMS; the spin decouples them. Watch CPI guidance, the free-cash-flow conversion and any server-ODM commentary on the SMCI legal overhang.

OTIS ($75.15) — an elevator compounder at a 52-week middle. Street EPS $1.01 on $3.86B, $28.6B cap, 15.5x, 5.2% short, 32.5% implied vol. Workbook only: stock is 20% below its $94.56 high. The call will be about new-equipment weakness (China) versus service growth.

DINO ($121.66) — the other refiner, near its high at a 60% implied vol. Street EPS $7.81 on $8.89B (a note: revenue seems low relative to EPS), $21.6B cap, 15.2x forward, 4.4% short, range $45.71 to $129.37. Workbook only. Three-fold up from the low, the stock is priced for the same $103 WTI crack story as PSX; the implied vol is higher than PSX's 48%.

The rest, by cluster

Utilities and grid. NI ($43.28, 0.23 EPS) is at 22% implied vol, 4.5% short, within 12% of its high. OGE ($48.41, 1.37 EPS) is $10B, 7.1% short, closest to its high of the group ($50.59). Both are grid-demand names read against AEP.

Banks and financials. HOPE ($14.07, 0.29 EPS) is within 4% of its high, 7.8% short. PB ($69.50, 1.61 EPS) is 9.3x forward. EVR ($251.88, 2.48 EPS) is 35% under its high, ahead of the investment-banking read. JLL ($300.30, 6.18 EPS) is real estate services, 10.4x forward, 24% under its high. AON appears in Tier 1.

Healthcare and services. LH ($328.95, 4.64 EPS, $26.7B) is at the top of its range ($341.80). AVTR ($17.29, 0.21) is at the top of its range at $17.45, 7.1% short, with 61% implied vol. SCI is reclassified (see below).

Industrials and building products. FTV ($60.25, 0.70) is 7.8% short. IEX ($229.05, 2.24 EPS) is near its $243.80 high. MAS ($76.01, 1.03) is 4.9% short. LII ($376.01, 7.36) is 9.8% short and 36% under its high, a rate-sensitive HVAC name. FELE ($98.36, 1.40), GNRC ($186.92, 2.43, 70% implied vol, a data-center power name 37% under its high), KEX ($133.15, 1.98), TEX ($51.29, 1.42, 7.1% short), DAN ($26.83, 0.70), DMC ($29.51, 0.46, 8.7% short), HAYW ($12.67, 0.15), CSTM ($23.22, 0.75, 37% below its high), LFUS ($351.39, 4.98, 30% under its high with 59% implied vol), EXTR ($22.39, 0.28, 65% implied vol) and RDWR ($31.10, 0.29, near its high) round out the group. SW ($41.85, 0.57 EPS on $8.28B, 5.7% short) and IP ($33.19, 0.29 EPS on $6.29B, 15.5% short interest, the largest in the packaging group) are the box-demand read.

Services and waste. CLH ($318.76, 3.22, near its $335.94 high, 34.5x forward) is the environmental-services bellwether. CHRW ($141.17, 1.75, 5.3% short, 50% implied vol, 33% under its high) is the freight-brokerage read with ODFL. PAG ($212.33, 3.34, 14.2% short but only 6.6% implied vol, which looks like a data glitch) and GPI ($244.97, 9.50, 17.6% short, 43% under its high) are the auto-retail pair.

Energy and shipping. STNG ($85.92, 2.14 EPS, $256M revenue, near its $90.06 high, 47% implied vol) is a product-tanker name that benefits from the same crude dislocation; it is a foreign private issuer. PUMP ($7.32, -0.01) is at 91% implied vol, 18.6% short, near its low of $6.91,; the pressure-pumping read alongside PTEN tonight.

Consumer, restaurants and retail. EAT ($182.70, 2.44, 18.4% short, 61% implied vol), WING ($119.54, 1.02, 18.5% short, 82% implied vol, 60% below its $302.80 high) and CHEF ($105.50, 0.59, 13.0% short) are the restaurant set with the largest short interest. VFC ($17.06, 0.54, 9.2% short) and ETSY ($86.93, 0.74, 16.7% short, 66% implied vol) are the consumer discretionary read; ULCC ($4.94, -0.06, 40.1% short, 102% implied vol) is the most-shorted name of the entire session. SITE ($103.16, 1.48, 10.0% short, 39% under its high). PSN ($49.04, 0.78, 14.8% short, 44% under its $88.00 high, 66% implied vol) is the government-services name with the second-largest short position in the industrial group.

Small and mid caps, mixed. BLKB ($55.54, 1.33, 11.6% short), OSW ($23.86, 0.30), BLCO ($17.47, 0.22), SCL ($63.91, 0.72), MGPI ($15.60, 0.32, $0.3B cap, 62% implied vol) and JMKE ($16.77, 0.06 EPS on $209M revenue) round out the sub-$6B group. I could not confirm what JMKE is from the workbook alone and have flagged it.

Reclassified from Wednesday TBD. SCI ($83.31, 0.99 EPS, near its $90.99 high) and WHD ($63.15, 0.77, a Cactus Inc. wellhead name) report Wednesday after the close, and PTEN ($11.95, 0.04, 9.6% short, 67% implied vol) very likely does too; they belong in tonight's session. HESM ($30.61, 0.71) and LKFN ($58.39, 1.09, 12.3% short) do not report Wednesday; see below.

Where the asymmetries sit

Implied vol looks rich against the setup in VRT (69%) and FLEX (92%): both have the fundamental guide in hand (VRT's Q3 organic 34 to 36%, FLEX's CPI up 45 to 55%), so the vol is paying for a repeat of the post-guide drift lower rather than for an estimate risk. GEV at 57% implied after a 32% drawdown, a raised guide and 2.8% short interest looks fairly priced; the shorts are not the fuel.

Thin implied vol sits where the beat is already in the stock: ADP ($304.16 versus a $309.40 high, 35% implied) and TEL (44%, three straight guide beats) are priced to confirm; a slow pays-per-control read would move ADP more than the options imply. PAG's reported 6.6% implied vol is clearly a data error against 14.2% short interest.

Crowded shorts into prints: ULCC (40.1%), WING (18.5%), EAT (18.4%), GPI (17.6%), ETSY (16.7%), IP (15.5%), PAG (14.2%), CHEF (13.0%) and LKFN's 12.3% (though it reports Monday). The restaurant and consumer names are where a beat could squeeze, and WING's 82% implied vol is the market saying so.

Names at 52-week extremes: BSX 57% off its high, VRT 49%, WING 60%, FLEX 54%; AVTR, ADP, LH, PSX, DINO and STNG within 5% of their highs. Guidance-reset candidates are BSX (already reset, so the question is whether the H2 Watchman decline holds), BIIB (reported guidance cut on charges against a raised underlying), and GSK (EPS in the lower half on Nuvalent financing). The utility cluster is reset-neutral but financing-heavy: AEP with 5.4% short and OGE with 7.1% short are unusually crowded for regulated names and are positioned against the 5.00% 10-year.

Dominoes

The first read-through is the grid and electrification complex into tonight's hyperscaler capex: GEV, VRT, APH, TEL and FLEX report ahead of the cloud names and set the supply-side tone. If VRT or GEV shows decelerating backlog adds, expect the "peak capex" argument to be priced into MSFT, GOOGL and META names before they print. If they show acceleration and the stocks still sell, the problem is funding, which brings in AEP's $3B equity raise as a model of the financing burden. The same names then pre-position Thursday's INTC, SNDK and AMZN prints and the Micron barometer: APH, TEL and FLEX are all memory-adjacent. In the afternoon, FOMC at 1:00 PM CT is the common factor for the 5.00% 10-year and for the rate-sensitive group (LII, MAS, JLL, utilities).

Refiners: PSX and DINO set the tone for VLO and MPC and for the Friday XOM and CVX prints; STNG gives the shipping side. ADP is the labor-market read the morning of FOMC and a data point for the UMich/inflation debate. BSX is a company-specific read for medtech peers (EP competitors, GEHC on capital equipment at the margin). UBS and GSK are the two big foreign names; neither will be caught by the 8-K watcher.

Flagged as unverified

Foreign private issuers filing via 6-K in this session (Carl's EDGAR 8-K watcher will not catch them): UBS, GSK, AER, STNG, RDWR (the last three from knowledge of their filer status, not checked in this pass). I believe SW, TEL, GRMN, AON and FLEX file 10-Ks as domestic filers, so they are covered. CSTM and BLCO I believe file 10-K but did not check.

Dates: ADP (October 28) is confirmed on its IR PDF. UBS's October 28 date rests on German press reports (second-tier). GSK's Q3 date is unverified; the workbook placement rests on Briefing.com. WHD (Cactus) confirmed Wednesday October 28 after the close, call Thursday 9:00 AM CT (Cactus release). SCI confirmed release Wednesday October 28, call Thursday 8:00 AM CT (SCI release). PTEN's call is Thursday 9:00 AM CT; the release time was not stated, and the company's practice is the prior evening, so Wednesday after the close is inferred. HESM has no company-announced Q3 date that I found; the aggregator estimate is November 2 and last year's call was November 3. LKFN is not Wednesday: an aggregator shows Monday October 26 before the open, consistent with its Monday April 27 and July 27 pattern. Note also that "WHD" is Cactus, not Watts Water (WTS), which reports November 4.

Workbook oddities: APH EPS and price appear post-split (inferred, not confirmed); BSX consensus EPS ($0.72) and revenue ($5.05B) look stale against the company's own Q3 guide; BIIB consensus ($1.97) reflects charge treatment and is not comparable to Q2's $3.60; GSK revenue appears in sterling and EPS in dollars per ADS; PAG 6.6% implied vol looks wrong; DINO revenue of $8.89B looks low against EPS of $7.81; LKFN implied vol is shown as "++". JMKE could not be identified. AON, GRMN, ODFL, GEHC, OTIS, DINO and the long tail are workbook-only; the web-search budget ran out before I could check their last guidance.

Sources: https://www.sec.gov/Archives/edgar/data/0001996810/000199681026000147/gevpressrelease2q26.htm · https://www.sec.gov/Archives/edgar/data/0001674101/000162828026050323/q22026exhibit991vrt07292026.htm · https://www.marketbeat.com/instant-alerts/amphenol-q2-earnings-call-highlights-2026-07-29/ · https://www.ubs.com/global/en/media/display-page-ndp/en-20260729-2q26-quarterly-result.html · https://www.nasdaq.com/articles/ubs-group-q2-earnings-call-highlights · https://s205.q4cdn.com/887941133/files/doc_news/ADP-to-Announce-First-Quarter-Fiscal-2027-Financial-Results-on-October-28-2026-2026.pdf · https://www.sec.gov/Archives/edgar/data/0000008670/000000867026000025/q4fy26exhibit99.htm · https://www.sec.gov/Archives/edgar/data/0001534701/000153470126000030/psx-2026630_ex991.htm · https://www.sec.gov/Archives/edgar/data/0001131399/000165495426006949/a1493o.htm · https://www.sec.gov/Archives/edgar/data/0000004904/000000490426000055/a2q20268kpressreleaseex991.htm · https://www.nasdaq.com/articles/aep-q2-earnings-call-highlights-load-growth-strategy · https://www.nasdaq.com/articles/boston-scientific-q2-earnings-call-highlights · https://www.fool.com/investing/2026/05/29/why-boston-scientific-stock-was-sliding-this-week/ · https://investors.te.com/news-releases/press-release-details/2026/TE-Connectivity-delivers-results-above-guidance-with-14-sales-growth-and-19-EPS-growth-in-third-quarter-of-fiscal-2026 · https://www.sec.gov/Archives/edgar/data/0000875045/000087504526000073/exhibit991-q22026pressrele.htm · https://www.marketbeat.com/instant-alerts/flex-q1-earnings-call-highlights-2026-07-29/ · https://finviz.com/news/402732/cactus-announces-timing-of-third-quarter-2026-earnings-release-and-conference-call · https://finviz.com/news/403155/service-corporation-international-announces-schedule-for-third-quarter-2026-earnings-release-and-conference-call · https://finviz.com/news/400092/patterson-uti-energy-announces-third-quarter-earnings-conference-call-and-webcast · https://finviz.com/news/400083/watts-water-technologies-inc-announces-third-quarter-2026-earnings-release-and-conference-call · https://unusualwhales.com/stock/LKFN/earnings · https://unusualwhales.com/stock/HESM/earnings

Wednesday 10/28 — p.m.: Hyperscaler capex and funding, hours after the Fed

The frame

This is the marquee session of the heaviest week of Q3 season. The FOMC decision lands at 1:00 PM CT, roughly three hours before MSFT and GOOG print, and the debate going in is hike versus hold, not cuts: October hike odds were about 5% at Friday's close, with the 10-year at 5.00%, the 2-year at 4.69% and the 30-year at 5.33%. A hold with hawkish language and a long-duration stock at 25x forward earnings is a different setup from a hold that reads as the end of the discussion. Add WTI at $103 and Brent at $117 on Iran headlines, UMich one-year inflation expectations at 4.7%, and a tape that has sold beats four sessions running when the slope decelerated or cash burn rose. The first Q3 GDP print also lands this week, so growth and inflation inputs will have been refreshed before these companies speak.

Three of Carl's threads converge tonight. First, funding strain: Alphabet reported no buybacks in Q2, raised $49.6B net in a June equity offering and stood up a $40B at-the-market program (8-K Ex. 99.1, July 2026); ServiceNow bought back nothing in Q2 either; Microsoft's capex narrative has moved into leases (a $329B pipeline of leases not yet commenced, per the FY26 Q4 disclosure as summarized by second-tier sources); and Equinix has lifted capex to $5-6B while saying leverage rises by about a turn. Second, "peak AI capex" versus backlog: Microsoft commercial RPO of $678B (84% y/y, about 25% ex-OpenAI), Google Cloud backlog near $514B, KLA saying wafer-fab equipment is supply-constrained rather than demand-constrained, and Sterling's backlog more than doubling. Third, agents versus seats: NOW is the bellwether and prints the same night as Fortinet, the layer agents need.

Underneath is the Anthropic proxy angle. Google TPU demand and Azure Foundry are the two Wednesday-night places where Anthropic-related consumption can leak into disclosure, usually as backlog commentary or capacity-constraint language rather than a named customer. Read the cloud growth rates and the supply-constraint language, not the press release.

Off the hyperscalers, the session is broad: 76 names, 20 in Tier 1, with the memory/semi-equipment cluster (KLAC, FORM, COHU, SIMO, OLED, PI) feeding the Micron barometer, power and gas (AR, AM, NXT, MYRG, STRL) feeding the grid bottleneck, and a consumer/transport slate (CMG, F, FDX, CVNA, EBAY, ORLY, CP, TMUS) that reads the real economy against 4.7% inflation expectations. Dates below are checked against company IR or wire releases where noted; everything else is the Briefing.com session.

Tier 1 — after the close

MSFT ($524.92) — Azure guide of about 45% and a $678B RPO against a flat-sequential revenue guide. The Street has EPS of $4.72 on revenue of $90.75B, against fiscal Q1 guidance of $89.85-90.95B (16-17% growth), so consensus sits near the top of the guided range. Microsoft confirmed the release for after the close Wednesday with a 2:30 PM PT call (Microsoft IR release, via Finviz). At the July report the company guided Azure growth to roughly 45% for fiscal Q1 after 43% in Q4, and guided Intelligent Cloud to about $41.1B, +33%; commercial RPO was $678B (up 84% y/y, about 25% ex-OpenAI), and FY26 revenue from OpenAI arrangements was $24.1B (these figures come from a second-tier summary of the July release; confirm against the 8-K). The stock is at $524.92, 5% under its $553.72 high and 50% above its $349.20 low, after rising roughly 35% from late-July levels near $390. Implied vol is 35.6%, short interest 0.8%, forward P/E 25.1.

The one metric is Azure growth against the 45% guide, with a close second in whether capex per dollar of Azure revenue is stable. Management cut the calendar-2026 capex figure to about $175B from $190B, but attributed it to a shift from finance to operating leases, not less investment, and said FY27 capex rises. That is the funding-strain thread in one line: the spend moves to a place that does not show in purchases of property and equipment. Watch the leases-not-yet-commenced total (was $329.1B), the lease-adjusted capex figure, any new debt, and whether the buyback is described as a priority or a residual. Anthropic proxy: Foundry model-mix and Azure commentary on capacity constraints; the OpenAI concentration in RPO means ex-OpenAI RPO growth near 25% is the number the commoditization debate lives on.

Bull read: Azure at or above 45% with RPO still compounding and capex that stays below cloud revenue growth. Bear read: 45% is the number everyone already owns after a 35% run, gross margin (67.6% last spring, the lowest since 2022) keeps sliding as depreciation climbs, and a hawkish Fed at 5% yields compresses the multiple. Tape reaction function applies: beats have been sold when the slope decelerates.

GOOG ($318.10) / GOOGL — Cloud at +82% with free cash flow negative. GOOGL has no row in the workbook; the stats below are GOOG. Consensus EPS is $2.97 on revenue of $127.83B (about +25% y/y); the Street's EPS excludes equity-investment gains, which inflated Q2 reported EPS to $9.11 (about $6.26 from a $98B net equity gain). The date rests on a third-party educational article (PrimeXBT: after the close Wednesday, call 4:30 PM ET, with some aggregators wrongly showing 10/27); I could not retrieve Alphabet's own date notice, so treat the date as likely but unconfirmed against abc.xyz/investor.

Q2 per the 8-K Ex. 99.1: revenue $119.8B (+24%), Google Cloud $24.8B (+82%, from $13.6B), Cloud operating income $8.8B, consolidated operating margin 34%, capex $44.9B versus $22.4B a year earlier, free cash flow negative $5.9B, zero repurchases versus $13.2B in Q2 2025, and the $49.6B equity offering plus the $40B ATM (none sold as of 6/30). Capex guidance for 2026 has been raised three times, to $195-205B in July from $175-185B in February, with 2027 "significantly" higher and CFO language that free cash flow stays under pressure (second-tier summary). Backlog was about $514B per that summary; the release itself does not mention it. The stock fell 7.1% on the July report and sits at $318.10 today, essentially unchanged since, 21% under the $404.47 high; implied vol is 40.1%, forward P/E 23.4.

The one metric is the Cloud growth rate against the capex step-up, because the whole thread is whether +82% Cloud revenue earns the $200B-plus spend. Both sides are visible: backlog and TPU demand argue capacity is sold before it is built, while negative free cash flow, an ATM and no buyback argue the funding gap is already being paid by shareholders. Watch for any ATM usage in Q3, 2027 capex framing, debt issuance, and Cloud margin (it went from $2.8B to $8.8B of operating income in a year, so any sequential flattening matters). Anthropic proxy: TPU capacity commentary, any multi-year commitments called out in the backlog roll.

NOW ($159.35) — the agents-versus-seats bellwether, with cRPO growth guided to decelerate. Consensus EPS is $1.02 on revenue of $4.09B. ServiceNow's IR confirms after the close Wednesday, with the call at 2 PM PT. Prior guidance from the Q2 8-K: Q3 subscription revenue $3,975-3,980M (+20.5% y/y, 20% constant currency), cRPO growth of 19.5% (20% cc) with a roughly $35M FX headwind, and non-GAAP operating margin of 31%; full-year subscription revenue was raised to $15,760-15,780M (+22.5%), with a 31.5% non-GAAP operating margin and 35% free cash flow margin. Q2 itself was subscription revenue of $3,877M (+24.5%), cRPO of $13.20B (+21%), total RPO of $29.0B, and non-GAAP EPS of $0.90. No shares were repurchased in Q2 (YTD $2.2B).

The stock is at $159.35, 17% under the $192.97 high and nearly twice its $81.24 low, which looks like a split-adjusted history; it was down roughly 38% YTD going into the July print. Implied vol of 66.4% and 2.9% short interest say the options market expects a large move without a crowded short. The metric that matters is cRPO growth versus the guided 19.5%: the guide already embeds deceleration from 21%, so a hold at 20% or better would read as agents adding to rather than substituting for seats, while a print at or under the guide with softer Now Assist commentary feeds the seat-cannibalization argument. Watch pricing language (consumption or agentic SKUs versus per-seat), net-new ACV from AI products, and any agent-partner mention (Anthropic included). Operating margin is the other swing: 31% guided, with GAAP at 8% leaving little cushion if hiring ramps to chase agent demand.

KLAC ($146.19) — the WFE call and the memory barometer. Consensus EPS is $1.18 on revenue of $4.04B, against guidance for the September quarter of EPS $1.06-1.26 and revenue $3.80-4.20B (gross margin 62.5%, with a DRAM-cost headwind of a bit over 100 bps). The date is October 28 after the close per a second-tier summary; I could not retrieve KLA's own IR date notice (ir.kla.com carries the earnings-date release), so the date is likely but unconfirmed. Management's last update, per that summary, lifted the 2026 wafer-fab-equipment view to the low-$150B range, the fourth raise of the year, said demand is not the constraint (long-lead optical components and customer fab space are), and cited backlog around $12.5B. Those figures carry a second-tier caveat, and the same article quotes a share price ($166) and a 52-week high ($214.80) that do not match the workbook ($146.19 and $307.37); I use the workbook.

The stock is down 52% from its high at 1.9% short interest with 65.7% implied vol, so it is priced as a name that has already de-rated. Metric: December-quarter guide against the roughly $4.5B the second-half comment implies, and whether WFE "low-$150B" is raised a fifth time or merely repeated. Read-through to Micron's barometer: DRAM capacity adds are the demand driver for process control; and the memory-cost headwind in KLA's own margin is the mirror image of Micron's pricing strength. Services (about $820M last quarter) is the steadier line.

TMUS ($146.96) — at the 52-week low, the carrier that fell on SpaceX. Consensus EPS is $2.91 on revenue of $23.14B. T-Mobile's release (Business Wire, 9/17) sets the release at about 4:05 PM ET and the call at 4:30 PM ET Wednesday. The price is $146.96 versus a $146.32 low and $224.75 high, 35% off the top, with 3.0% short interest and 41.8% implied vol, which is rich for a defensive. I did not retrieve the Q2 guidance table, so prior guidance is not cited here; the Street has FY EPS at $10.95 and a forward P/E of 17.8.

Friday's tape set the context: towers (CCI +11.7%, AMT +7%) ripped on SpaceX cell-site talks while VZ, T and TMUS fell, which says the market is pricing a satellite-direct-to-device competitor as a threat to carrier pricing power and tower leverage as an owner of the scarce asset. The call is therefore less about the quarter than about postpaid phone net adds, churn, ARPA, the capex and free-cash-flow trajectory, and management's answer on satellite spectrum and any SpaceX relationship. Bull: a defensive at 17.8x and the low is already priced. Bear: a stock at its low into a print means the quarter has to be clean on both adds and pricing, because the market has just been shown a new competitor.

FTNT ($181.01) — the cyber bid, guided conservatively. Consensus EPS is $0.86 on revenue of $2.06B. Fortinet's own notice (GlobeNewswire, 10/2) sets the call at 1:30 PM PT / 4:30 PM ET Wednesday. Q3 guidance from the Q2 8-K: revenue $2.010-2.100B, billings $2.250-2.350B, non-GAAP operating margin 35-37%, EPS $0.83-0.87; full-year revenue $8.020-8.180B (about +19%), billings $9.350-9.550B, EPS $3.41-3.47. Q2 came in at revenue of $2,047.9M (+26%), billings $2,372.1M (+33%), product revenue +52%, non-GAAP operating margin 38% and EPS $0.90.

Consensus sits at the midpoint of a guide that Fortinet has been beating at the high end, so the print is about the raise. The stock is $181.01, 8% below the $197.13 high, with implied vol of 68.5% (high for a $132B name) and 2.1% short interest. The cyber bid (PANW, NET +7% last week) argues the buyers are already in. Watch product revenue growth (+52% looks like a firewall refresh cycle, which is lumpy), billings against the 33% comp, and the operating-margin guide stepping down from 38% to the mid-30s. For the agents thread, the question is whether security spend is following agent deployment or just the existing refresh.

EQIX ($955.03) — record guidance raise, steep capex ramp. The workbook's consensus EPS of $3.96 on revenue of $2.56B is a GAAP figure; an earnings preview cites non-GAAP at $10.51 and AFFO per share consensus differently, so do not compare. Equinix's Q2 8-K: revenue $2.625B (+16%), adjusted EBITDA $1.396B (53% margin), AFFO per share $11.78 (+19%), full-year revenue $10.205-10.285B, adjusted EBITDA $5.21-5.27B, AFFO per share $42.69-43.29, and capex of $5.0-6.0B, with $2.419B of senior notes raised in H1. A second-tier preview adds that the company flagged leverage up roughly a turn, blended cost of capital about 150 bps higher, and a need to double second-half cabinet deliveries and pull over 7,000 cabinets forward from 2027. Date: after the close Wednesday per that preview; not confirmed from Equinix IR.

The stock is $955.03, 15% under the high, below its 200-day, with implied vol of 40.6% and 1.8% short interest. This is the funding-strain thread among the landlords: a data-center REIT raising capex by roughly $1B-plus in a quarter while its cost of capital rises. Metric: cabinet deliveries against the pulled-forward plan, and MRR growth (reported to have moved from 8% to 11% over four quarters). Watch for any xScale joint-venture financing, which is the off-balance-sheet piece of the thread.

AEM ($173.94) — gold at $4,010, a foreign private issuer. Consensus EPS is $2.58 on revenue of $3.51B. Agnico Eagle's own notice (6-K, 9/28) puts the release after trading hours Wednesday 10/28, with the call Thursday 10/29 at 11:00 AM EDT, so the "Wednesday p.m." slot is right but the call and the read-through arrive Thursday morning. AEM files 6-K/40-F, so Carl's EDGAR 8-K watcher will not catch the release. The stock is 32% below its $255.24 high, which is the notable divergence: gold at $4,010 and a 16.8x forward multiple with the equity far under its peak implies the market has been discounting either lower prices or cost inflation. I did not retrieve 2026 production or cost guidance. Metric: all-in sustaining cost against the realized price, and free cash flow and buyback pace. Implied vol 45.6%, short interest 1.3%.

CP ($89.51) — rail near the highs into a soft-tape quarter. Consensus EPS $1.31 on revenue of $4.21B; the stock is $89.51 versus a $96.90 high, forward P/E 20.7, implied vol of only 25.8%, the lowest in Tier 1. Date from the Briefing session; I did not verify on CPKC's IR page and no prior guidance is cited. The cross-border carload mix (autos, grain, intermodal) and the operating ratio are the figures; read-through to FDX, F and tariff-sensitive freight.

ORLY ($90.01) — a steady comp story at a low implied vol. Consensus EPS $0.93 on revenue of $5.01B, forward P/E 23.4, 3.1% short, implied vol 29.3%. The stock sits 12% under its $102.46 high. Date and guidance from the Briefing session only. Comparable-store sales and the DIY versus professional split are the numbers; with consumers at 48.0 sentiment and oil at $103, the commercial mix is the better read on miles driven and fleet maintenance.

FDX ($299.00) — a changed fiscal calendar. Consensus EPS $3.38 on revenue of $22.58B. A calendar aggregator lists the report for after the close 10/28 covering the quarter ending September, so the date appears confirmed by the company, but I could not retrieve FedEx IR to verify. The quarter-end is notable, because FedEx has historically reported on a May fiscal year; I could not confirm how the reporting calendar changed after the Freight separation. The stock is 13% under its $345.37 high at 15.2x forward earnings with 40.9% implied vol. Watch fuel surcharge recovery with Brent at $117, parcel yields, and the tariff-driven import volume story.

CVNA ($57.85) — 12.6% short, 80% implied vol and a stock 41% under its high. Consensus EPS $0.44 on revenue of $7.68B. Carvana's release notice (Finviz, 9/30) lists the call at 5:30 PM ET Wednesday. The stock is only 6% above its $54.46 low, with the highest short interest in Tier 1 and an 80.2% implied vol. Metric: retail units and gross profit per unit, then adjusted EBITDA margin; with auto loan rates tied to a 5.00% 10-year, financing spreads and the securitization market matter. No prior guidance was retrieved. Setup is the tape's cleanest squeeze-or-slip candidate in the session: a clean beat into a 12.6% short is the bull case, and deceleration in units against a high-multiple stock is the bear case.

EBAY ($121.00) — a stock one tick from its 52-week high. Consensus EPS $1.41 on revenue of $3.11B; the stock is within 3% of the $124.59 high, forward P/E 17.1, short interest 3.9%, implied vol 41.9%. Date from the Briefing session only. Metric: gross merchandise volume growth, with the collectibles and refurbished categories, and the take rate. A stock at its high with a 17x multiple has the tape's usual challenge: needs a beat and a raise.

F ($11.58) — tariffs and the BlueOval charge. Consensus EPS $0.40 on revenue of $45.81B. A calendar aggregator lists the report for after the close 10/28; not confirmed from Ford IR. Prior guidance from the Q2 8-K (7/28): adjusted EBIT raised to $10.0-11.0B from $8.5-10.5B, adjusted free cash flow $6.0-7.0B from $5.0-6.0B, capex $9.5-10.5B unchanged, Ford Pro EBIT $7.0-7.5B, Ford Blue $5.0-5.5B, Model e loss of about $4.0B. Q2 adjusted EBIT was $2.5B (5.2% margin) with $4.2B of special items, mostly a non-cash BlueOval SK disposition charge. Tariff recovery is built in (about $500M of 2026 cash from the $1.3B IEEPA reimbursement), but guidance excludes new tariffs announced after July 28. The stock is $11.58, 4% above its $11.11 low and 35% under its high, at 7.3x forward earnings. Metric: guidance versus the raised range, Model e losses, and the warranty line.

CMG ($27.55) — at the 52-week low with a Q4 business update. Consensus EPS $0.29 on revenue of $3.29B. A secondary source puts the release at 4:30 PM ET Wednesday with a Q4 business update on the call; not confirmed from Chipotle IR, and I did not retrieve prior comp guidance. The stock is $27.55 versus a $27.31 low, 34% off the $41.52 high, 3.4% short, 49.6% implied vol, 28.5x forward earnings. Metric: comparable restaurant sales and restaurant-level margin, then what management says about October traffic. A name sitting on its low has little left to lose on a miss and a lot of ground to recover on a clean traffic print.

RJF ($157.70) — capital markets and wealth. Consensus EPS $3.27 on revenue of $4.24B, forward P/E 11.4, 3.9% short, implied vol 32.6%, 14% under its $182.73 high. Date from the Briefing session only. With the 10-year at 5.00%, net interest income and client cash sweep balances are the swing, and investment banking is the read on whether deal timing has slipped given the volatility.

TYL ($390.14) — seat-based public-sector software, 8.8% short. Consensus EPS $3.49 on revenue of $652M, forward P/E 23.7, implied vol 48.1%, 25% below the $517.51 high. Date from the Briefing session only. It is Carl's agents-versus-seats list; the metric is subscription and ARR growth and whether any AI product is being priced separately. Short interest of 8.8% with the stock far off its high is a setup where a steady print can move it.

STRL ($356.72) — data-center construction down 65% from the high. Consensus EPS $6.17 on revenue of $1.19B. Prior guidance from the Q2 8-K (8/3): Q2 revenue $1.17B (+90%), adjusted EPS $5.80, backlog $4.33B (+116%; +50% organic) and combined backlog $5.62B; full-year 2026 revenue $4.00-4.15B, adjusted EPS $19.70-20.30, adjusted EBITDA $891-916M. E-Infrastructure revenue was up 192% on acquisitions. The stock is at $356.72 versus a $1,005.68 high (a 65% drawdown from its peak), with implied vol of 90.6%, the highest in Tier 1, and 4.4% short. This is the "peak AI capex versus backlog" thread in a single chart. Metric: organic E-Infrastructure backlog growth, because acquired backlog flatters the headline. Watch gross margin, any customer concentration language and the guide against the $20 adjusted EPS midpoint. I did not verify the Q3 date with Sterling IR.

ARXS ($51.72) and AMRZ ($39.35). ARXS: consensus EPS $0.29 on revenue of $547M, $22.3B market cap, 39.8x forward earnings, 78.2% implied vol, 6.8% short, 16% under its $61.50 high. I could not identify the company from the workbook alone and did not verify the date; this is a name to watch for a vol-led move. AMRZ (Amrize): consensus EPS $1.00 on revenue of $3.83B, forward P/E 16.9, implied vol 42.8%, 2.0% short, and a stock 40% under its $65.94 high. Cement and aggregates volumes, price realization and the construction backlog are the metrics; read-through to data-center and infrastructure build rates.

The rest, by cluster

Memory, semis and equipment (Micron barometer). FORM ($99.50; IV 89.5%, 5.9% short) is 38% under its $160.27 high; consensus EPS $0.86 on revenue of $271M, and it is the probe-card read on DRAM capacity. COHU ($48.10; IV 97.1%, 22.9% short) has the highest short in the cluster, consensus EPS $0.34 and revenue of $170M, up 128% from its low. SIMO ($188.00; IV 101.9%, the highest in the session) is 47% off its $355 high at EPS $3.33 on $529M; it is a Taiwan-based issuer, so expect a 6-K. OLED ($86.98; IV 60.2%, 10.2% short) has EPS $1.14 on $163M. PI ($167.07; IV 89.3%, 13.0% short) is 32% off its high, with forward P/E 75 on EPS $0.61. PLXS ($216.98; EPS $2.55, revenue $1.36B, 5.0% short) and BHE ($65.81; EPS $0.79, revenue $776M, IV 61%) are the server and EMS tie to the SMCI thread, but only if the call mentions AI rack volume.

Software and internet. TENB ($44.80; 16.7% short, IV 82.6%) is at its 52-week high ($44.72), consensus EPS $0.51 on $272M; a stock at the high with a heavy short and 83% implied vol is the volatility setup of the cluster. QTWO ($69.39; IV 65.4%, 10.8% short) is 9% under its high at EPS $0.70 on $221M. GEN ($24.90; 6.5% short) has EPS $0.72 on $1.34B at 9.3x forward. ALKT ($16.00; 8.9% short) is at EPS $0.20 on $134M. TDOC ($6.35; IV 78.1%, 16.7% short) is losing $0.19 a share on $590M. The seat-based names are the agents-versus-seats read; the stocks have not been getting paid.

Power, gas and grid. AR ($40.16; EPS $0.98, revenue $1.61B) is 12% under its $45.75 high; AM ($20.85; EPS $0.36 on $341M) is 13% under its $23.84 high; both are gas-to-power names, so the metric is realized price and any data-center-linked volume. NXT ($78.35; IV 83.6%, 8.8% short) is 52% under its $163.13 high at EPS $1.10 on $1.06B, the solar-tracker name with the second-highest implied vol in the group. MYRG ($254.49; IV 61%) is 49% under its $503.57 high, EPS $2.98 on $1.15B, and a T&D contractor, so backlog is the grid-bottleneck data point, alongside STRL above. AWK ($142.75) sits within 1% of its $144.14 high with 8.9% short interest, EPS $2.04 on $1.55B.

Aerospace and industrials. HONA ($163.31; $51.8B) reports after the Nasdaq close Wednesday with a call at 5:00 PM EDT (Honeywell Aerospace IR release via Finviz); consensus EPS $1.87 on $4.58B, 45% under its $297.50 high, which makes it a post-spin recent listing, so there is limited history. FLS ($68.20; IV 62%, 7.2% short) has EPS $0.98 on $1.24B; CSL ($345.04; 6.8% short) EPS $5.90 on $1.42B; EPAC ($35.79) EPS $0.52 on $173M; AIN ($62.61) EPS $1.48 on $326M; DAR ($56.24) EPS $1.66 on $1.78B.

Insurance, financials and fintech. EG ($398.60) is within 3% of its $409.82 high, EPS $7.97 on $3.03B; THG ($237.73) is a hair under its $239.91 high, EPS $4.57 on $1.80B; AXS ($102.63; EPS $2.85), EIG ($52.08; at 97% of its high, EPS $0.57), PFS ($23.24; EPS $0.61), WEX ($197.46; 10.7% short, at 97% of its high; EPS $5.66 on $750M) and HLI ($131.31; 36% under its $204.18 high; EPS $1.65 on $632M, the M&A advisory read next to RJF).

REITs and housing. VICI ($23.82; EPS $0.72 on $1.06B), INVH ($27.54; EPS $0.14 on $743M), MAA ($119.78; EPS $0.80 on $558M), EPR ($55.97; 14.2% short; EPS $0.83 on $203M) and FCPT ($22.15; EPS $0.28) are rate-sensitive at a 5.00% 10-year; the sector print is same-store rent and occupancy. Builders: MTH ($64.19; 9.0% short; EPS $1.14 on $1.29B), GRBK ($64.42; 9.4% short; EPS $1.43 on $476M), CCS ($57.92; 9.4% short; EPS $1.22 on $958M); gross margin and order cancellation rates are the numbers, with mortgage rates the obvious headwind.

Consumer, gaming and food. MGM ($28.14; 15.9% short, within 2% of its $27.68 low; EPS $0.08 on $4.21B), CHDN ($83.73; EPS $1.10 on $695M), RSI ($15.90; IV 75.3%, near its $15.51 low; EPS $0.14 on $389M), BOOT ($115.18; IV 62.3%, 10.2% short; EPS $1.63 on $580M), MUSA ($534.63; EPS $8.60 on $6.20B, which will react to gasoline margins with crude at $103), PPC ($28.13; EPS $0.54 on $4.65B), SFM ($66.20; 18.7% short and 38% under its $107.31 high; EPS $1.23 on $2.33B), PBI ($17.35; 16.9% short, forward P/E 7.2; EPS $0.35 on $453M), EFOR ($43.59; IV 79.9%, 10.3% short; EPS $1.04 on $1.01B). SFM at 18.7% short is the consumer name with the most positioning.

Healthcare and biotech. ALGN ($153.95; 6.8% short; EPS $2.77 on $1.00B), EHC ($124.09; within 5% of its high; EPS $1.36 on $1.60B), GKOS ($178.88; within 7% of its high; IV 74.5%, 7.9% short; loss of $0.09 on $168M), CNMD ($49.25; EPS $1.00 on $336M), NEO ($16.59; 13.0% short; EPS $0.06 on $207M), CYH ($2.92; IV 91.1%; loss of $0.32 on $2.80B), VKTX ($24.45; IV 75.1%, 21.4% short, essentially at its $24.36 low; pre-revenue with a loss of $1.06). Others: HAPN ($14.11; IV 78.1%; EPS $0.45 on $273M) which I did not identify beyond the workbook, and CLB ($9.91; 25.4% short, the highest in the session; EPS $0.16 on $132M).

Where the asymmetries sit

Implied vol looks rich where the stock is already deeply de-rated and short interest is heavy: COHU (97% IV, 22.9% short), CLB (25.4% short), VKTX (21.4% short at the low), CVNA (12.6% short, 80% IV), SFM (18.7% short), TENB and TDOC (about 17% each). In those names a clean quarter can squeeze, but the options market is already pricing it.

Implied vol looks thin where the setup has changed the most: TMUS at its 52-week low with 41.8% IV, and CP at 25.8% IV against a competitor-heavy tape. A name at the low into a print is a cleaner binary than the vol suggests. By contrast, MSFT at 35.6% IV and 5% under its high has the market pricing a calm print into a Fed day, which compares with a 6.5% implied move cited going into the July report.

Names at 52-week extremes: TENB (at the high), EBAY (3% under), EG, THG, EIG, WEX and AWK (all within 3%); at or near the low: TMUS, CMG, MGM, VKTX, RSI, CVNA, F. Names at the high while carrying real short interest (TENB, WEX at 10.7%) are the ones where the tape's four-session pattern, selling beats, applies most directly.

Guidance-reset candidates: NOW (cRPO growth is guided down to 19.5% from 21%, so the reset has been announced), KLAC (the next WFE number, after four raises), and EQIX (a record raise plus a capex ramp that needs flawless delivery). The funding-strain names, GOOG and MSFT, are not guidance-reset names so much as financing-disclosure names: the risk is a new equity, debt or lease number rather than a revenue miss.

Dominoes

MSFT and GOOG set the capex number for the rest of the chain: a higher 2027 figure helps KLAC (process control demand), EQIX (colocation and xScale), STRL and MYRG (construction and grid) and the optics and server names that report Thursday; a lower or lease-shifted number would lean on the same set. Cloud growth rates feed AMZN Thursday night, and Azure's 45% versus Google Cloud's trajectory sets the bar for AWS. NOW and FTNT read across to the Thursday software slate and to the cyber bid; TYL and TENB are the seat-based and security read on the same night. KLAC feeds Thursday's SNDK, INTC and TER and Friday's memory reads, and sets the tone for MU as the barometer. TMUS sets the carrier read after Friday's tower move, ahead of the VZ and T numbers already out. CVNA, F and FDX are the consumer and freight read on a 5.00% 10-year, ahead of the first Q3 GDP print and Friday's XOM and CVX prints. AEM's Thursday call is the gold read once the equity reaction to the Fed is known.

Flagged as unverified

Dates confirmed from company or wire releases: MSFT (after close, call 2:30 PM PT, via Finviz relay of Microsoft's notice), NOW (IR, call 2 PM PT), TMUS (Business Wire, 4:05 PM ET release, 4:30 PM call), FTNT (GlobeNewswire, call 4:30 PM ET), AEM (own notice, release 10/28 after hours, call 10/29 11:00 AM ET), HONA (call 5:00 PM EDT), CVNA (5:30 PM ET call, via Finviz relay of the company release). Dates resting on aggregators only: GOOG (PrimeXBT), KLAC, EQIX, FDX (aggregator lists the quarter ending September), F, CMG (secondary source, 4:30 PM ET). Not checked at all, so Briefing session only: CP, ORLY, EBAY, RJF, TYL, STRL, ARXS, AMRZ and the long tail.

Workbook oddities. GOOGL has no row; the GOOG row is used. The KLAC price and 52-week high in the second-tier article ($166.40 and $214.80) differ from the workbook ($146.19 and $307.37). EQIX consensus EPS of $3.96 is not comparable to its AFFO or non-GAAP figures (a preview cites $10.51). NOW's 52-week low of $81.24 looks split-adjusted. GKOS shows a forward P/E of 1,666.7 on negative FY EPS and VKTX and TDOC show negative P/Es; ignore. FDX's reporting calendar after the Freight separation is unconfirmed. ARXS, EFOR and HAPN could not be identified from the workbook and I did not research them. MSFT figures on RPO, capex-in-leases and the Q1 guide come from second-tier summaries of the July release and should be confirmed against the 8-K. The Alphabet 8-K does not mention backlog; the $514B figure is a third-party summary.

Foreign private issuers (6-K, not caught by the 8-K watcher): AEM (confirmed 6-K filer), SIMO (Taiwan-based; likely 6-K). CP and AMRZ file domestic forms to my knowledge but I did not confirm.

Sources: https://finviz.com/news/400058/microsoft-announces-quarterly-earnings-release-date · https://www.sec.gov/Archives/edgar/data/0001652044/000165204426000066/googexhibit991q22026.htm · https://primexbt.com/for-traders/alphabet-earnings-date/ · https://investor.servicenow.com/news/news-details/2026/ServiceNow-to-Announce-Third-Quarter-2026-Financial-Results-on-October-28/default.aspx · https://www.sec.gov/Archives/edgar/data/0001373715/000137371526000072/erq2fy26.htm · https://www.businesswire.com/news/home/20260917015300/en/T-Mobile-to-Host-Q3-2026-Earnings-Call-on-October-28-2026 · https://www.sec.gov/Archives/edgar/data/0001262039/000126203926000018/ftntq2-2026ex991.htm · https://finviz.com/news/398289/fortinet-to-announce-third-quarter-2026-financial-results · https://www.sec.gov/Archives/edgar/data/0001101239/000110123926000145/a991eqix-q226xpr.htm · https://finviz.com/news/405255/equinix-must-prove-its-record-guidance-raise-can-survive-a-steep-capex-ramp · https://finviz.com/news/405234/kla-must-prove-its-fourth-wfe-upgrade-stuck-as-stock-sinks-toward-lows · https://techstock01.substack.com/p/microsoft-cloud-and-ai-revenue-accelerating · https://www.tastylive.com/news-insights/microsoft-earnings-preview-can-azure-justify-a-220-billion-capex-bill- · https://finviz.com/news/395847/agnico-eagle-provides-notice-of-release-of-third-quarter-2026-results-and-conference-call · https://www.sec.gov/Archives/edgar/data/0000002809/000110465926111750/tm2626580d1_ex99-1.htm · https://briefglance.com/companies/chipotle-mexican-grill-inc/pulses/74113 · https://finviz.com/news/397006/carvana-to-report-third-quarter-2026-results-and-host-quarterly-conference-call-on-oct-28 · https://www.sec.gov/Archives/edgar/data/0000037996/000003799626000155/exhibit99tojuly282026for.htm · https://nextearningsdate.com/ford-motor.html · https://therighttrader.com/earnings-calendar/fdx · https://www.sec.gov/Archives/edgar/data/0000874238/000087423826000100/a20260803ex991earningsrele.htm · https://finviz.com/news/396372/honeywell-aerospace-to-release-third-quarter-financial-results-and-hold-its-investor-conference-call-on-wednesday-october-28

Thursday 10/29 — a.m.: GDP, CAT, LLY, MA and a hundred more before the open

The frame

This is the heaviest morning of the heaviest week of Q3 season: 116 names in the Briefing pre-market session, and the first Q3 GDP print lands at 7:30 AM CT, the same minute Caterpillar and Carrier start their calls. It also follows the FOMC decision Wednesday at 1:00 PM CT, with October hike odds near 5% going in. The hike-versus-hold debate, not a cut debate, is the backdrop. With the 10-year at 5.00%, the 2-year at 4.69%, the 30-year at 5.33% and WTI at $103, a hot GDP deflator or a hawkish Wednesday statement lands on a tape that sold beats four sessions running when slope decelerated or cash burn rose (BE -11%, FIX -9%, AXP -3.7% on a raise with a restructuring charge). The S&P closed Friday at 7,623.68 with a 7,600 put wall and 7,650 wall overhead; SPX has not been given a reason to chase.

The cross-section is unusually broad. PWR and EME speak directly to Carl's backlog thread (CAT and TT on the equipment side), DHI leads the housing-at-5% question (BLDR, FOR, PATK, AOS in the cluster), and LLY, MRK, BMY, ALNY and INCY give a full read on pharma. MA and ICE are the toll-road financials. LNG, EPD and CNX are the gas-to-export and gas-to-power leg of the power/grid thread with WTI at six-month highs. STM is the memory/auto-analog barometer on the day Micron's read-through names report. CTSH is the AI-services-versus-seats test.

The skew into the open: 32 of the 116 carry implied vol above 60%, most of them sub-$5B small caps where one number can move the stock 15%. The large caps are mostly bunched near 52-week highs (LLY, MA, MRK, LIN, BUD, BMY, MO, LNG all sit within roughly 8% of the top of their ranges), which is a different setup from last week's prints, where the damage came in names that had run. The names sitting far off their highs (CAT -36%, PWR -31%, EME -32%, ALNY -54%, ARES -33%, STM -46%, HWM -40%) carry the burden of showing that the drawdown was positioning, not fundamentals.

Tier 1 dates and times were checked against company notices; CRH, BUD and ICE could not be confirmed from a primary source and are flagged at the bottom. Nothing found conflicts with the Briefing session.

Tier 1 — before the open

LLY ($1,279.00) — the $1.1T bellwether prints into the highs. Street: $6.67 EPS on $22.62B revenue; FY EPS $34.59, 24.8x forward. Company confirms the release and a 10:00 AM ET call on October 29 (lilly.gcs-web.com). The stock is at 92% of its 52-week range ($809.63-$1,321.21), 3% under the high, with 0.8% short interest and 41.5% implied vol. That combination says the print is being asked to hold a premium, not rescue one. The metric is the incretin franchise: Mounjaro/Zepbound volume versus net price, because the price erosion from direct-to-consumer and employer channels is what bears point to, and the volume ramp (orals, supply expansion) is what bulls point to. A raise built on volume with falling realized price per script would not look as clean as one with stable price. Watch Zepbound vials versus pens mix, the manufacturing capex run-rate, and any commentary on pricing agreements with the government. Read-through: LLY is the largest single weight in healthcare and anything it says about obesity pricing reaches INCY, ALNY and the rest of the pharma group the same morning.

MA ($623.80) — spending data with a 5% 10-year. Street: $5.17 on $9.66B; FY $19.95, 30.7x. Call at 9:00 AM ET (Mastercard IR notice). At 98% of its range ($464.52-$633.29) with 0.7% short and 27.2% implied vol, it is the quietest options book in the session. The one metric is cross-border volume growth and the US payments-volume trend, because the consumer-confidence read from UMich (48.0, 1-year inflation expectations 4.7%) argues against strength while flash services PMI at 57.9 argues for it. A 30x multiple leaves little room for cross-border to decelerate, and AXP's reaction last week shows the tape parsing the quality of a beat, not its size. Watch value-added services growth, rebate/incentive rate (the swing in net revenue), and the Visa read-through on Tuesday.

MRK ($145.32) — Keytruda cliff versus the cheapest multiple in large-cap pharma. Street: $2.09 on $17.35B; FY EPS $2.65 (a low FY number versus the quarterly run-rate implies an acquired-IPR&D charge somewhere in the year; confirm). 9.1x forward is the lowest in the group by a wide margin, 1.1% short, 36.5% implied vol, price at 93% of its $82.01-$156.92 range. Call at 9:00 AM ET (merck.com notice). The metric is Keytruda subcutaneous conversion pace, since the subcutaneous formulation is the mechanism meant to extend franchise life past the loss of exclusivity, followed by Gardasil China and the Winrevair ramp. Bears say a 9x multiple is the market discounting the patent cliff regardless of a good quarter; bulls say a near-doubling off the low is a rerating a clean guide sustains. Watch for how any deal flow shapes the guide (MRK has historically folded acquired-IPR&D into guidance as a line item).

CAT ($686.26) — the AI power-gen story, down 36% from the high. Street: $7.03 on $20.69B; FY $27.33, 24.4x. Release at 5:30 AM CDT, call at 7:30 AM CDT, the same minute as GDP (Caterpillar IR notice, caterpillar.com). Price is 26% of the way up a $521.43-$1,073.46 range, with 1.9% short and 48.9% implied vol, the highest of the large industrials. The market is pricing a stock $387 off its high as though it faced a binary. The thesis that carried it to $1,073 was the Power Generation backlog (reciprocating engines and turbines for data-center behind-the-meter power), the tariff cost headwind is the reason the stock has de-rated. The metric is Energy & Transportation segment margin and backlog; the tariffs line (management has guided a net tariff cost, see the Q2 release) is the second. Bears note the stock fell even as AI-infrastructure language stayed intact, implying lumpy orders or a margin concern; bulls say the 10-year at 5% and its construction and mining drag are already in the multiple. I did not re-pull the Q2 outlook figures; use the IR release for the prior full-year margin range. Read-through: TT, PWR, EME and HWM.

LIN ($508.32) — industrial-gas pricing as the macro tell. Street: $4.52 on $9.16B; FY $17.88, 23.6x. Release by 6:00 AM EDT, call 9:00 AM EDT (Linde notice via placera.se/EQS, Oct 5). At 94% of range ($387.78-$548.20), 1.3% short, 27.4% implied vol. The one metric is price/mix against volume: Linde has been delivering price-led growth with flat to down volumes and an expanding backlog in electronics and clean-energy projects. The quality multiple rests on a beat-and-raise record, with no cushion if volume goes negative against a 56.0 manufacturing PMI. Watch the project backlog (data-center and semiconductor fabs are the AI-adjacent demand), and the Q4 guide against a strengthening dollar.

BUD ($84.13) — a 6-K filer with the stock one step from its high. Street: $1.17 on $16.28B; FY $4.42, 14.5x (workbook revenue and EPS appear to be USD; the company reports in USD). At 98% of range ($59.64-$86.60), 0.7% short, 31.4% implied vol. AB InBev's FY26 guide per the Hudson Labs aggregator is 4-8% organic EBITDA growth with net capex of $3.5-4B and a 26-28% normalized tax rate; I could not locate the company's own page and treat that as second-tier. Q2 context from the same source: revenue $16.34B (+5.6%), EBITDA +5.8%. The metric is revenue per hectoliter against volume, with Brazil and China volumes the swing. The bear case is that a stock at a 52-week high needs the volume line to turn. The bull case is that EBITDA margin expansion and deleveraging are running regardless. This is a 6-K filer, so Carl's EDGAR 8-K watcher will not catch it; the filing is at AB InBev's investor page and the 6-K appears afterwards. The Briefing session was not independently confirmed by an IR notice.

BMY ($61.48) — Q2 raised the guide by $3B of revenue; the print has to hold it. Street: $1.25 on $12.73B; FY $6.57, 9.9x. Call at 8:00 AM ET (BMS notice, news.bms.com). At 78% of range ($42.52-$68.64), 2.2% short, 36.1% implied vol. The Q2 release (SEC 8-K) shows what makes this print unusual: total revenue $13.0B (+6%), non-GAAP EPS $2.04, and the full-year guide raised from $46.0-47.5B to $49.0-50.0B of revenue and from $6.05-6.35 to $6.75-7.00 of non-GAAP EPS, with Eliquis growth lifted from 10-15% to 20-25%. The consensus quarterly EPS of $1.25 sits well below the Q2 $2.04, which tells you either a large acquired-IPR&D charge is in the Street number or the quarter has a seasonal and one-time mix; confirm against the release. The metric is Growth Portfolio: it grew 15% to $7.6B in Q2 and Legacy fell 4% to $5.4B; Opdivo Qvantig (+200%), Camzyos ($416M), Breyanzi ($484M) and Reblozyl ($735M) are the products to track. A Eliquis-driven raise is lower-quality than a Growth Portfolio raise, and that is the bear framing. Watch the Q4 implied revenue and whether Legacy erosion accelerates.

MO ($74.31) — dividend yield stock at its high. Street: $1.51 on $5.31B; FY $5.68, 11.8x. Release about 7:00 AM ET, webcast 9:00 AM ET (Altria notice). At 96% of range ($54.70-$77.06), 2.3% short, 28.3% implied vol. Q2 per the 8-K: adjusted EPS $1.48 (+2.8%), flat net revenue, FY adjusted EPS guide narrowed to $5.61-$5.72 (3.5-5.5% growth off $5.42), capex guide raised to $375-450M for the USSTC consolidation. Domestic cigarette shipments fell 3.2% (about 4.5% adjusted), Marlboro shipments -7.4%, retail share down 1.5 points to 39.5%, discount brands up 67% in shipments. The metric is Marlboro share and the discount-tier shift; if the consumer is under the pressure UMich implies (sentiment 48.0), that line gets worse before it gets better. The upside case is a stock that has a floor from its yield and the range narrowing to the top end. Watch whether the guide is narrowed up again and whether the NJOY/on! volumes show up.

TT ($444.90) — data-center cooling against a 12% drawdown. Street: $4.73 on $6.50B; FY $15.28, 25.2x. Call at 10:00 AM ET (Trane notice, finviz copy of the Business Wire release; release time not stated). At 66% of range ($348.06-$505.87), 1.7% short, 37.4% implied vol. This is the cooling leg of the AI-capex thread, and the backlog evidence matters more than the quarter: the Americas commercial HVAC and the Thermal Management (data-center) bookings. Read CARR (7:30 AM ET) first for the commercial and residential demand picture. Bulls have the data-center cooling secular story; bears say the multiple does not discount peak AI capex flattening chiller orders. Watch book-to-bill, the backlog total and any change in the tariff cost assumption.

ICE ($162.74) — volatility and mortgage data in the same report. Street: $1.97 on $2.74B; FY $8.18, 17.7x. At 92% of range ($121.78-$176.05), 1.4% short, 32.0% implied vol. The date rests on an aggregator (bullstory.io lists October 29 pre-market, EPS estimate about $1.98); ICE's own IR notice did not surface in search, so treat as second-tier. Last year's call was 8:30 AM ET. The metrics are energy and rates futures volume (Brent at $116.72 and a 5% 10-year are positive for ICE's core franchises) and Mortgage Technology revenue, where FICO's pricing freeze (-6.6% AH Friday) is a sidelight. ICE publishes monthly statistics, so the volumes are known; the guidance for Q4 expenses and the mortgage line are the new information.

PWR ($545.00) — the grid backlog thread's anchor. Street: $5.00 on $10.91B; FY $16.75, 33.0x. Release before the open with a 9:00 AM ET call (Quanta notice). Price at 31% below the $788.75 high ($408.36-$788.75), 2.4% short, and 64.0% implied vol, the second-highest among the large caps. Backlog is the number: if it is still growing against a record base, the peak-AI-capex framing is wrong for the power-delivery layer; if growth stalls, the multiple at 33x gets a hard look. The tape punished FIX 9% on a beat last week, and PWR is the same type of company. Bulls have transmission, utility capex (XEL and WEC print this morning) and data-center interconnect; bears have a 33x multiple, with the vol implying a double-digit move either way. Watch backlog growth in Electric Power versus Underground, the margin guide and any customer concentration comment.

HWM ($185.91) — engine castings with a 40% drawdown and a multiple that still says 44x. Street: $1.37 on $2.59B; FY $5.34, 44.1x. Release about 7:00 AM ET, call 10:00 AM ET (Howmet notice). Price is 2% above its 52-week low ($183.52-$310.00), 2.6% short, 51.8% implied vol. That is the stranger setup: a premium-multiple aerospace compounder trading within a dollar or two of its low. The metric is commercial aerospace revenue growth versus the engine-spares story and the pace of Boeing/Airbus build rates; the second is whether the margin expansion that justified 44x is still in the guide. The bulls have a business that beat and raised for years. The bears have a tape that has already marked the multiple down 40% without a thesis change being obvious. Watch the FY guide midpoint and the commentary on titanium and nickel costs, which tie to ATI this morning too.

LNG ($298.67) — at the high, with the Q2 raise a week-old memory. Street: $4.73 on $5.37B; FY $23.13, 13.6x. Release before the open, call 11:00 AM ET / 10:00 AM CT (Cheniere notice). Price $298.67 against a $300.89 high, 2.3% short, 35.9% implied vol. The Q2 8-K raised FY consolidated adjusted EBITDA from $7.25-7.75B to $7.90-8.40B and DCF from $4.75-5.25B to $5.30-5.80B, with production narrowed to 53-54 mtpa; Q2 revenue was $5.73B and the buyback ran about $550M. Corpus Christi Stage 3 is 98.4% complete with Train 7 first LNG imminent, and Sabine Pass expansion FID depends on FERC and DOE approvals. The metric is whether a second raise is delivered: unlike the other names here, a stock at its high with the guide already lifted has the highest bar. Oil at $103 and Brent at $116.72 support the contract-linked international gas price, which is the demand story. Watch SPL expansion FID timing, buyback pace and the 2027 marketing margin. Read-through: EPD, CNX and the Carl power/grid thread (gas demand from power).

CRH ($84.89) — the date is the first question. Street: $2.03 on $11.56B; FY $5.57, 19.3x. Price is 12% of the way up a $78.62-$131.55 range, 35% below the high, with 2.2% short and 42.7% implied vol. The Briefing session is Thursday a.m.; I found no CRH IR notice for Q3 2026 (the Q3 2025 results came after the US close on Wednesday November 5, 2025 with an 8:00 AM EST call on the 6th; the Q2 2026 release was Thursday July 30 before the open with an 8:00 AM EDT call). Treat the date and time as unconfirmed. The Q2 8-K reaffirmed net income of $3.9-4.1B, adjusted EBITDA of $8.1-8.5B and EPS of $5.60-6.05, cut capex to $2.7-2.9B, and paused a new buyback tranche because of the Arcosa agreement. The metric is Americas infrastructure volume and pricing against the weather comp. For the 10-year at 5% and the housing question, CRH plus VMC (also today) is the aggregates read.

STM ($44.09) — memory-barometer neighbour, 6-K filer, 68% implied vol. Street: $0.41 on $3.72B; FY $1.34, 20.4x. Release before European open, call 4:30 AM ET (STMicroelectronics notice via GlobeNewswire, Oct 5). Price is 38% of the way up a $21.11-$81.42 range, 2.4% short. The Q2 6-K guide set Q3 revenue at about +6.7% sequentially (plus or minus 350 bp) from $3,487M, which maps to roughly $3.72B and matches the Street, with gross margin around 37.0% (plus or minus 200 bp). Q2 revenue was +26% y/y, non-GAAP EPS $0.31; the P&D segment lost $99M at the operating line; net capex is at the high end of $2.0-2.2B for cloud optical interconnect; first-half FCF was -$648M after a $895M MEMS acquisition. The metric is Q4 guide and gross margin: the Q3 gross margin guide of 37% against 34.8% in Q2 is the number to be delivered. The bear framing is cash burn with capex stepped up, exactly the combination this tape has sold. This is a 6-K filer and will not appear in the 8-K watcher; the release lands before the US open and the call is at 4:30 AM ET. Read-through: ALGM, ENTG, MBLY in the memory/analog thread.

EME ($647.66) — second backlog name, 32% off the high. Street: $8.35 on $5.19B; FY $33.48, 19.9x. Release before the open, call 10:30 AM EDT (EMCOR notice). Price at 22% of the way up a $564.92-$951.96 range, 1.7% short, 54.0% implied vol. The metric is remaining performance obligations, the cleanest backlog number in the group: an EME RPO print that is still growing in the data-center and high-tech manufacturing segments neutralizes the peak-capex bear case on the contractor layer. The two-sided read is that FIX fell 9% last week on a beat, and EME has the same duration of expectations. Watch margin in Electrical and Mechanical Construction, the RPO split between data-center and other, and the language on labor availability. Pairs with PWR at 9:00 AM ET and TT at 10:00.

ALNY ($224.03) — 54% off the high, with 66% implied vol. Street: $2.25 on $1.43B; FY $8.83, 19.7x. Release before the open, 8:30 AM ET call (Alnylam notice, Business Wire Oct 15). Price is 7% of the way up a $197.81-$485.36 range, 7.7% short. This is the worst drawdown in the Tier 1 list and has a vol to match. The metric is Amvuttra (ATTR-CM) quarterly sales versus the consensus ramp: the whole decline is a debate over the pace and competitive position of the transthyretin franchise. Bulls point to a $1.43B revenue run-rate and a profitability inflection (positive EPS). Bears point to share risk and the 7.7% short interest. Watch the Amvuttra TTR guide, patient-start data, and any change in the guided operating margin.

INCY ($115.00) — a negative EPS quarter by design. Street: -$3.85 on $1.47B; FY $3.10, 14.7x. The loss is not a surprise: the Q2 8-K guided a roughly $1,270M Q3 IPR&D charge for the Vega Therapeutics acquisition (latarcibart), and it hits GAAP and non-GAAP. Release 7:00 AM ET, call 8:00 AM ET (Incyte notice). Price at 65% of range ($84.02-$132.60), 8.4% short, 47.4% implied vol. Q2 guidance raised FY net sales to $5,130-5,260M (from $4,770-4,940M), Opzelura to $1,050-1,100M (from $750-790M), Jakafi unchanged at $3,220-3,270M, and a $246M one-time CMS-settlement benefit inflated Q2 (underlying sales +17%). The metric is Jakafi, growing only 7% in Q2 with the franchise coming into its exclusivity decline later in the decade. The bear case is that a good chunk of the raise is non-recurring. The bull case is the Opzelura run-rate even excluding the benefit ($204M, +24%) and the pipeline. Watch the CMS impact ($40-50M per quarter in 2H), the post-charge opex guide and any further business development.

CTSH ($70.55) — the AI-services-versus-seats test, 7.3% short. Street: $1.46 on $5.65B; FY $5.75, 9.4x. Release before the open, call 8:30 AM ET (Cognizant notice). Price at 66% of range ($37.08-$87.03), implied vol 56.1%, which is high for a services name. The Q2 8-K: revenue $5.48B (+4.5%), adjusted EPS $1.37, adjusted margin 16.0%, FY adjusted EPS guide raised to $5.70-5.82, FY cc revenue growth 4.0-5.5%, but Q2 bookings fell 6% y/y (trailing 12-month +5% to $29.1B). The metric is bookings: it is the leading indicator, and a second quarter of declines would be the data point agents-eat-services bears want. The bulls have 9.4x forward earnings and a raised EPS guide. Watch Financial Services (+12%), the AI deal commentary, pricing on renewals, and the Q4 revenue guide against $1.46 consensus. Read-through: the seat-based thread (NOW, PEGA) from the services side.

ARES ($122.08) — 14.4% short and a private-credit overhang. Street: $1.25 on $1.24B; FY $5.76, 24.0x. Call 9:00 AM ET (time updated October 2 per Ares notice). Price is 31% of the way up a $95.80-$181.19 range, implied vol 50.4%. The short interest is the highest among the Tier 1 financials. The metric is fee-related earnings and management fees together with the fundraising pace for flagship direct-lending and real-asset funds, because the public debate is whether private-credit marks and redemptions at peers (TPG, APG-adjacent, BDC names) are spreading. With the 10-year at 5.00% and loan marks sensitive to base rates, watch the credit-quality commentary, deployment, realized performance income and the dry-powder number. The squeeze case is a 14% short against a clean print. The bear case is the stock already pricing a multi-quarter fee slowdown and 24x not being cheap.

DHI ($147.48) — housing with a 5% 10-year. Street: $3.00 on $9.11B; FY $10.43, 11.9x. Release before the open, call 8:30 AM ET (D.R. Horton notice). Price at 42% of range ($130.40-$170.79), 5.1% short, 42.9% implied vol. The fiscal Q3 8-K: EPS $3.20 (-5%), revenue $9.2B, closings 23,983 (+4%), gross margin 20.7%, orders 23,084 flat, cancellations 20% (from 17%), and incentives expected to stay elevated in Q4; fiscal 2026 guide revenue $32.5-33.0B, closings 83,800-84,300, buyback about $2.5B, operating cash flow at least $3.0B. Q4 implied revenue is $8.8-9.3B against a $9.11B consensus, so the Street sits at the midpoint. This is the fiscal Q4 and the FY27 guide is the event: management said Q4 gross margin guidance would come on the call. The metric is gross margin after incentives, which determines whether the 20.7% holds with mortgage rates anchored by the 10-year at 5%. Watch the cancellation rate, the order trend through October, land spend and the FY27 closings guide. Read-through: BLDR, FOR, PATK and the whole housing cluster.

CARR ($56.24) — first of the HVAC tape at 7:30 AM ET. Street: $0.77 on $6.09B; FY $2.88, 17.0x. Call 7:30 AM ET (Carrier advisory). Price 23% of the way up a $50.24-$76.76 range, 3.2% short, 42.4% implied vol. The metric is Residential HVAC volume and the destocking narrative, with the commercial (data-center chiller and applied) side the offset; it reports before TT, so it gives the first read on both. The two-sided read: a stock 27% off the high has already discounted the residential trough, but with the 10-year at 5.00% and mortgage rates anchoring housing turnover, the volume line is not yet supported. Watch the FY guide range, the Commercial HVAC orders and any change in refrigerant-transition pricing.

The rest, by cluster

Utilities and water. XEL ($78.05, 8.9% short, IV 32.8%) is near its $84.23 high and carries the highest short interest of the group; capital plan and load-growth language is the power/grid read. WEC ($111.09, IV 23.0%) is the quiet one at 93% of range; the data-center load forecast for Wisconsin is the line. IDA ($140.68, 13.8% short, IV 20.9%) has an unusual 13.8% short for a utility and the lowest vol on the page. POR ($44.55, 7.5% short) is hugging its $43.26 low against a $54.62 high; the Oregon data-center load story is the bull argument, regulatory lag the bear. CWT ($48.04, IV 54.6%) is a water utility with an elevated vol for the group; rate case timing drives it.

Energy, midstream and oilfield services. EPD ($37.08, 21.1% IV) is near its $40.17 high with WTI at $103; volume growth and the Permian pipeline in-service dates matter. DTM ($123.91, 8.1% short) is a Haynesville/Appalachia gas pipe tied to power demand. CNX ($36.54, 15.8% short, IV 37.5%) is the gas-to-power leg with the highest short in the cluster; realized price against $103 oil. PBF ($75.83, IV 82.5%, 13.2% short, $25.62-$92.46) is the refiner with the widest range: crack spreads on $116.72 Brent and the runup from $25 are why the vol is high. FTI ($69.89, IV 44.9%) is subsea orders and backlog, with the range of $40-$80.70 showing the run. RES ($6.25, 39.1% short, IV 17.0%) is the most-shorted energy name here and a low-vol one, a lopsided setup for a squeeze or a bust.

Materials, metals and chemicals. TECK ($59.05, 0.0% short, IV 50.5%) is the copper name; as a Canadian issuer it may report under 40-F/6-K, which is flagged below. ATI ($160.00, IV 63.6%, 5.3% short, $90.00-$243.57) is the aerospace materials name 34% off its high, and the HWM read-through. AXTA ($34.14, 10.0x) is near its $38.61 high. VMC ($261.69, 4.7% short, IV 34.6%) is the aggregates read alongside CRH. AVY ($181.83, IV 29.2%) is the labels and packaging name near the upper half of the range. SLGN ($39.30, IV 45.7%, 10.2% short) is metal and plastic packaging, and BC ($65.88, 12.5x, 9.5% short) is the marine and recreation name, 27% off its high.

Housing, building products and construction. BLDR ($56.85, IV 65.7%, 10.2% short, $49.67-$131.50) is 57% off the high, the most distressed housing name in the session and a direct read on DHI. FOR ($26.09, IV 87.0%) is the lot developer with the vol of a small cap. PATK ($68.86, 26.3% short, $63.00-$148.50) is the RV/manufactured-housing components name 54% off its high with the most crowded short here. AOS ($61.65, 12.1% short) is the water heater name; residential replacement demand. FSS ($113.23, IV 49.4%), CSW ($296.50, 42.6x) and TRS ($39.60, 16.1% short) are the small industrial manufacturers. CSW at 42.6x forward is the richest multiple among them.

Defense, aerospace and government services. LHX ($253.32, 2.8% short, IV 34.2%) is 33% off the $379.23 high. TXT ($76.83, 5.5% short) and HII ($274.00, IV 48.7%, $255.36-$460.00) are both well off the highs; HII at 40% below. DRS ($34.51, IV 44.8%, $32.43-$50.59) is near its low. KBR ($39.23, 9.8% short, 8.4x) is government services and engineering. FTAI ($154.38, IV 75.3%, $146.48-$323.51) is 52% off the high with a 75% vol. The common thread is the defense group trading as a drawdown, not a bid; the question is whether budget and procurement timing is the cause.

Industrials, transports and autos. XPO ($183.21, 6.1% short, IV 48.4%) and SAIA ($332.14, IV 59.3%, $249.32-$494.71, 33% off the high) are the LTL read on freight demand. GATX ($165.47, 10.9% short) is railcar leasing. TRN ($25.54, IV 46.7%) is railcar manufacturing near its low. OSK ($131.70, 3.9% short), AGCO ($106.10, IV 53.4%) and WNC ($12.87, IV 80.8%, -$0.46 EPS) are the vehicle and ag equipment names, with CAT as the anchor. BWA ($54.96, 9.5x) and GTX ($21.55, IV 56.6%, $15.54-$36.25) are auto suppliers. LKQ ($17.50, IV 59.1%, at the bottom of a $17.21-$37.13 range, 53% off the high) is the aftermarket parts name sitting on its low. HOG ($28.96, 27.5% short) is up against its $29.27 high with a 27.5% short, the squeeze candidate of the group. SAH ($61.28, 24.4% short, IV 59.0%) and MNRO ($13.23, 44.0% short, IV 82.2%) are the dealer and auto-service names; MNRO has the highest short interest in the entire session. WCC ($318.02, IV 60.1%) is electrical distribution, a data-center beneficiary adjacent to EME and PWR. FCN ($157.24, 18.7% short), GVA ($106.45, 14.2% short, $97.26-$162.08) and APG ($39.45) are services and construction names; GVA and FCN carry large shorts.

Healthcare outside Tier 1. BAX ($25.30, IV 53.2%, 7.4% short) is a turnaround near its $30 high. WST ($392.15, IV 47.5%, 37.0x) is at its $397.16 high, the richest multiple in the sector and the one with the biggest downside from a miss. THC ($268.45, 12.5x, IV 53.5%) is at 97% of range and tied to exchange subsidies and Medicaid policy. INSM ($93.39, -$0.38 EPS, IV 68.1%) is 56% off the high with a revenue of $499M. KYMR ($110.76, 15.3% short, IV 145.9%) is the highest vol on the page, a pre-revenue biotech ($3M revenue) with a binary profile. LGND ($303.53, 16.1% short) is royalty-based at 93% of range. NVCR ($14.68, 13.0% short, IV 70.0%), OMCL ($37.75, IV 67.0%) and MD ($29.29, 8.1% short, IV 63.6%, at its $29.70 high) round out the group. FTRE ($23.96, IV 95.2%, 15.5% short, 6.1x) is the clinical-research (CRO) name pressed against its $24.84 high with a 95% vol. ESTA ($63.80, 16.7% short, IV 81.3%) is the loss-making medtech at -$0.23.

Financials, asset managers and real estate. AMP ($492.19, 10.6x, 4.0% short) and TROW ($104.10, 14.6% short, 10.4x) are the asset managers; TROW's short interest is high for a name at this multiple, and the flow story (net outflows) is the metric. TPG ($44.65, 9.2% short, IV 46.6%, $36.95-$70.38) and PWP ($12.42, 12.7% short, 52% off the high, at a $12.12 low) are alternatives and advisory, with ARES as the anchor. WTW ($325.14, 17.4x, IV 35.0%) is near its $351.51 high on pricing in commercial insurance. CFR ($157.05, IV 28.8%) benefits from the rate level. TW ($122.57, 31.2x) is near its high, a volume read on the market structure. NMRK ($11.52, 5.7x, $11.26-$19.62) sits at its low, commercial brokerage with a 5% 10-year. PGY ($19.00, 15.2% short, IV 86.0%) is the AI-lender with a 5.1x forward multiple; credit quality is the issue. MPT ($2.70, 32.8% short, $2.61-$6.47) is the distressed hospital REIT at its low with the largest REIT short. KIM ($23.62, 6.3% short; the workbook's implied vol shows "++," which is an RTD artifact) is the shopping-center REIT. DFIN ($55.52, IV 60.3%) is at the top of its $36.11-$56.33 range.

Consumer, food, leisure and media. HSY ($170.31, 7.2% short, 29.2x, $156.16-$239.48) is 29% off the high with cocoa still the issue. QSR ($75.34, 6.1% short) is near its high. BG ($103.22, 9.6x, IV 40.5%) is the ag processor and a read on crop prices and biofuel. CROX ($119.15, 14.0% short, IV 63.2%, 8.1x) is the cheapest multiple in the consumer group, with the HEYDUDE drag. NCLH ($15.07, 23.9% short, IV 61.3%, $13.63-$25.13) is the cruise name with the second-highest short in the session and fuel at $103 oil is the exposure. H ($172.58, 35.0% short) has the largest short interest on the page by percentage in a large cap, a likely index/arbitrage artifact to verify. HGV ($35.89, 16.7% short, IV 56.3%), SIRI ($27.55, 18.6% short, 8.9x), UPBD ($17.25, 18.2% short, 3.5x) and LAUR ($38.48, 3.9% short, near its $40.92 high) are the lower-multiple consumer and services names. LTH ($41.93, 8.3% short, IV 55.6%, 20.2x) is the premium fitness operator at 89% of its range. STGW ($8.98, IV 111.3%, at its $9.64 high) is marketing services with the second-highest vol among non-biotechs. NSP ($54.44, 77.8% IV) and TNET ($75.78, at its $76.59 high, 11.7x) are the HR/PEO names, both near highs with an employment read.

Small-cap tech and semiconductors. ENTG ($134.52, IV 83.1%, 7.3% short) is the semi-materials name and the memory-cycle read with STM. ALGM ($31.47, IV 87.4%, 11.6% short, $22.41-$71.77) is analog power, down 56% from the high. MBLY ($6.57, 25.1% short, IV 76.1%, near a $6.40 low) is the ADAS name, the most-shorted semiconductor here and at its low. IDCC ($327.28, 13.3% short, 29.4x) is licensing. BAND ($44.18, IV 128.6%, 15.9% short, $12.50-$79.08) has the second-highest vol on the page; its CPaaS exposure puts it in the seat/usage-pricing thread with TWLO. FVRR ($8.40, IV 69.0%, $8.31-$23.85) sits at its low, down 65%, an agents-versus-marketplace read. XRX ($2.56, 34.2% short, IV 103.6%, -$0.12) is the print-hardware turnaround with the most binary balance-sheet profile. PRLB ($85.61, IV 65.0%, 35.7x) is on-demand manufacturing.

Where the asymmetries sit

Implied vol looks thin against the setup in names whose last two quarters were about guide raises and whose stock is at the high: MA (27.2% IV, 98% of range), LIN (27.4%, 94%) and MO (28.3%, 96%) all price modest moves into prints where the bar is "no deceleration." LNG (35.9%, at the high after a guide raise) belongs here too. With the 10-year at 5.00% and GDP at 7:30 CT, the cost of being wrong on quality multiples is asymmetric to the downside.

Implied vol looks rich against the setup in names that are already drawn down: PWR (64.0%), EME (54.0%), ALNY (66.4%), STM (67.9%) and ARES (50.4%). The market is paying up for a double-digit move in names that fell 30-54%. HWM at 51.8% and 44x forward and within 1.3% of its 52-week low is the one where the multiple and the price disagree with each other.

Crowded shorts into prints: H (35.0%), MNRO (44.0%), RES (39.1%), MPT (32.8%), XRX (34.2%), HOG (27.5%), PATK (26.3%), MBLY (25.1%), NCLH (23.9%), SAH (24.4%). HOG is at its high with a 27.5% short, and MNRO's 44% short against 82% vol is a coin-flip squeeze. ARES (14.4%) and INCY (8.4%) are the Tier 1 shorts to watch.

Guidance-reset candidates: INCY (the FY guide includes a $246M one-time benefit and a $1.27B Q3 charge, so the optics of the print are set), CTSH (bookings -6%), DHI (FY27 guide with cancellations at 20%), STM (Q4 guide and capex) and CAT (stock down 36% with tariffs as a swing factor).

Names at 52-week extremes: at or within 2% of the high: LLY, MA, BUD, LNG, MD, STGW, HOG, TNET, TW, WST. At or within 2% of the low: HWM, MBLY, MPT, POR, PWP, LKQ, FVRR, DRS, NMRK.

Dominoes

Pre-open order: STM (4:30 AM ET) frames the semis; GDP at 7:30 CT / 8:30 ET lands as CARR and CAT calls start; INCY, BMY, DHI, CTSH, ALNY, MO, LIN follow at 8:00-9:00 AM ET; MA, PWR, MRK, ARES at 9:00; TT, HWM, LLY at 10:00; EME at 10:30; LNG at 11:00.

CARR then TT then CAT: three reads on the industrial capex cycle in one morning, with HVAC and data-center cooling as the AI-capex arm. PWR and EME inform the backlog thread and read into the rest of the week's FIX/STRL/MTZ names. LNG, EPD, CNX and the utilities (XEL, WEC, IDA, POR) all feed the power/grid thread; XEL and WEC capital plans are the demand side of PWR's backlog. DHI, BLDR, FOR, PATK and AOS read together on housing at a 5% 10-year. LLY, MRK, BMY, INCY and ALNY read on pharma pricing and Medicare policy. CTSH feeds the AI-versus-seats thread and sets up Thursday night's AMZN/INTC/SNDK read; STM, ENTG and ALGM are the memory-cycle neighbours ahead of the SNDK print after the close. ARES, TPG and TROW feed the private-credit debate. MA and ICE read on volumes into Friday's XOM/CVX/ABBV session.

Flagged as unverified

Dates and times were confirmed from company IR notices for LLY, MA, MRK, CAT, LIN, BMY, MO, TT, PWR, HWM, LNG, STM, EME, ALNY, INCY, CTSH, ARES, DHI and CARR. Not confirmed from a primary source: CRH (no Q3 2026 IR notice found; Q2 2026 reported Thursday July 30 pre-market and Q3 2025 reported after the close on Wednesday November 5, so the Thursday a.m. placement is unconfirmed), BUD (no company date notice surfaced; the AB InBev guide figures here come from an aggregator and are second-tier) and ICE (bullstory.io lists October 29 pre-market; no ICE IR notice found). TT's notice gives the call time but not the release time. LLY's notice gives the call time only. The long tail (the roughly 94 names in the clusters) was not individually date-checked and relies on the workbook only.

Foreign private issuers reporting via 6-K that Carl's EDGAR 8-K watcher will not catch: BUD and STM (both confirmed), and likely TECK and FVRR (not verified; check form type).

Workbook oddities: KIM and PWP show implied vol as "++" (RTD artifact). MRK's FY EPS of $2.65 against a $2.09 quarterly consensus implies a large acquired-IPR&D charge somewhere in the year and should be checked against the release. BMY's quarterly consensus of $1.25 against a Q2 non-GAAP of $2.04 is large and likely reflects an IPR&D charge in the Street figure. INCY's -$3.85 is the Vega Therapeutics IPR&D charge guided in the Q2 8-K, not an error. H shows a 35.0% short interest that looks high for a $16B hotel company. The STM and BUD revenue figures appear to be in USD and consistent with company guidance. CAT, MA and the other large caps showed no obvious data breaks. Tier 1 prior-quarter guidance for CAT, MA, MRK, LIN, TT, PWR, HWM, EME, ALNY and CARR was not re-pulled in this pass; figures cited for those names come from the workbook only.

Sources: https://lilly.gcs-web.com/news-releases/news-release-details/lilly-confirms-date-and-conference-call-third-quarter-2026 · https://www.caterpillar.com/en/news/corporate-press-releases/h/caterpillar-to-announce-3q-2026-financial-results-on-oct-29.html · https://s25.q4cdn.com/479285134/files/doc_news/Mastercard-Incorporated-to-Host-Conference-Call-on-Third-Quarter-2026-Financial-Results-2026.pdf · https://www.merck.com/news/merck-to-hold-third-quarter-2026-sales-and-earnings-conference-call-oct-29/ · https://www.globenewswire.com/news-release/2026/10/05/3374171/0/en/index.html · https://www.sec.gov/Archives/edgar/data/0000932787/000093278726000058/stm-6k_q2x2026.htm · https://www.placera.se/pressmeddelanden/linde-linde-announces-third-quarter-2026-earnings-and-conference-call-schedule-20261005 · https://news.bms.com/news/details/2026/Bristol-Myers-Squibb-to-Report-Results-for-Third-Quarter-2026-on-October-29-2026/default.aspx · https://www.sec.gov/Archives/edgar/data/0000014272/000001427226000018/a2026q2ex991-filing.htm · https://www.sec.gov/Archives/edgar/data/0000764180/000076418026000093/exhibit991erq22026.htm · https://finviz.com/news/403181/altria-to-host-webcast-of-2026-third-quarter-and-nine-months-results · https://finviz.com/news/400175/trane-technologies-schedules-third-quarter-2026-earnings-conference-call · https://finviz.com/news/401544/quanta-services-announces-third-quarter-2026-earnings-release-webcast-schedule · https://finviz.com/news/397643/howmet-aerospace-to-host-webcast-and-announce-third-quarter-2026-results · https://finviz.com/news/397743/cheniere-announces-timing-of-third-quarter-2026-earnings-release-and-conference-call · https://www.sec.gov/Archives/edgar/data/0000003570/000000357026000030/cei20262ndqtrerex991.htm · https://www.sec.gov/Archives/edgar/data/0000849395/000162828026050752/q2resultsannouncement2026.htm · https://www.crh.com/wp-content/uploads/2026/07/CRH-Confirms-Date-for-Q2-2026-Results.pdf · https://finviz.com/news/403148/emcor-group-inc-sets-third-quarter-2026-earnings-release-date-and-webcast · https://finviz.com/news/402960/alnylam-to-webcast-conference-call-discussing-third-quarter-2026-financial-results · https://finviz.com/news/400338/incyte-to-report-third-quarter-financial-results · https://www.sec.gov/Archives/edgar/data/0000879169/000087916926000053/incy-q22026xexx991.htm · https://finviz.com/news/398222/cognizant-schedules-third-quarter-2026-earnings-release-and-conference-call · https://www.sec.gov/Archives/edgar/data/0001058290/000105829026000030/exhibit9916302026.htm · https://finviz.com/news/398403/ares-management-corporation-updates-the-time-of-its-earnings-conference-call-for-the-third-quarter-ending-september-30-2026 · https://finviz.com/news/391025/dr-horton-inc-to-release-2026-fourth-quarter-and-fiscal-year-end-earnings-on-october-29-2026 · https://www.sec.gov/Archives/edgar/data/0000882184/000088218426000092/a6302026exhibit991.htm · https://finviz.com/news/400650/carrier-third-quarter-2026-earnings-advisory · https://bullstory.io/en/stocks/ice/earnings/2026-q3 · https://www.hudson-labs.com/research/anheuser-busch-inbev-q3-2026-earnings-preview-abi-results-preview

Thursday 10/29 — p.m.: AMZN, INTC and SNDK carry the AI-capex tape

The frame

Thursday night is where the week's AI-infrastructure question gets its second and third answers. Wednesday night brings the GOOGL/MSFT/META-adjacent capex numbers, and the FOMC decision lands at 1:00 PM CT that day with the first Q3 GDP print also midweek. By Thursday's close the market will know whether the hyperscaler guides are still stepping up. AMZN (5:00 PM ET per Amazon's own IR notice), INTC (release after the close, call 2:00 PM PT per Intel IR) and SNDK (call 1:30 PM PT per Sandisk IR) then show what that spend turns into on the supply side: cloud revenue and capital intensity, foundry and server CPU, and NAND pricing. Seventy-three names are on the Briefing p.m. list, and fifteen more were unplaced (TBD); the calendar check on those is at the end of the cluster section, and only a few turn out to belong here.

The tape that arrives at this session has been punishing good prints. The last four sessions sold beats that came with a decelerating slope or rising cash burn (BE -11%, FIX -9%, LRCX, WDC -3%, DECK -5%, AXP -3.7% on a raise with a restructuring charge) and paid only commodity-levered beats (SLB +7% on $103 WTI). The S&P closed Friday at 7,623.68, down a second week, with the 10-year at 5.00%, the 30-year at 5.33% and the 2-year at 4.69%. The Fed debate is hike versus hold, with October hike odds near 5%. At those yields, long-duration growth stories and anything funded by new debt or equity are being asked harder questions, and several Thursday names are exactly that: DLR is issuing equity and debt to build, AMZN has trailing free cash flow below zero, MSTR is a financing vehicle for a bitcoin position, and RKT and PFSI sit on the mortgage rate.

Three of Carl's threads run through this session. Thread 3 (hyperscaler funding strain) is AMZN's cash flow and DLR's ATM. Thread 5 (memory as the cycle barometer) is SNDK, with MU near $880 and SNDK broken below its 200-day at roughly $1,231 on Friday, so the print is a test of whether NAND pricing is still running ahead of the stock or whether the stock has been discounting a turn. Thread 8 (Anthropic revenue proxies) is AMZN, where the Anthropic stake is already showing up in reported net income. Thread 4 (agents against seat-based software) is touched by TWLO, RDDT and PINS on the ad-tech and communications-API side, and GDDY and SPSC in the rest.

One more read-through is specific to tonight. AMZN agreed in April to buy Globalstar. GSAT is listed here as unplaced, but it has suspended guidance and calls, so the more useful number for GSAT is the AMZN share price (see the cluster section).

Tier 1 — after the close

AMZN ($248.78) — the print where AWS growth, a rising capex line and Anthropic marks all hit at once. The workbook has Q3 EPS of $1.96 and revenue of $202.20B. Amazon's own Q2 release (July 30, 2026) guided Q3 net sales of $197.0B to $202.0B, so the Street sits at the very top of the range, and operating income of $22.5B to $26.5B against $17.4B a year ago. Q2 was $200.6B (+20%), AWS $42.2B (+37%, a $169B annualized run rate) with AWS operating income of $16.6B, which is a 39% margin, and total operating income of $27.5B. The stock is at 24.2x forward earnings, 13% below its $287.20 high and 27% above its $196 low, with 0.9% of the float short and implied vol at 47% annualized. At that vol the market is paying a baseline of about 3% a day before any event premium. The one metric is AWS growth against capex, and Q2 set the bar: reported growth of 37% with gross property and equipment purchases of $54.2B in the quarter, up from $32.2B. A print at or above 37% with the capex line still climbing reads as pull-through of backlog (thread 2). A deceleration with capex still rising is the pattern the tape has been selling.

The funding-strain side (thread 3) is already in the Q2 release. Trailing-twelve-month operating cash flow was $161.4B, but trailing free cash flow was an outflow of $7.6B, which Amazon ties to a $66.1B year-over-year increase in net property and equipment purchases. The Q3 release will update that trailing number. If it widens, it adds to the case that even the largest balance sheet is borrowing against AI demand; if the quarter's operating cash flow absorbs the capex step-up, the trailing outflow narrows and the argument softens. The Anthropic angle (thread 8) has two parts. First, the commercial one: Trainium and Bedrock demand, which management usually describes in the call rather than the release. Second, the accounting one: Q2 net income was $62.6B ($5.75 a share) including $53.4B of non-operating pre-tax income that Amazon says came "primarily from our investments in Anthropic." The $1.96 consensus is evidently an operating-driven number (about $21B of net income on roughly 10.9B shares), so the GAAP headline EPS on Thursday night can be far from it in either direction depending on the next Anthropic mark. Read operating income and AWS, not the headline per share.

Watch on the call: AWS backlog and the stated capacity adds, the full-year capex framing relative to Q2's $54B quarterly pace, Trainium capacity commentary, the Anthropic mark, and any update on the Globalstar timeline (the deal is expected to close in 2027, per the Q1 Globalstar release).

INTC ($86.64) — can a 56x forward multiple be defended by 18A and the government-backed foundry story? Consensus is $0.40 EPS on $16.47B revenue. Intel's Q2 release (July 23) guided Q3 revenue of $15.8B to $16.8B, non-GAAP gross margin of 42.0% and non-GAAP EPS of $0.38 at the midpoint, so the Street is $0.02 above the guided EPS and just above the revenue midpoint of $16.3B. Q2 was $16.1B (+25%), with Data Center and AI at $6.3B (+59%), Client Computing and Physical AI at $8.9B (+13%) and Intel Foundry at $5.8B (+31%), non-GAAP gross margin of 41.8% and non-GAAP EPS of $0.42. GAAP EPS was $(2.16), driven by a roughly $12.5B mark-to-market charge on escrowed shares tied to the U.S. government agreement. That charge is a function of Intel's share price, so GAAP EPS is a derivative of where INTC trades at quarter-end; the non-GAAP line is the one to anchor on. The stock is 39% below its $142.35 high and 2.6x its $32.89 low, with 3.2% short interest and implied vol of 72%, so the market is treating this as a high-variance print.

The one metric is data-center growth and the gross-margin path off 42%. The DCAI growth of 59% is the best evidence in the release that server CPU demand is part of the AI build (thread 5, and a counterpoint to the "standard infrastructure commoditizes" worry in thread 1, since agentic workloads are CPU-hungry). On the foundry side, the Q2 release says 18A-P entered risk production on schedule, Xeon 6+ launched as the first 18A server part, and Panther Lake is in volume on a subset of parts using High-NA EUV. The release gives no 14A progress update, so any named external 14A customer on the call would be new information. Capex was $2.65B gross in Q2 and the CFO described "meaningfully increasing" equipment, clean-room and substrate spend, with no full-year figure given. A full-year capex number would be new, and at 5% yields the market will read it against free cash flow. Bear points: the escrowed-share structure means the government's interest keeps moving GAAP results; the multiple already leans on the foundry narrative. Bull points: the segment growth rates are real, and the guide has been met.

SNDK ($1,239.85) — the NAND barometer; the bar is $46 and the stock is already 47% off its high. Consensus is $46.41 EPS and $10.70B revenue. Sandisk's fiscal Q4 release (August 5, 2026 via its 8-K) guided FQ1 revenue of $10.30B to $10.80B, non-GAAP gross margin of 83.0% to 85.0%, operating expenses of $520M to $540M and EPS of $44.00 to $46.00 on about 155M diluted shares and a 15% tax rate. So the Street's EPS is above the top of the guided range, and revenue is $100M under the top. Backing the EPS out, $10.70B at an 84% margin less $530M of opex and 15% tax gives about $46.4, so consensus is pricing roughly an 84% margin on near-top revenue. Each point of gross margin is worth about $0.59 a share and each 1% of revenue about $0.49, so a normal-looking beat on revenue with a one-point slip in margin lands on consensus. FQ4 was $8.97B (+51% sequentially, +372% year over year) at an 84.6% gross margin and $39.25 non-GAAP EPS, and management attributed roughly two-thirds of the sequential increase to price and one-third to volume. That split is the whole debate: a price-led quarter says the cycle is still in the part where supply is tight, and the stock's slide through its 200-day and 47% drawdown from $2,354.39 says the market doubts that can hold. Aggregator headlines after the August print described a roughly 7% after-hours drop on the guide falling short of expectations, which is a reminder that this stock has not rewarded in-line prints.

Short interest is 3.3% and implied vol 81.7%. The setup into the print is that MU, at about $880 (+3.5% Friday), is holding up better than SNDK. Watch for the FQ2 guide relative to $10.7B, the price-versus-volume split again, contract versus spot commentary, and bit-supply discipline from the NAND makers. Any change in the gross-margin guide midpoint from 84% matters more than the revenue figure. The read-through lands on MU, STX and WDC, and on MPWR in this session on the power side.

GILD ($156.09) — a stock at its 52-week high into a print where the headline EPS will be distorted again. Consensus is $2.21 and $7.81B. Gilead's Q2 release (August 4) reported revenue of $7.8B (+10%), product sales of $7.6B (+8%), Descovy of $967M (+48%) and Yeztugo (lenacapavir for PrEP) at $232M versus $15M a year ago. It lifted 2026 product-sales guidance to $30.1B to $30.4B (from $30.0B to $30.4B), raised ex-Veklury product sales to $29.8B to $30.1B (from $29.4B to $29.8B) and cut Veklury to about $300M from $600M. Non-GAAP EPS was $(6.75) because of $9.08 a share of acquired IPR&D, and the full-year non-GAAP EPS guide is negative at $(0.65) to $(0.30), which is what the workbook's FY consensus of $(0.43) reflects. Strip the IPR&D out and Q2 was about $2.33, so $2.21 for Q3 looks like a number that excludes any new deal charge. The point to watch is whether Q3 carries another acquisition write-off, which would make the reported EPS read worse than the underlying. The stock is within 3% of its $160.51 high on 1.8% short interest and 38% implied vol. The one metric is Yeztugo's ramp, from $232M, and whether Descovy's price-driven growth is giving way to the new product rather than cannibalized by it. Watch Veklury's trajectory after the cut, and the ex-Veklury guide, which is the cleaner measure.

SYK ($307.15) — a low bar after a cyber incident, with the full-year consensus sitting on the bottom of guidance. Consensus is $3.55 and $6.62B. Stryker's Q2 release (July 30) showed sales of $6.6B (+9.4% reported, +9.0% organic), adjusted EPS of $3.69 (+17.9%) and adjusted operating margin of 27.4%. It narrowed 2026 guidance to 8.3% to 9.3% organic growth and $14.95 to $15.10 adjusted EPS. The workbook's full-year consensus is $14.95, the very bottom of that range, and the Q3 estimate is $0.14 below the Q2 print. The release says the company has "made significant progress in our recovery from the cyber incident" first reported March 11, 2026, and does not quantify the impact. The stock is 21% below its $389.33 high, 15% above its $267.00 low, with 1.6% short interest and 43% implied vol. Upside risk: a print on the $14.95 to $15.10 path that lifts the FY floor. Downside risk: organic growth below the 8.3% floor, or incident-related drag that extends longer than guided. Watch for Mako and Q3 procedure volumes, the cyber recovery language, and where the bottom of the organic range goes.

SBUX ($100.80) — a turnaround trading 9% below its high; the question is whether a 7.9% comp is already in the price. Consensus is $0.71 and $9.24B. The FQ3 release (July 29) showed revenue of $9.3B (-1%, because of the China joint-venture transfer), global and U.S. comps both +7.9% (transactions +4.2%, ticket +3.5% globally), non-GAAP operating margin of 14.4% (+430 bp) and non-GAAP EPS of $0.85 (+70%). FY2026 guidance was raised to U.S. comps slightly above 6.0%, global comps near 6.0%, non-GAAP operating margin above 11.0% and non-GAAP EPS of $2.55 to $2.65 (workbook FY consensus: $2.61), with an explicit Q4 U.S. comp of 6.5% or greater. That explicit Q4 target is the reference for the print. Short interest is 4.1%, implied vol 35%, and the stock sits 9% below its $110.51 high and 29% above the $77.99 low. The metric is U.S. transactions, because ticket-led comps wear out faster than traffic-led ones. A U.S. comp at or just above 6.5% with traffic positive is expected; a comp that slides back toward 6.0% while margins hold would be the market's reason to question a 31x forward multiple.

MDLZ ($63.86), RSG ($240.45) — two defensives sitting at or near 52-week highs on thin implied vol. MDLZ (cons $0.71, $9.99B; high $66.65; 2.9% short; IV 27.6%) and RSG (cons $1.93, $4.42B; high $243.22; 2.5% short; IV 24.7%) are covered here from workbook stats only. The setup for both is that the stock, not the estimate, is the risk: each is within 4% of its high at a time when the broad tape is falling and rates are rising, so a clean beat has to clear a position that has already been rewarded. RSG at 27x forward is the richer of the two. For MDLZ, watch cocoa-cost and price-elasticity commentary; for RSG, recycled-commodity pricing and volume.

DLR ($172.37) — the data-center REIT is funding a larger build with equity at a higher price than today's. The workbook's $0.57 is a GAAP EPS figure, not the core FFO per share that DLR guides; the relevant number is the Q2 reported core FFO of $2.65 ($2.13 excluding $188M of net promote income). Q3 revenue consensus of $1.76B compares with Q2 revenue of $1.92B, which included $249M of fee income. DLR's Q2 8-K (July 23) raised 2026 core FFO guidance, excluding net promote, to $8.15 to $8.20 from $8.00 to $8.10, and raised development capex to $4.25B to $4.75B from $3.5B to $4.0B with construction in progress at $9.8B. The funding section is the thread-3 evidence: about $1.2B of net ATM proceeds in Q2 at a weighted-average $191.63 a share (about $2.5B year to date), 2026 debt issuance guided to $1.5B to $2.0B with the assumed coupon raised to 4.5% to 5.5% from 4.0% to 4.5% and timing pushed to the second half, and JV and disposition proceeds raised to $1.0B to $1.5B. With the stock at $172.37, 10% below that average ATM price, equity issuance now dilutes more. Backlog was a record $1.9B (100% share), with two more hyperscale leases adding $410M in July. The stock is 17% below its $208.14 high, with 2.7% short and 43% implied vol. Watch for raised core FFO again, the backlog conversion, ATM usage since July and the cost on the second-half debt.

MSTR ($146.54) — earnings are a bitcoin mark, and BTC has moved from $58.7K to about $81K since the last quarter-end. The workbook shows EPS of $17.98 on $129M revenue, against a FY consensus of $(19.12), which tells you the quarterly figure is a fair-value mark and not operations. Strategy's Q2 (per press coverage; not independently confirmed against the 10-Q) showed a net loss of $8.22B, with 843,775 BTC held at an average cost of about $75,578 and BTC falling from about $67.8K to $58.7K over the quarter. Software revenue was about $122M, and preferred dividends were about $401M for the quarter. The stock is 51% below its $299.80 high, with 7.3% short and 85% implied vol. The arithmetic is that at $81K the position sits roughly 7% above cost, and every quarterly mark is determined by the BTC price on the last day of the period, not the current price. Watch for holdings, any change in the preferred-dividend load, and how the company funds the roughly $1.6B annualized preferred burden (about $400M a quarter) now that the premium to net asset value is the lever.

MPWR ($1,139.99) — AI power-delivery name 33% off its high, with 70% implied vol. Consensus is $7.75 on $1.16B; the FY estimate is $27.55 and forward P/E 38.8. Short interest is 5.1% against a 52-week range of $833.18 to $1,714.09. Workbook-only here. The metric is data-center revenue as a share of the total and the gross-margin line, and the read goes to thread 2 (are the AI server programs still ramping) and thread 5 (analog and power as part of the memory-cycle complex).

COIN ($164.28) — a 0.07 EPS estimate on $1.22B means the print is a volume and marks story. Short interest is 11.1%, implied vol 76% and the stock is 56% below its $373.25 high. With BTC about $81K, Q3 trading activity and any crypto-portfolio marks drive the line; I have not verified Q3 volumes from a primary source. FY consensus is $(1.68), so the estimates are not comfortable. It trades alongside MSTR and the BTC tape on the night.

ILMN ($269.75), TWLO ($261.79), RDDT ($145.09), PINS ($22.32), RBLX ($52.75) — five high-vol growth names, each priced for a different problem. ILMN (cons $1.36, $1.15B; 10.3% short; IV 73%) has risen to within 13% of its $309.35 high from a $94.00 low, at 40x forward, so the print has to defend a rerating. TWLO (cons $1.47, $1.51B; IV 84.8%; 5.3% short) trades at 20x forward but with an implied vol higher than most of the session, and as the communications layer for voice and messaging agents it is the clearest thread-4 name tonight: watch usage-based revenue growth against seat-linked products. RDDT (cons $1.32, $875M; 15.2% short; 62.5x forward; 45% below the $263.50 high) has the second-largest short interest in Tier 1, and ad revenue growth against a year ago is the one number. PINS (cons $0.49, $1.21B; 12.1% short; 9.0x forward; IV 69.5%) is the opposite valuation case on the same ad-tech read; its range is $13.84 to $35.42 and the stock is 37% off the top. RBLX (cons $(0.42), $1.62B; 4.3% short; IV 82%; 61% below the $134.67 high) is a bookings and engagement story where the EPS is not the metric.

RMD ($252.86), RKT ($11.74), FSLR ($172.50), RIVN ($11.83) — three names at the edge of their ranges and one at the top. RMD (cons $2.67, $1.39B; 9.1% short; IV 41.6%) is within 9% of its $277.67 high, and the short interest is notable for a 19x forward multiple; the debate is GLP-1 read-through on sleep-apnea demand, which the company has addressed in past calls. RKT (cons $0.14, $2.60B; 7.6% short; IV 71.7%) is near its $10.18 low with a 10-year at 5.00%; the number to watch is origination volume and gain-on-sale margin, and PFSI (below) is the paired read. FSLR (cons $4.64, $1.29B; 13.5% short; fwd P/E 8.3; IV 62.8%) is within 2% of its $168.60 low, so the setup is a stock that has already de-rated and a high short base; watch bookings and the ASP trend, and for policy commentary on tariffs and credits. RIVN (cons $(0.72), $1.99B; 14.9% short; IV 74.9%) is 2% above its $11.60 low; gross profit per vehicle and the cash-burn line are the swing factors, and the tape has been selling cash-burn increases.

The rest, by cluster

Insurance, brokers and credit. AJG ($268.04; cons $2.99, $4.00B; 3.2% short) is 5% below its $281.66 high at 16x. CNO ($53.66; 21.5% IV, among the lowest on the list) is within 7% of its $57.59 high. CACC ($541.61; 28.1% short, the highest of the group; cons $12.34, $596M; range $401.90 to $668.86) is the crowded name here, with provisioning and credit-loss commentary the hinge. AX ($91.79; cons $2.26, $387M; 9.6x forward) and HTGC ($16.41; cons $0.48; IV 27%) round out the cluster. ALHC ($7.94; IV 90.8%, 11.7% short; range $6.01 to $25.12) is the high-variance one in the health-plan space; medical-cost ratio is the metric. MIAX ($33.98; 11.3% short; 41% below its $57.14 high; cons $0.38, $131M) is the exchange-volume play, and option volume is the number. PFSI ($63.68; cons $1.23, $537M; 11.3% short; 60% below its $160.36 high) is the paired mortgage read with RKT.

Utilities and power (thread 6). EIX ($57.35; cons $1.81, $5.34B; 8.5x forward; 6.1% short; 30% below its $81.62 high) is the most discounted regulated name in the group, and LNT ($69.66; cons $1.31, $1.32B; 12.2% short, unusual for a utility; IV 26%) is the quiet one. Both are tied to load-growth capex plans and rate-case timing; capital-plan raises tied to data-center load are the thing to look for.

REITs. GLPI ($39.55; cons $0.80; IV 24.1%; 21% below its $49.95 high), CUBE ($40.16; cons $0.42; within 7% of its $43.26 high), HR ($17.95; cons $0.00 on a FY of $(0.10); IV 29%), CUZ ($28.87; cons $0.10; 10.6% short), PEB ($20.39; 28.4% short, the highest in the cluster; cons $(0.02); range $9.99 to $21.26, so the stock has doubled off its low into the print) and WY ($19.49; cons $0.05, $1.91B; 7% above its $18.26 low). Workbook EPS for REITs is GAAP and almost uninformative; FFO and same-store guidance are what moves them.

Industrials, materials and chemicals. IR ($73.48; cons $0.90, $2.05B; 27% below its $100.96 high; 4.0% short) and SPXC ($160.33; cons $2.13, $708M; 36% below its $251.08 high) have both de-rated hard into the print. MTZ ($171.05; cons $2.96, $4.94B; 7.2% short; IV 82.2%; 61% below its $441.43 high) is the thread-2 backlog name in this session, and with the tape having sold FIX -9% on a beat, the backlog growth rate and margin are what the stock needs; implied vol of 82% reflects it. VLTO ($104.33; at its $105.61 high; IV 29.6%) and ATR ($126.55; cons $1.47, $981M) sit near the top of their ranges. EMN ($64.93; cons $1.92; 9.2x forward; 7.8% short), OLN ($15.66; cons $0.16 on a FY of $(0.60); 14.4% short) and FMC ($5.05; $0.8B market cap; IV 97%; 23.2% short; 84% below its $30.95 high) are the chemicals set, where oil at $103 raises input costs for some and helps others. MEOH ($63.08; cons $2.83, $1.29B; at its $66.75 high; zero reported short interest; IV 63.8%) is the methanol name and the one with a direct energy tie. MHK ($124.72; cons $2.58, $2.82B; 14.5% short), EXPO ($77.43), MTX ($62.90), KWR ($155.65; 15.4% short), FHI ($56.81; 10.3x), OSIS ($197.48; 16.3% short; 37% below its $311.72 high), SKYW ($93.03; 7.7x) and SPSC ($91.56; software; 9.4% short) complete the group, each at the range positions in the table above. COLM ($61.35; 17.5% short), FND ($47.83; 13.2% short) and BFAM ($71.40; 22.6x) are the consumer-facing names, and WKC ($36.54; 30.2% short, the highest short interest in the session; cons $0.96 on $12.34B revenue) is the fuel-distribution one that benefits from volatility in oil.

Technology services, distribution and software. DXC ($16.09; IV 77%; 19.0% short; at its $16.18 high after doubling from $7.90) is the one with the most to lose from a miss: a 4.4x forward multiple on a stock at its 52-week high, with revenue of $3.00B. INGM ($27.69; cons $0.78, $13.85B; 23.5% short, the second-highest on the list; 7.2x forward) is a distributor and an indirect read on server and PC channel demand (thread 1). SNDR ($30.35; cons $0.30, $1.58B; 11.4% short; IV 59%) is a trucking name for freight. GDDY ($112.79; cons $1.90, $1.33B; 7.0% short; IV 60.7%; 18% below its $137.93 high) is the thread-4 small-business-web name, where the question is whether AI site builders are a tailwind or a substitute.

Healthcare, biotech and services. DVA ($183.64; cons $3.57, $3.52B; 15.9% short; 9.9x forward; range $101.00 to $247.49) is the dialysis name; treatment volume and the mix are the metrics. MMSI ($93.30; at $94.75 high). EXEL ($64.00; within 2% of its $65.50 high; 15.6% short; cons $0.90, $649M) is the profitable-biotech name at the top of its range. BBIO ($68.56; cons $(0.56), $296M; 11.2% short) and PTCT ($60.59; cons $0.30, $305M; 14.9% short, close to its $58.80 low) are launch-driven names. SUPN ($40.58; 9.5x forward; 31% IV), ATEC ($11.01; IV 80.9%; 10.5% short; range $6.82 to $23.29) and CDNA ($69.42; IV 82.2%; 13.0% short; at 156x forward; just under its $72.71 high after rising from $14.22) round it out. COUR ($5.08; IV 92%; 10.5% short) is edtech and REAL ($10.84; the highest implied vol in the session at 101.7%; 16.3% short; cons $0.00) is consumer resale.

The Thursday-unplaced names, with what I could and could not confirm. Only a few have a primary-source confirmation.

Confirmed from the company: VNT ($34.36) reports Thursday, November 5 at 8:00 AM ET, per its own October 15 notice, so it is not a 10/29 name. For CQP ($66.15; cons $1.17, $2.57B), parent Cheniere's IR notice sets the Cheniere release for Thursday October 29 before the open with a 10:00 AM CT call; the notice does not mention CQP's separate release, and CQP has historically reported in the same slot as Cheniere, so I treat CQP as Thursday a.m., unconfirmed (an aggregator shows November 5, which looks like a placeholder). GSAT ($82.55; cons $(0.01), $75M) has suspended guidance and calls because of the pending Amazon merger ($90.00 cash or 0.3210 AMZN shares per share, cash capped at 40%, expected close 2027, per its Q1 release); no primary date was found. At AMZN's $248.78, the stock leg is worth about $79.86, so a 40/60 cash/stock blend is about $83.92, against a $82.55 GSAT price, a spread of about 1.6%. GSAT trades on AMZN more than on its own print.

Aggregator-only (Earnings Whispers; no company notice found): CCC ($7.67; cons $0.11, $291M) is listed as Thursday October 29 at 7:05 AM ET, which would make it a Thursday a.m. name. SXI ($240.47; cons $2.34, $230M) is listed Thursday October 29 at 4:00 PM ET, consistent with this session. MNST ($46.59; cons $0.30, $2.49B), KTOS ($38.75; cons $0.20, $470M; IV 70%), LNTH ($99.80), PCRX ($36.42; 29.1% short), SNDX ($13.66), GPRE ($13.98), AD ($33.56), LXP ($61.10), PPL ($34.98) and TNK ($99.47) all show dates in the week of November 2 or later on aggregators (MNST November 5 after the close; KTOS November 4 after the close; LNTH November 4 a.m.; PCRX, SNDX and GPRE November 5 after the close; AD November 5 a.m.; LXP November 4 a.m.; PPL November 6 a.m.; TNK November 9 after the close). Those look like pre-announcement estimates, since none of these companies had posted a Q3 date notice I could find, so none of them should be treated as Thursday-night names. MNST and KTOS in particular follow last year's early-November pattern (Monster reported November 6, 2025; Kratos reported November 7 in 2024), not Thursday 10/29. Of the three with notable short interest, PCRX (29.1% short, stock $36.42 against a $36.67 high) is worth a look when it does report.

Where the asymmetries sit

Implied vol looks thinnest where the stock is most extended. RSG (24.7%), MDLZ (27.6%), GLPI (24.1%), LNT (26.3%) and VLTO (29.6%) all sit at or within a few percent of a 52-week high with option markets pricing little, and the last four sessions have punished beats at the highs. The reverse is the high-variance group where implied vol is close to or above 80%: SNDK (81.7%), RBLX (82.2%), RDDT (82.2%), TWLO (84.8%), MSTR (85.0%), MTZ (82.2%), CDNA (82.2%), ATEC (80.9%), ALHC (90.8%), COUR (92.1%), FMC (97.0%) and REAL (101.7%). TWLO at 20x forward earnings carrying the same implied vol as a name with no earnings is the one that looks rich relative to the setup.

Crowded shorts into prints: WKC (30.2%), PEB (28.4%), CACC (28.1%), INGM (23.5%), FMC (23.2%) and DXC (19.0%) are the heaviest, with RDDT (15.2%), RIVN (14.9%), PTCT (14.9%), FSLR (13.5%), COLM (17.5%), OSIS (16.3%), DVA (15.9%) and EXEL (15.6%) next. PEB and DXC are both at or near 52-week highs with heavy short interest, which is the squeeze-or-fade combination. FSLR and RIVN are the opposite, with shorts piled on stocks at their lows.

Names at 52-week extremes: at or within 2% of the high are GILD ($156.09 vs $160.51), RSG, VLTO, MEOH, EXEL, MMSI, DXC, CUBE and RMD; at or within 4% of the low are FSLR, RIVN, PTCT, WY and RKT. Guidance-reset candidates are the ones where consensus has been left on the guide's edge: SNDK (EPS cons above the top of the range), AMZN (revenue cons at the top of the range), and SYK, where the FY estimate sits on the bottom of the range and could move up on a clean quarter. GILD's headline EPS depends on acquired-IPR&D charges that the consensus does not appear to carry.

Dominoes

Wednesday night comes first. If the hyperscaler capex lines (MSFT, GOOGL, META-adjacent) step up again, AMZN's capex gets read as part of a rising tide and the focus moves to AWS growth and funding. If they hold flat or the language softens, AMZN's $54B quarterly pace stands out and INTC and SNDK carry the full "peak capex" question (thread 2).

Same night: AMZN's AWS number and capex read to DLR (thread 3), INTC's data-center line, SNDK's price/volume split and, in the next sessions, anything exposed to cloud demand. The Anthropic mark and Trainium commentary are the cleanest thread-8 data point of the week. SNDK moves MU (thread 5) and the memory complex on Friday: STX, WDC, KLAC, TER, ENTG and the packaging names. INTC reads to AMKR, TER, FORM and COHU on the test and packaging side, and to the server-ODM chain. DLR reads to EQIX and the power names (VRT, GEV) through the rate at which hyperscale leases are signing. GILD and SYK read to the large-cap healthcare names reporting Friday and the following week. TWLO, RDDT and PINS read to the ad-market and agent-usage questions that matter for NOW, PEGA and MNDY when they report. MSTR and COIN trade on BTC at about $81K and read to the crypto complex. FSLR and the utilities (EIX, LNT) connect to the thread-6 load-growth and policy debate. Friday's XOM, CVX and ABBV open into whatever AMZN, INTC and SNDK do.

Flagged as unverified

Report dates: AMZN, INTC and SNDK are company-confirmed for Thursday after the close (Amazon IR, Intel IR, Sandisk IR, linked below). Everything else in the p.m. list rests on the Briefing placement; I did not check the long tail against company pages. For the unplaced names, only VNT is company-confirmed (November 5, 8:00 AM ET) and CQP is inferred from Cheniere's own October 29 a.m. notice. The rest rest on Earnings Whispers, which is second-tier.

Workbook oddities: DLR's $0.57 is a GAAP EPS figure and not core FFO, so beat/miss versus the company's $8.15 to $8.20 guide cannot be read off it. AMZN's $1.96 appears to exclude Anthropic marks, which were $53.4B of pre-tax income in Q2. GILD's Q3 consensus excludes the IPR&D charges that made Q2 non-GAAP EPS negative. MSTR's $17.98 EPS is a fair-value mark. REIT EPS figures (HR, CUZ, GLPI, CUBE) are GAAP. The CQP "TBD" is a year-ago pattern, not a confirmed date. MSTR Q2 figures are from press coverage, not the 10-Q. Short interest and implied vol are as of the Friday 10/23 pull.

Foreign private issuers filing 6-Ks that Carl's EDGAR 8-K watcher will not catch: none identified among the p.m. names. TNK (Teekay Tankers) has historically filed 6-Ks as a foreign private issuer; I did not confirm its current filer status, and its listed date is November 9, so it is outside this session.

Sources: https://www.aboutamazon.com/md/news/company-news/amazon-earnings-q3-2026-report · https://www.nasdaq.com/press-release/amazoncom-announces-second-quarter-results-2026-07-30 · https://www.intc.com/news-events/press-releases/detail/1782/intel-to-report-third-quarter-2026-financial-results · https://www.sec.gov/Archives/edgar/data/0000050863/000005086326000155/q226earningsrelease.htm · https://www.sandisk.com/company/newsroom/press-releases/2026/2026-09-29-sandisk-to-report-first-quarter-fiscal-year-2027-results-on-october-29-2026 · https://www.sec.gov/Archives/edgar/data/0002023554/000162828026053346/sndkq4-26ex991xpressrelease.htm · https://www.businesswire.com/news/home/20260804436824/en/ · https://www.sec.gov/Archives/edgar/data/0000310764/000031076426000048/sykex991earningsq22026.htm · https://www.sec.gov/Archives/edgar/data/0000829224/000082922426000129/sbux-06282026xearningsrele.htm · https://www.sec.gov/Archives/edgar/data/0001297996/000110465926086270/dlr-20260723xex99d1.htm · https://www.sec.gov/Archives/edgar/data/0001366868/000136686826000027/gsat20260331-ex991.htm · https://finviz.com/news/397743/cheniere-announces-timing-of-third-quarter-2026-earnings-release-and-conference-call · https://s203.q4cdn.com/187135268/files/doc_news/Vontier-Schedules-Third-Quarter-2026-Earnings-Call-2026.pdf · https://www.kucoin.com/blog/strategy-reports-8-22-billion-q2-2026-loss-as-bitcoin-holdings-drive-major-unrealized-charge · https://www.earningswhispers.com/stocks/MNST · https://www.earningswhispers.com/stocks/KTOS · https://www.earningswhispers.com/stocks/SXI · https://www.earningswhispers.com/stocks/ccc

Friday 10/30 — a.m.: Oil at $103 meets the majors' scorecard

The frame

Friday is the oil-and-pharma morning of the heaviest week of Q3 season, and it lands after the Wednesday-night megacap tech prints and the Thursday-night AMZN/INTC/SNDK block have already set the tone. The tape has been punishing beats for four straight sessions when the slope decelerates or cash burn rises (BE, FIX, LRCX, WDC, DECK, AXP) and paying only commodity-levered beats (SLB +7% on $103 oil). Friday's lead names are the cleanest test of that second clause. XOM ($183.28, 0.2% under its 52-week high of $183.75) and CVX ($233.37, a hair under its $233.74 high) both go into the print with WTI at $103.27 and Brent at $116.72, six-month highs after a +14% October. The stocks have already paid for the commodity. The question for the tape is whether the print and the call give it a reason to pay for more.

One timing point matters for reading these numbers. The quarter being reported is July through September. By the MTD math, WTI was roughly $90 at the September close, so the $103 oil on the screen is not in the Q3 P&L; it is in the Q4 run-rate and in the call. Expect the questions to be about capex discipline at $100-plus oil, buyback pace, Permian and Guyana volumes, and refining margins, not about the quarter's EPS. The same logic applies to BP, which sits at its own 52-week high ($51.48 vs. $51.49) and has the weakest balance sheet of the group.

The rest of the morning is a cross-section of the market's pressure points. The 10-year at 5.00% and the 30-year at 5.33% are a direct weight on the regulated utilities (D, EXC) that Carl tracks for the power/grid thread; both sit well off their highs while the data-center load story stays intact. ABBV, REGN and SNY report into a pharma tape where Dupixent, Skyrizi/Rinvoq and Eylea HD are the line items that matter. GD brings a $136.5B backlog into a defense-budget and Iran-headline tape. NVT (data-center liquid cooling) is the AI-capex backlog test, a name down about 32% from its high into the print on 70% implied vol. CCJ and UUUU (the latter's date unconfirmed) carry the uranium/nuclear thread. FOMC is Wednesday and is already behind us by Friday; October hike odds were ~5%, so the debate is hike vs. hold, and a hot Friday print in the cyclicals would not change that.

The calendar for this session also has real housekeeping. Several names the Briefing workbook puts in this session do not appear to report today (see Flagged as unverified): KOP and AMR report November 6, MOG.A is expected around November 20, and PAYP is a yen-denominated Japanese issuer whose workbook row mixes currencies.

Tier 1 — before the open

XOM ($183.28) — at the high, with the commodity already in the stock. The Street has $4.03 EPS on $106.02B revenue (mkt cap $753B, fwd P/E 15.0, short interest 1.1%). Last quarter ExxonMobil reported adjusted earnings of $14.7B, or $3.52 per share, up from $2.09 in Q1, on $23.6B operating cash flow and $17.2B free cash flow; it returned $9.4B ($4.3B dividends, $5.1B buybacks) and declared a $1.03 dividend. Note the quality of that $3.52: the release cites about $2.5B of favorable timing effects (roughly $0.60 per share on my arithmetic, ~4.2B shares), so consensus at $4.03 is asking for a higher number with that tailwind presumably reversing, which implies the street is already underwriting a much better underlying quarter. Upstream earned $9.2B (vs. $6.3B), Energy Products $4.1B, Chemical $1.2B (vs. $0.1B), Specialty $1.0B. Production was 4.51 Mboe/d, slightly down sequentially, with the Permian at a record above 1.8 Mb/d and the fifth Guyana FPSO (250 kb/d) on plan to start up in Q4. Q2 capex was $6.8B ($13.0B year to date), with management saying 2026 investment runs 20% above the nearest IOC. ExxonMobil Q2 8-K

The one metric is the buyback line against the capex line at $100-plus oil. The $5.1B Q2 repurchase pace is the baseline; any move up is a read on how much of the price spike management considers durable, and any hold at $5B with capex at a 20%-above-peers pace tells you they are not chasing the price. Implied vol is 33.4% (about 2.1% a day, a general-vol read rather than a pure event straddle), which for a stock 0.2% from its high is not demanding. The bear side: the stock has made 63% off its $112.51 low, adjusted EPS is flattered by timing effects, and a Brent number that is October's, not Q3's, makes the call the real event. The bull side: Guyana start-up, a record Permian, and chemical margins coming off a $0.1B quarter all have room. The release is 5:30 a.m. CT with the call at 8:30 a.m. CT per the company (ExxonMobil IR). Watch for: refining and timing-effect commentary, Guyana ramp timing, the Q4 capex run-rate, and any Iran/Hormuz language in the outlook.

CVX ($233.37) — Hess synergies, a record debt paydown, and a consensus that steps down. The Street has $4.83 EPS on $61.65B (mkt cap $457.5B, fwd P/E 15.9, short 1.2%, IV 32.7%). That compares with Q2 adjusted EPS of $6.06 ($12.0B), which included about $1.4B of timing effects (roughly $0.70 per share on my arithmetic, ~2.0B shares). Q2 production was 4,070 Mboe/d, up about 20% year over year on legacy Hess assets and the Permian, with U.S. upstream at a record 2,077 Mboe/d. Cash flow from operations was $22.6B and free cash flow $18.1B; buybacks were $3.1B, the dividend $1.78 a quarter, and total debt fell a record $8.4B to $37.1B (net debt ratio 13.1%). Structural savings reached $3B run-rate, ahead of the $3-4B target, with $1.5B of Hess synergies. The release also disclosed a 20-year, 2.67 GW behind-the-meter power agreement with Microsoft for a West Texas data center, which ties CVX directly into Carl's power/grid thread, and a pending sale of the 50% Singapore Refining Company stake (close in 2027). Chevron Q2 8-K

Chevron gives no numeric guidance in the release; the forward numbers sit in a separate sensitivities document, so the call and that document are the news. The one metric is the buyback rate now that debt has been cut: with net debt-to-CFFO at 0.6x, the constraint on repurchases is policy, not balance sheet, and a step up from $3.1B would be the signal that $100 oil is changing behavior. Compared with XOM, CVX trades at the same forward multiple with a larger sequential consensus decline, which makes the bar look lower on the surface. The risk is the opposite reading: a stock at its high with consensus below last quarter's adjusted number could be priced for the beat. Watch for: the data-center power agreement economics, Permian growth vs. the lower Permian spend noted in Q2, and where Hess synergies go from $1.5B.

ABBV ($285.64) — guidance versus a consensus that appears to be on a different basis. Mkt cap $505B, fwd P/E 16.2, short 1.0%, IV 33.1%, 52-week range $190.75-$291.40 (1.9% under the high). The workbook has $3.78 EPS on $17.35B. The company's own Q3 guide, per a third-party summary of the Q2 release, is $3.84-$3.88 adjusted EPS (including about $0.14 of Apogee dilution) on roughly $17.2B revenue, so the workbook EPS sits below the guide range; treat that as a basis difference (the same source shows a GAAP-based $2.39 consensus elsewhere) rather than a miss setup. Hudson Labs Q2 delivered $16.98B revenue (+10.2%), adjusted EPS $3.65 (+13.2%), Skyrizi $5.5B (+24%) and Rinvoq $2.5B (+23.7%), neuroscience $3.2B (+20%). Full-year guidance stood at $67.6B revenue and $13.87-$14.07 adjusted EPS after a $300M raise in Q2 and $600M year to date.

The one metric is Skyrizi plus Rinvoq: roughly $8B of a $17B quarter growing north of 20%. The stock has run to within 2% of its high, so the print is a test of whether a fourth raise is in the numbers. The same source flags immunology pricing as a low-single-digit headwind and the Apogee dilution as a drag on EPS. Both sides: the compounding immunology franchise is the cleanest large-cap growth story in pharma; the counter is multiple (16x forward) already reflecting that, and a Skyrizi subcutaneous Crohn's decision in Q4 plus HS Phase 3 readouts in 2H as the next catalysts. Watch for: whether FY EPS guidance moves by more than the Q3 beat, and the pace of Skyrizi sequential adds.

BP ($51.48; 6-K) — at the high with the weakest balance sheet in the group. The Street has $2.62 per ADS on $64.54B (mkt cap $132B, fwd P/E 9.8, short 0.2%, IV 37.2%, 52-week $33.22-$51.49). Q2 underlying replacement-cost profit was $5.7B (vs. $3.2B in Q1), with net debt of $22.3B essentially flat from year-end and only $114M of buybacks in the first half. Management said debt reduction "is still not enough." Q3 guidance: upstream production of 2,100-2,250 mboe/d (Q2: 2,201), a "significantly lower" customers result, throughput of 1,300-1,360 kb/d, taxes paid about $1B higher than Q2, and a $1.0B hybrid repayment. Full-year guide: capex $13.5-14.0B, divestments of $8-9B including about $6B from Castrol. CEO Meg O'Neill's five-point reset (balance sheet first) is the frame. BP Q2 6-K

The one metric is net debt against $103 oil: whether it falls decisively, and whether the buyback conversation restarts. The stock is up 55% off its low and is the highest-beta expression of the commodity in the group on a balance-sheet-repair story. Risk to that read: a lower customers result and higher cash taxes are already guided, and the Castrol proceeds are not yet in hand. BP reports via 6-K, which Carl's EDGAR 8-K watcher will not catch.

SNY ($41.25; 6-K) — Dupixent compounding against a stock near the bottom of its range. The Street has $1.51 per ADS on $13.28B (mkt cap $99.7B, fwd P/E 8.6, short 0.5%, IV 32.8%, range $39.07-$52.68, 22% below the high). The revenue figure is probably not in the reporting currency (Sanofi reports in euros); I would not compare it to the company's euro numbers without a conversion. At Q2 Sanofi raised 2026 guidance to roughly 10% sales growth at constant FX (from high single-digit), business EPS growth slightly faster than sales, vaccines growth slightly negative in H2, with Dupixent above EUR 5B in the quarter (+37%) and a EUR 25B 2030 ambition. Sanofi Q2 6-K EMJ summary

Regeneron's side of the same product gives a cross-check: Sanofi-reported Dupixent global sales were $6.0B in Q2 (+38%). The stock at 8.6x forward with a record Dupixent says the market is discounting something other than the near-term P&L: vaccines (Beyfortus offsetting flu), pipeline pruning, Dupixent growth moderating in H2 as comparisons toughen (management's own words), and the REGN alliance economics. Watch for: whether the 10% growth guide moves, the H2 Dupixent deceleration slope, and any BD commentary. The report date is a Briefing placement I could not verify on Sanofi's IR page (see Flagged).

GD ($349.36) — backlog at $136.5B in a stock 13% off its high. The Street has $4.13 on $13.73B (mkt cap $94.5B, fwd P/E 18.5, short 0.9%, IV 28.8%, range $306.77-$400.00). Q2 revenue was $14.1B (+8.1%), operating margin 10.4% (vs. 10.0%), EPS $4.24 (+13.4%), orders $20B (book-to-bill 1.4x), and backlog of $136.5B vs. $103.7B a year earlier, with total estimated contract value of $186.9B. Aerospace grew 15.1% at a 14.5% margin; Marine rose 10.4% at 7.3%; Combat Systems (+0.3%, 13.9% margin) and Technologies (+4.1%, 9.4%) saw margins slip. Free cash flow was $1.65B in the quarter, net debt $3.2B. The release carries no numeric guidance; it points to the call and slides. GD Q2 8-K

Consensus EPS of $4.13 is below the Q2 $4.24, so the bar is a modest sequential decline. The metrics that matter are Gulfstream deliveries and Aerospace margin, and Marine Systems margin (the submarine-supply-chain constraint). The two-sided read: a 1.4x book-to-bill and a backlog up 32% is as strong as the defense order picture gets, while a stock 13% below its high with a fwd P/E of 18.5 says the market is wary on margin conversion and cash. Iran-strike headlines are a sentiment support, but the P&L is about execution.

REGN ($804.00) — a collaboration-revenue step-up is the set-up. The Street has $16.19 on $4.56B (mkt cap $82.9B, fwd P/E 14.1, short 2.2%, IV 40.3%, range $575.93-$859.34, 6% below the high). Q2 non-GAAP EPS was $14.29 (+11%), including a $0.99-per-share hit from acquired IPR&D, on revenue of $4.29B (+17%). Net product sales were roughly flat at $1.64B while Sanofi collaboration revenue rose 51% to $2.17B; Regeneron's share of antibody profits hit $2.03B (vs. $1.28B). EYLEA HD U.S. sales rose 52% to $596M; EYLEA fell 45% to $412M. The key setup point for Q3: the Sanofi Development Balance was fully repaid in Q2, so it stops reducing collaboration revenue starting in Q3, which is part of why the $4.56B consensus sits 6% above Q2. Buybacks were $1.2B in Q2 ($2.0B in the half), with $2.5B remaining. Regeneron Q2 8-K

The one metric is EYLEA HD net price versus volume as the franchise migrates. Catalysts on the calendar: cemdisiran (gMG) has a priority-review action date in November. Negative: the fianlimab Phase 3 melanoma trial missed its PFS endpoint vs. pembrolizumab. IV at 40% is the richest in the pharma trio, which is consistent with a name where one product line can move the quarter. Watch for: acquired-IPR&D noise in the EPS, EYLEA HD share against the new 20-week dosing label, and the buyback pace.

CL ($94.04) — a staples name near its high with the margin guide just raised. The Street has $0.93 on $5.33B (mkt cap $75B, fwd P/E 21.4, short 3.4%, IV 27.3%, range $74.55-$99.33). Q2 net sales were $5.36B (+4.9%), organic +2.4% (volume +0.8%, pricing +1.6%), gross margin 61.5% (+140 bp), and Base Business EPS $0.99 (+8%). FY guide: net sales +2% to +6%, organic +1% to +4% (maintained), gross margin now roughly flat (previously down), and Base Business EPS growth now mid-single-digit (previously low-to-mid). A headline from the Q2 coverage noted that new tariffs would outweigh a refund windfall. Colgate Q2 8-K

Consensus at $0.93 sits below the Q2 $0.99 base number, so the setup is a modest sequential step down. The metric is organic volume: 0.8% is thin, and the tape's reaction function (sell the slope deceleration) applies to a staple whose price/mix is carrying the growth. Both sides: the gross-margin guide improvement is a quality beat; the stock at 21x forward and 5% under its high is priced for it. Read across to CHD and KVUE this morning.

CNI ($123.15; 40-F/6-K) — rails as the cyclical-industrial read. The Street has $2.08 on $4.65B (mkt cap $74.4B, fwd P/E 18.8, short 0.0%, IV 22.1%, range $90.74-$131.55). The workbook figures are likely in Canadian dollars against a U.S.-dollar ADS price, so compare only like with like. I could not retrieve CN's Q2 2026 release or its full-year guidance this session, so I am not stating the prior guide. The stock is 6% under its high with the lowest implied vol of the Tier 1 group (about 1.4% a day), so the market is not pricing a surprise. Watch for: carload volumes (intermodal, grain, energy), operating ratio, and the tariff/trade commentary. As a Canadian foreign private issuer CN files 40-F and furnishes results on 6-K, which the EDGAR 8-K watcher will not catch. Briefing places it Friday a.m.; I could not confirm that against CN's IR page (see Flagged).

D ($65.04) and EXC ($44.43) — the regulated-utility pair on the power/grid thread, against a 5% 10-year. D: cons $1.21 on $4.74B (mkt cap $57.3B, fwd P/E 16.8, short 2.8%, IV 21.4%, range $55.85-$72.99, 11% below the high). EXC: cons $0.79 on $6.82B (mkt cap $45.8B, fwd P/E 13.7, short 3.7%, IV 21.4%, range $39.73-$50.65, 12% below the high). I could not pull either company's Q2 release this session, so there is no sourced prior-guidance comparison here; this is a workbook-only read. The analytical frame for Carl: with the 10-year at 5.00% and the 30-year at 5.33%, utility multiples are fighting the discount rate, which is why both trade 11-12% under their highs even as the data-center load story is the strongest it has been. D's number to watch is contracted data-center capacity in Virginia and the capex plan that goes with it; EXC's is the large-load pipeline in the PJM wires utilities and the rate-case outcomes. The tell on the thread is whether either raises its capex plan or the EPS growth rate; a raise with a financing mix tilted to equity is the funding-strain angle. Short interest of 3.7% in EXC is the higher of the pair.

CBOE ($340.42) — vol-sensitive and richly priced in implied vol. The Street has $3.43 on $706M (mkt cap $35.6B, fwd P/E 23.2, short 3.0%, IV 42.2%, range $227.15-$371.18, 8% under the high). Implied vol of 42% is high for an exchange operator (about 2.7% a day) and prices real event risk. The workbook-only read: with VIX at 19.45 and index options volume the profit driver, the questions are SPX and 0DTE volumes, net revenue capture, and any commentary on October volumes (a month with oil spiking and a two-week S&P decline is typically a good one for index-option activity). I could not retrieve CBOE's Q2 release, so no sourced guidance comparison. For Carl's gamma work specifically: the SPX put wall at 7,600, wall at 7,650 and flip at 7,729 are the structure the volume is trading around.

CCJ ($78.60; 40-F) — near the 52-week low despite a firmer long-term uranium price. The Street has $0.27 on $754M (mkt cap $34.2B, fwd P/E 51.8, short 0.0%, IV 49.5%, range $76.92-$135.24, 42% below the high and 2% above the low). Currency caution: Cameco reports in Canadian dollars, and Q2 adjusted net earnings were C$77M (C$281M year to date) with adjusted EBITDA of C$391M, so compare the $0.27 and $754M against the company's own CAD presentation. Q2 uranium deliveries were 7.1M lb, with uranium-segment adjusted EBITDA down to C$252M (from C$281M and C$352M in the prior year, per the release's two comparisons) on lower planned 2026 sales; Westinghouse swung to a C$10M Cameco-share net loss from C$126M earnings a year earlier, against a roughly US$170M Dukovany contribution in the comp. Production guidance was unchanged at 19.5-21.5M lb, Inkai's allocation is 4.2M lb for 2026, and the company holds contracts for average annual deliveries of more than 28M lb over five years. It said the long-term price strengthened further in the first half. Q2 inventory purchases averaged US$66.60 per lb. Cameco Q2 release

The tension is the one to flag: a stronger long-term contract price and a 91-reactor AP1000 pipeline on one side, and a stock at the bottom of its range on the other. The metric is Westinghouse earnings versus a hard 2025 comp, and the outlook for 2027 deliveries (commitments are above average through 2028 and below average in 2029-2030). Cameco has historically reported after the close; Briefing shows Friday a.m. I could not verify that, so treat the session as unconfirmed. Cameco furnishes results via 6-K as a foreign private issuer.

KVUE ($19.57) — no call, no guidance, a deal stock. The Street has $0.29 on $3.86B (mkt cap $37.6B, short 3.5%, IV 30.4%, range $14.02-$20.13). Kenvue stopped guiding because of the pending Kimberly-Clark acquisition, which both sets of shareholders approved January 29 and for which the HSR waiting period expired February 4; closing is expected in Q4 2026 pending foreign approvals. Kenvue does not host calls. Q2 sales were $3.96B (+3.0%, organic +1.6%), adjusted EPS $0.31. Kenvue Q2 8-K The stock trades on the deal spread and the closing timetable, so the print matters mainly as a regulatory-risk and Tylenol-litigation disclosure checkpoint, plus a read on consumer-health volume (+0.7% organic volume in Q2).

CHD ($105.19) — at the high with the highest short interest in the staples trio. The Street has $0.90 on $1.58B (mkt cap $25B, fwd P/E 23.4, short 5.9%, IV 25.9%, range $81.33-$108.93, 3.4% below the high). Workbook only; I did not retrieve the Q2 release. A stock 29% above its low at 23x forward with 5.9% short is a setup where organic growth versus guidance and the gross-margin bridge decide the reaction. Staples have been bid while growth sold off; CL this morning is the same-day read on whether the tape is paying for volume or only for margin.

LYB ($66.45) — the chemicals read on $103 crude. The Street has $2.55 on $8.89B (mkt cap $21.5B, fwd P/E 9.7, short 4.8%, IV 46.2%, range $41.58-$83.94, up 60% from the low). Workbook only; I did not retrieve LYB's Q2 release or outlook. The analytical frame: oil at $103 lifts naphtha-based feedstock cost for non-U.S. crackers and supports U.S. ethane-based margins, which is the case for LYB's integrated U.S. assets; the counter is demand destruction, a 10-year at 5%, and the dividend question the company has faced. Implied vol of 46% (about 2.9% a day) with 4.8% short says the market expects a large move. Watch for: Q4 volumes and margin outlook, and XOM's Chemical Products line (which went from $0.1B to $1.2B) for the same-morning cross-check.

NVT ($125.40) — the AI-capex backlog test, down 32% from the high. The Street has $1.40 on $1.43B (mkt cap $20.3B, fwd P/E 22.7, short 3.4%, IV 70.2%, range $93.22-$184.64). Q2 sales were $1.47B (+53% reported, +47% organic; Systems Protection +70%), adjusted EPS $1.45 (+69%). Q3 guidance: sales +32% to +35%, adjusted EPS $1.35-$1.38. Full-year guidance was raised to +37-39% reported and adjusted EPS $5.00-$5.10 (from $4.45-$4.55). Management cited data-center growth and said new products added more than 30 points to growth; another liquid-cooling manufacturing expansion was announced. No backlog or orders figure was in the release. nVent Q2 release

Consensus EPS of $1.40 is above the top of the $1.35-$1.38 guide, which means the Street has already moved up past guidance and sells-the-beat risk is real under this tape's reaction function. IV of 70% (about 4.4% a day) is the richest in Tier 1. The metric is orders and backlog, because the release does not report them and Carl's second thread is exactly that: whether backlogs are still growing and pricing is holding. The two-sided read: a company guiding to 32-35% growth in a quarter with the hardest comps yet is the opposite of peak AI capex; the stock's 32% drawdown says the market is worried about the second derivative (comps, cooling commoditization) rather than the level. Read-through to VRT, GEV and the liquid-cooling supply chain.

MGA ($63.97; 40-F) — auto supplier at 8x. The Street has $1.60 on $10.10B (mkt cap $17.1B, fwd P/E 8.1, short 2.8%, IV 43.7%, range $44.64-$73.22). Workbook only; I did not retrieve Magna's Q2 results or outlook, so no sourced guidance comparison. Magna reports in U.S. dollars, and the stock is 13% under its high. The questions are the 2026 outlook for sales and margin, tariff cost recovery, and North American build rates, with LEA (also Friday) as the same-day cross-check. Magna is a Canadian foreign private issuer; whether results arrive via 6-K or 40-F furnishing, the 8-K watcher will not see them. Briefing's Friday session is unverified.

AZN ($171.49) — moved here from Briefing's Monday slot; 6-K filer. Workbook consensus is $1.15 EPS on $16.00B revenue, which looks like an ADR-basis EPS (the ordinary-share core figure last quarter was $2.63, on $15.38B revenue). The company's own H1 release lists the 9M and Q3 results for 30 October 2026 (RNS), so the Briefing placement looks wrong. FY26 guidance (reconfirmed in July): revenue up mid-to-high single digits, core EPS up low double digits, core gross margin stable to slightly up with a lower second half, finance costs higher in H2 (Pre-Q3 aide memoire). Headwinds on the table: US Farxiga -48% in Q2 on loss of exclusivity, Soliris -28%, China/Japan price cuts. Stock is 19% below its $212.71 high, 12% above the low, 0.2% short, 35.9% IV. Pipeline reads to watch: tozorakimab peak-sales raised to $5B+, volrustomig cut to $3-5B.

The rest, by cluster

Financials and asset managers. PIPR ($64.63, mkt cap $4.6B) has cons $0.93 on $467M and sits 32% below its $95.06 high with 4.7% short; the investment-banking fee line is the debate in a tape where deal flow and the 5% 10-year are pulling opposite ways. OMF ($55.72, $6.4B) has cons $1.56 on $1.34B at 7.4x forward and 3.5% short, with the credit-loss provision the swing factor. WT ($21.20, $3.2B) has cons $0.30 on $181M and 17.5% short, the highest short in the cluster, 18% under its high; it is a crypto and gold-ETP flow story with BTC near $81K and gold at $4,010. CBOE is in Tier 1.

Autos and industrial cyclicals. LEA ($116.69, $5.8B) has cons $3.32 on $5.81B at 7.4x forward and 8.4% short, 22% under its $150.33 high. AN ($161.05, $5.3B) has cons $5.08 on $6.93B at 6.9x with 13.4% short and sits near the bottom of its range ($151.82-$235.81), 32% under the high, so it combines the heaviest short in the cluster with the cheapest multiple. GTES ($25.08, $6.3B) has cons $0.44 on $905M at 14.2x and 5.5% short. RBC ($471.98, $14.9B) has cons $3.53 on $515M at 36.9x forward, 29% under its $667.69 high; the multiple is the premium-aerospace-bearings valuation, and the move down says the market has marked down the growth. SXT ($132.65, $5.6B) has cons $1.09 on $459M, 26.6x and 5.4% short, 4% under its high.

Consumer. NWL ($5.36, $2.3B) has cons $0.20 on $1.86B at 7.5x, with 15.7% short and 85% implied vol, the richest vol in the session after VRRM; it is up 75% off a $3.07 low. TILE ($36.41, $2.1B) has cons $0.62 on $378M and 10.0% short, 10% under a $40.50 high. CPRI ($15.87, $1.8B) has cons $0.21 on $781M, 12.8% short, 74% implied vol, and 44% below its $28.27 high. KVUE and CHD are in Tier 1.

Real estate and services. FRT ($108.72, $9.5B) has cons $0.69 on $338M, 6.4% short and the lowest vol on the board (18.3%); it is 15% under its $128.21 high with the 10-year at 5%. BTSG ($60.09, $11.9B) has cons $0.47 on $3.87B at 23.4x with 9.4% short and 59% implied vol, 18% under its high; the thing to watch is the pharmacy and home-health growth against the guide. OIS ($8.60, $0.5B) has cons $0.12 on $163M; the workbook's implied-vol field returned "++" and is unreadable. The $8.60 price sits 41% below the $14.50 high; oilfield services names are the group where $103 oil should matter most, and SLB's +7% print is the template.

Distressed and unusual. VRRM ($3.03, $0.5B) is a workbook oddity and is flagged below. MOG.A and PAYP are flagged below.

Where the asymmetries sit

Implied vol looks thin where the setup is binary. XOM and CVX at about 33% implied (roughly 2.1% a day) sit at their 52-week highs on a day that includes the commodity's own six-month high and a capex/buyback decision. If the call does not raise the return of capital and the stock sells off, the move can be larger than the options imply because both stocks have already priced $100 oil, and the group's 1.1-1.2% short interest means there is no squeeze fuel on the other side.

Implied vol looks rich where the narrative is least settled. NVT at 70% and CCJ at 49.5% are names where the stock has already taken a 32% and 42% drawdown. NVT's consensus EPS is above the top of guidance and the release does not carry orders; CCJ is within 2% of its 52-week low with short interest at zero. For CCJ that means there is no short-covering fuel if the Westinghouse comparison improves. The 49.5% implied move says the market expects something large.

Crowded shorts into the print: WT (17.5%), NWL (15.7%), AN (13.4%), CPRI (12.8%), TILE (10.0%), BTSG (9.4%), LEA (8.4%) and, among the lead names, CHD (5.9%). AN is the combination to note: 13.4% short, lowest forward multiple in the session at 6.9x, a stock 32% below its high. The reaction function (beats sold if the slope decelerates) cuts the other way for the names near highs: XOM, CVX, BP, ABBV, CL, CHD and KVUE are all within 2-6% of their highs, so a clean in-line print offers less room than for the names that have already been marked down.

Guidance-reset candidates: the setup for ABBV is another raise (revenue guidance was lifted $300M in Q2 and $600M year to date), so the risk is the size, not the direction. For BP the guided lower customers result and higher cash taxes are already out; the unknown is a buyback restart. REGN's collaboration revenue step-up from the Sanofi balance repayment is in the consensus ($4.56B vs. $4.29B). The only name in the session where I see a plausible reset downside from the facts in hand is NVT on valuation rather than guidance: consensus is above the guide range.

Dominoes

XOM and CVX move the energy complex on the open: SLB, HAL, the E&Ps and the refiners (PSX, VLO, MPC) trade on the capex and buyback language, and LYB trades on XOM's Chemical Products line and the $103 oil. The BP 6-K (if it is in fact today) is the European-major cross-read for net debt and the buyback restart. Those prints inform Carl's power/grid thread through CVX's 2.67 GW Microsoft power agreement and the gas-to-power names (EQT, EXE, AR, RRC, CNX; OKE, EPD, LNG, CQP), which trade with oil and gas into the open.

D and EXC are the regulated-utility read on the power/grid thread: a capex-plan raise in either lifts the AEP/XEL/WEC/CNP/CMS/NI/FE group and the transformer and switchgear backlog names (GEV, VRT, PWR, EME, STRL, MTZ, FIX). NVT feeds the AI-capex thread directly: a strong orders number reads through to VRT and the liquid-cooling chain, and a miss on the second derivative reads as a commoditization signal for thread 1. CCJ (and UUUU, whenever it reports) are the uranium half of the power thread; Westinghouse commentary is the read for new-build AP1000 timing.

ABBV, REGN and SNY form a cluster around immunology and Dupixent: Sanofi's alliance economics with REGN (Dupixent $6.0B in Q2) and ABBV's Skyrizi/Rinvoq share trade against each other. CL, CHD and KVUE are the staples cross-read: volume vs. price/mix, and the tariff cost line. GD is the defense read for the rest of the group and the aerospace-supply names (RBC, MOG.A when it reports). The 10-year at 5.00% frames the regulated utilities, FRT, and every yield-sensitive name on the list.

Flagged as unverified

MOG.A (Moog). The workbook row is empty ($0.00, no consensus). From stockanalysis.com: last $341.34 (10/23 close, $355.10 after hours), market cap $10.81B, trailing EPS $11.77, trailing revenue $4.32B; the site shows fiscal-2026 consensus EPS of $11.77 and revenue of $4.41B but no quarterly estimate. Moog's own fiscal Q3 release (7/31) raised guidance to about $4.4B sales and adjusted EPS of $11.65 (plus or minus $0.10). Moog Q3 8-K Moog's fiscal Q4 report last year was November 21 (announced October 27, 2025), and stockanalysis lists an estimated November 20, 2026. I could not confirm a Friday 10/30 date on Moog's IR page, and the evidence points to the Briefing placement being wrong.

PAYP. PAYP is PayPay Corp (Nasdaq: PAYP), the Japanese mobile-payments and financial-services company. The workbook row is not a broken price feed so much as a currency mix: the price ($15.02) and market cap ($10.2B) are U.S. dollars for the ADS, while cons EPS 31.02 and revenue 115.15B are yen (the forward P/E of 19.2 reconciles at roughly 157 yen to the dollar). That is about $0.20 of EPS and $0.73B of revenue. Investing.com lists the next earnings date as 2 December 2026, which is an aggregator, so I treat both that date and the Friday placement as unconfirmed. As a Japanese issuer it presumably reports on 6-K. Investing.com PAYP

VRRM ($3.03). The row is internally inconsistent: a $3.03 price and $0.5B market cap against a 16.0x forward P/E on $1.14 of FY EPS (which implies roughly $18) and a $25.45 high. Either the price is broken or the stock has fallen about 88% for a reason I could not verify; do not trade this row without a live quote. OIS implied vol shows "++".

Sessions and dates. KOP reports Friday November 6 before the open with a call at 11:00 a.m. ET (Koppers IR); AMR already issued preliminary Q3 numbers on 10/23 (net loss $9.3M or $0.73 a share, adjusted EBITDA $29.4M, realization $121.09 a ton, liquidity $443.4M) and will report full results Friday November 6 before the open with a 10:00 a.m. ET call (Alpha 8-K), against a workbook consensus of -$0.79. MSGS: the Rangers spin-off was expected to complete October 26 with MSG Sports renamed MSG Knickerbockers Corp.; I found no fiscal Q1 date on the IR site, so the session stays TBD and the ticker and comparability may change (MSGS 8-K). UUUU: the IR site shows no Q3 call announcement (latest item August 28, which was the completed ASM acquisition); last year's Q3 call was November 4, so an early-November date is likely and Friday is not confirmed.

Foreign private issuers (8-K watcher will not catch): BP (6-K), SNY (6-K), CNI (40-F, 6-K), CCJ (40-F, 6-K), MGA (40-F, 6-K), PAYP (presumed).

Not independently confirmed against the company IR page: the Friday a.m. placement for BP, SNY, CNI, CCJ, MGA, ABBV, GD, REGN, CL, D, EXC, CBOE, CHD, LYB, KVUE and the lower-cap names (only XOM was confirmed: release 5:30 a.m. CT, call 8:30 a.m. CT). Cameco and CN have historically reported after the close, so those two are the likeliest session mismatches. Search budget ran out before D, EXC, CBOE, CHD, LYB, MGA and CNI prior-quarter releases could be pulled, so those blocks are workbook-only. The Hudson Labs Sanofi numbers are internally inconsistent and were used only for the guidance language that matches the 6-K and the EMJ summary.

Sources: https://investor.exxonmobil.com/company-information/press-releases/detail/1212/exxonmobil-to-release-third-quarter-2026-financial-results · https://www.sec.gov/Archives/edgar/data/0002115436/000211543626000006/livef8k2q26991.htm · https://www.sec.gov/Archives/edgar/data/0000093410/000009341026000162/a06302026ex9918-k.htm · https://www.sec.gov/Archives/edgar/data/0000313807/000031380726000016/bp-20260630.htm · https://www.sec.gov/Archives/edgar/data/0001121404/000112140426000008/pressreleaseq22026english.htm · https://www.emjreviews.com/emj-gold/news/sanofi-lifts-2026-outlook-as-dupilumab-tops-e5bn/ · https://www.hudson-labs.com/research/abbvie-q3-2026-earnings-preview-abbv-results-and-outlook · https://www.sec.gov/Archives/edgar/data/0000040533/000004053326000029/gd-20260705exhibit991.htm · https://www.sec.gov/Archives/edgar/data/0000872589/000087258926000023/exhibit991q22026.htm · https://www.sec.gov/Archives/edgar/data/0000021665/000002166526000041/q22026pressreleasetables.htm · https://www.sec.gov/Archives/edgar/data/0001944048/000194404826000141/q226earningspressrelease.htm · https://www.cameco.com/media/news/cameco-reports-2026-second-quarter-results · https://s22.q4cdn.com/268397047/files/content_files/Q2-2026-NVT-Press-Release.pdf · https://www.sec.gov/Archives/edgar/data/0000067887/000162828026051250/ex991-73126.htm · https://stockanalysis.com/stocks/mog.a/ · https://uk.investing.com/equities/paypay-corp · https://investors.koppers.com/news-releases/news-release-details/koppers-holdings-inc-schedules-third-quarter-2026-conference · https://www.sec.gov/Archives/edgar/data/0001704715/000170471526000038/a102326preliminarypressrel.htm · https://www.sec.gov/Archives/edgar/data/0001636519/000162828026056478/msgsportscorpex991forearni.htm · https://investors.energyfuels.com/